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Abstract
The inner cell mass undergoes orchestrated cellular divisions resulting in the formation of
the epiblast (EPI) and primitive endoderm (PrE). Understanding the process of cell fate
specification is crucial to appreciate the intricacies of proper embryonic development.
While the mouse embryo is an excellent model, limitations do exist with number, technical
challenges, and accessibility, therefore, in my thesis I employed two cell-based models to
recapitulate the EPI-PrE fate in vitro. Many signaling pathways have been implicated in
this lineage decision, metabolism and its downstream products have been recently regarded
as a driver of lineage commitment. Using various biochemical, molecular, and
computational modalities, I sought to understand how metabolism and ROS play a role in
XEN differentiation. In Chapter 2, I demonstrated that ROS generated by NOX1 and
NOX4, which are regulated by the GATA6 transcription factor, is required to induce XENlike differentiation. While exogenous ROS supplementation promoted XEN-like
differentiation, overexpressing Nox1 and/or Nox4 produced high levels of ROS yet failed
to promote XEN-like differentiation. Next in Chapter 3, I examined if mitochondrial ROS
played a role in XEN-like differentiation. Strikingly, the metabolic profile of XEN-like
cells was glycolytic in nature. Furthermore, these observations were further supported
using embryo-derived XEN cells (Chapter 4), which also relied on glycolysis as an energy
source. Metabolomic and biochemical analyses showcased how embryo-derived XEN cells
maintain high lactate levels by increased LDHA activity and re-routing pyruvate away
from the mitochondria. More importantly, modulating pyruvate-lactate fate using chemical
agents affected XEN differentiation in vitro. Collectively, my results emphasize how
metabolism, and its products contribute to XEN differentiation, and more broadly serves
to expand our knowledge of mammalian development.
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I

Summary for Lay Audience
One of the earliest cell type decisions that embryos make is the commitment of cells to
either the epiblast (EPI), which gives rise to the embryo proper, or the primitive endoderm
(PrE) lineage. Often neglected, the PrE supports the EPI by ensuring adequate nutrient and
gas exchange, and later its involved in gut organ formation. Many factors play a role in the
establishment of these lineages, but of interest to me is metabolism.
Metabolism is a set of chemical reactions that ensure the survival of an organism,
specifically, the building or breaking down of energy from food sources. Molecularly,
understanding how metabolites and by-products of metabolism, such as reactive oxygen
species (ROS), influence this lineage decision is crucial to understand normal embryonic
development. Due to the lack of accessibility of EPI and PrE cells from the embryo, I
turned to using embryonic stem (ES) cells and embryo-derived extraembryonic endoderm
(XEN) cells, which can be maintained in vitro indefinitely under specific culture
conditions. In addition, I employed the F9 model, which mimics the transition towards PrElike lineage when treated with differentiation factors. I hypothesized that both ES and F9
cells have distinct metabolic and Nox (enzymes that generate ROS) expression profiles
compared to their XEN counterparts, and that changes in these profiles direct cell fate
determination.
I found that GATA6, a PrE lineage inducer, increases Nox1 and Nox4 levels, which are
required but not sufficient to form XEN, suggesting that additional mitochondrial ROS
sources may be required for XEN differentiation. Surprisingly, XEN-like cells were more
reliant on glycolysis than oxidative phosphorylation (OXPHOS), a similar observation was
seen in embryo-derived XEN cells. Using cutting edge technologies, I implicated a key
metabolite, lactate, as a driver of XEN differentiation in vitro. This thesis is the first to
highlight a role for NOX-derived ROS in XEN-like differentiation and implicates lactate
in the differentiation towards the XEN lineage. This knowledge helps us understand how
factors influence fate decisions, which serves to enhance regenerative medicine therapies.
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Chapter 1

1

« Introduction »

1.1 « Overview »
1.1.1

Mouse development and stem cell fate

Embryonic development begins with fertilization where an egg and a sperm unite to form
a diploid cell, known as the zygote. The ability of the zygote to subsequently divide into
multiple cells results in the formation of the embryo proper and extraembryonic structures
required to support the embryo in utero (Figure 1-1). Preimplantation development, which
begins from fertilization to the blastocyst stage, is highly conserved amongst mammalian
species. Postimplantation development begins when the blastocyst interacts with the
maternal uterine lining, which results in vascularization and significant structural changes
to the embryo. Understanding how cells self-renew and differentiate into specific cell types
is the foundation of embryonic development. Self-renewal describes the process by which
stem cells divide symmetrically into identical daughter cells with a similar developmental
potential or asymmetrically where only one cell shares the developmental potential of the
mother cell [1]. The process of self-renewal is crucial to maintain and expand the number
of stem cell progenitors in a niche and repopulate tissue after damage. Differentiation on
the other hand is defined as the commitment of a stem cell towards a progenitor cell or a
specific cell type [2]. The equilibrium between self-renewal and differentiation is crucial
for development and to maintain organ function and integrity after injury.
Advancements in the field of stem cell biology on how genes regulate cell fate have
allowed us to further our understanding of normal development and disease. With
approximately 200 different cell types present in the adult body, most of these cells contain
the same DNA sequence. Thus, a layer of transcriptional and translational regulation exists
to ensure specific cell type expression and commitment to a fate [3]. Typically, stem cells
undergo specification followed by determination towards a cell lineage. Cell specification
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is defined when cells differentiate autonomously in a neutral environment towards a
specific lineage. However, these specified cells can revert to a stem cell fate. Alternatively,
when cells are determined, these cells can irreversibly differentiate into a specific lineage
even when placed in an environment that does not support the transition towards that
specific lineage. One of the earliest cell fate decisions observed in the mammalian embryo
is the specification of embryonic versus extraembryonic tissue.
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Figure 1-1: Lineage specification during mouse preimplantation development.
A schematic of the morphological changes and fate decisions during mouse
preimplantation development from a zygote to the late blastocyst. The first lineage
segregates at the morula stage giving rise to the ICM and TE. The second lineage
commitment occurs at the early blastocysts where cells either commit to PrE or EPI.
Blastomeres (grey), TE (trophectoderm, blue), ICM (inner cell mass, red), EPI (EPI,
purple), PrE (primitive endoderm, orange), PE (parietal endoderm) and VE (visceral
endoderm).
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1.2 « Early mouse mammalian development and cell fate
specification »
1.2.1

Mouse preimplantation development: zygote to blastocyst

In mouse, following fertilization, the zygote undergoes several mitotic divisions resulting
in progressively smaller cells without significant change in overall embryo size. The
embryo at this early stage is transcriptionally inactive, protein translation is exclusively
based on maternal mRNA deposits from the oocyte prior to fertilization. At the 2-cell stage,
the zygotic genome is activated, which results in the accumulation of zygotic RNA through
detailed mechanisms reviewed here [4], but proteins synthesized from maternal mRNA can
persist into later stages of development. The zygote and blastomeres from the 2- to the 8cell stage are considered totipotent, able to contribute to both embryonic and
extraembryonic tissues. Despite being morphologically similar and having the ability to
generate both tissue types, blastomeres from the 2-cell and 4-cell stage do have some
heterogeneity [5,6]. At the 8-cell stage, synchronous compaction takes place where
blastomeres polarize and tightly adhere to each other. Polarization of the blastomeres
establishes apical-basal polarity where the basolateral domain is characterized by
accumulation of adherens junction proteins, and the apical domain by tight junctions and
cell polarity proteins. At embryonic day 3 (E3.0), the subsequent cleavage divisions give
rise to the morula where the outermost cells maintain polarity while cells that move inside
adopt an apolar morphology. Cells of the morula are no longer identical, and their divisions
are asynchronous [7]. Developmental plasticity of these cells declines significantly when
compared to the 2- to 8-cell blastomeres. At the morula stage, the outermost cells commit
to the trophectoderm (TE) lineage while the innermost cells give rise to the inner cell mass
(ICM) [8], which establishes the first lineage specification. After ICM-TE specification,
through a process known as cavitation, the blastocyst forms a fluid-filled cavity, the
blastocoel, largely driven by Na+-water movement. Briefly, a membranous structure forms
to prevent fluid movement from the external environment into the blastocyst. Next,
Na+/K+-ATPases preferentially localize to the basolateral surface of TE cells [9], thereby
resulting in intracellular Na+ accumulation. The movement of water through aquaporins
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into the cavity results in its expansion, giving rise to the blastocoel cavity [10]. The embryo
adopts a characteristic blastocyst morphology, with cells being less developmentally
plastic as they prepare for the second lineage commitment and implantation.

1.2.2

Inner cell mass versus trophectoderm specification

One of the first lineage commitments in the mammalian embryo is the specification of cells
towards either embryonic or extraembryonic tissue. At the morula stage, the outermost
cells are destined to give rise to the TE, and placenta later, while cells remaining inside
form the ICM, comprising the embryo proper and supporting yolk sacs. Genetic analysis
sheds light on the role of key regulators and transcription factors in this process, most
notably SOX2 and CDX2, which are exclusive to their respective lineages [11,12]. SOX2
is restricted to the nuclei of cells destined towards the ICM at the 16-cell stage, which is
more evident in later stages [13]. This contrasts with NANOG, a marker typically
associated with ICM cells at later stages yet is present in outermost cells at the 16-cell
stage. Despite its abundance in future ICM cells, conditional deletion of maternal and
zygotic Sox2 have no effect on the segregation of ICM and TE lineage, suggesting that
other factors are also at play.
Blastomeres enriched in Cdx2 mRNA are more likely to commit to a TE lineage [14], while
those depleted of Cdx2 express Pou5f1 and Nanog in the outermost cells, resulting in
embryo death [12]. These results suggest that CDX2 functions as a cell fate determinant;
however, the inward migration of CDX2-positive outer cells at the 16-32 cell stage [14]
indicates that cell polarity and position may act upstream of certain cell fate determinants
like Sox2 and Cdx2.
It is now widely recognised that the HIPPO signaling pathway links cell positional
information to lineage-specific markers and cell fate determinants in the early mammalian
embryo. This pathway is widely conserved in the animal kingdom [15,16] and plays a role
in developmental processes such as tissue growth and homeostasis as well as disease [17].
Nishioka and colleagues were first to implicate HIPPO signaling in ICM-TE lineage
decision [18]. Mechanistically, in future ICM cells the serine-threonine kinases LATS1/2
are phosphorylated and activated by MST1/2, which phosphorylate YAP. This post-
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translational modification prohibits YAP from entering the nucleus and activating TEAD4,
which typically activates Cdx2 expression [15,19-22]. However, HIPPO signaling in the
outermost cells is inactive and this results in the expression of Cdx2 in the TE [18,23] and
Gata3 [24], while maintaining the Sox2 gene in the off configuration [13]. Thus, when
TEAD4 is deleted, embryos lack TE markers Cdx2, Eomes, Gata2/3 and Fgfr2, but express
ICM-specific markers Oct3/4 and Nanog, and this is phenocopied when Lats2 is
overexpressed [23]. Similarly, embryos containing a catalytically inactive LATS2 show
reduced nuclear phosphorylated YAP and increased Cdx2 expression in the innermost cells
[18]. Nevertheless, embryos lacking TE-specific transcription factors generate blastocysts
but fail to implant with defects in placental development [25,26].
In addition to the direct regulation on YAP, other factors exist to regulate the HIPPO
signaling pathway, namely, neurofibromatosis 2 (NF2) [27-31] and angiomotin (AMOT)
[32-37]. NF2 recruits LATS1/2 to the plasma membrane, ultimately causing the
phosphorylation of YAP [29], but when injected with a dominant-negative Nf2, embryos
have mislocalized YAP, which causes the ectopic expression of Cdx2 [27]. In addition,
embryos that lack maternal and zygotic Nf2 express Cdx2 in the ICM, suggesting that NF2
is required for proper ICM-TE specification. AMOT also regulates the HIPPO pathway
[35,37] and can interact with YAP and NF2 [32,35-37]. In the outermost cells, the PARaPKC complex (see below) sequesters AMOT to the apical domain thereby preventing its
interaction with LATS and keeping the pathway inactive [33,34]. While in the innermost
cells, AMOT is localized to adherens junctions when bound to the F-actin and E-cadherinα/β-catenin-NF2 complex. This conformation of AMOT is unstable and results in its
ubiquitination and degradation. In the innermost cells, LATS phosphorylate AMOT, which
results in its release from F-actin and its stabilization, thus activating the HIPPO pathway
and ensuring the exclusion of YAP from the nucleus, which prevents Cdx2 expression
(Figure 1-2).
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Figure 1-2: Schematic of the HIPPO signaling pathway in outer and inner cells of
the embryo.
In the outer cells, AMOT is bound by F-actin, preventing it from binding to LATS1/2NF2 complex thus inhibit LATS1/2. Consequently, allowing YAP to translocate into
the nucleus and binds to TEAD4 and induce the expression of TE marker Cdx2. In the
inner cells, AMOT is localized to AJs by a F-actin-E-cadherin-α/β-catenin-NF2
complex. LATS1/2 phosphorylate AMOT, which results in its release from the complex
and stabilization, thus binding to LATS1/2 and enhancing LATS-dependent
phosphorylation of YAP. The phosphorylation of YAP prevents it from entering the
nucleus thereby inhibiting the expression of Cdx2 and the upregulates of Sox2.
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While various players of the HIPPO signaling pathway play a crucial role in ICM-TE
specification, researchers have shifted their focus on targets upstream of the pathway that
link cell position and polarity to lineage decisions in the mammalian embryo. Historically,
two models attempt to explain the first cell fate specification: the inside-outside model; and
the cell polarity model. In the former, the position of a cell within the embryo dictates cell
fate [38]. Tarkowski and Wroblewska observed that with the decrease in embryo volume,
more cells were on the surface (outside) while fewer cells were on the inside. They
concluded that the condition in which the outside and inside cells are in, are vastly different
and that fate is a consequence of blastomere position. Alternatively, the cell polarity model
relies on the acquisition of apical-basal polarity [39], which is based on the fact that the 8cell stage blastomeres polarize and form stable apical domains. This stability during cell
division results in either two polar (outer) cells or one polar and one apolar (inner) cell
[40]. The outcome of these divisions leads to the formation of an apolar ICM and a polar
TE. Regarding this model, studies have implicated the PAR-aPKC complex in polarization
and subsequently ICM-TE specification. Embryos with reduced levels of Pard6b cleave
and compact properly but have a decrease in Cdx2 expression and fail to form cavities at
the blastocyst stage [41], raising the question of whether a link exists between cell polarity,
epithelium formation and specification. However, the deletion of maternal and zygotic Ecadherin blocks the formation of a polar epithelium, but this does not block ICM-TE fate
[42] and a higher ratio favouring Cdx2-expressing cells over ICM cells was observed in
these embryos. Thus, epithelium formation is required for the normal allotment of ICM
and TE cells rather than ICM-TE specification.
With regard to ICM specification, Pou5f1 [43], Nanog [44] and Sox2 [45] are required for
cell fate. Pou5f1 and Nanog are expressed in all cells early in development, but later they
become more restricted in ICM cells. In the TE, however, CDX2 binds to OCT4 and
prevents it from acting as a transcriptional activator [46]. Similarly, although Pou5f1null
embryos generate blastocysts, they are unable to produce derivates of the ICM, and instead
express TE lineage markers [47]. Finally, HIPPO signaling also ensures the activation of
cell fate markers in ICM cells [48]. Thus, the differential activation of HIPPO signaling
coupled with transcription factor-mediated cell fate decision provides a roadmap for the
regulation of ICM-TE lineage specification.
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1.2.3

Epiblast versus primitive endoderm specification

Once the first lineage establishes the TE from the ICM, the second lineage decision
determines the identity of the ICM: epiblast or primitive extraembryonic endoderm (PrE).
All blastomeres at the 8-cell stage contain the transcription factors NANOG and GATA6,
but more distinct localization takes place at the 32-cell stage where cells fated towards the
epiblast contain NANOG while those that will form PrE contain GATA6 [11,49]. This
mutual repression is seen in Gata6 mutant embryos that display uniform NANOG
expression in the ICM [50,51], while the ICM of Nanog mutants contain GATA6 thereby
repressing the epiblast fate [52]. Historically, the origin of these lineages was largely
positional, with cells closer to the blastocoel cavity destined to form PrE whereas those
bordering the TE form the epiblast. However, this model has been replaced through genetic
analysis and lineage tracing experiments with results showing the epiblast or PrE lineages
are genetically predetermined prior to separating into two layers [49,53-55]. Research has
since shifted to elucidate the mechanisms involved in resolving the heterogeneity observed
in the early ICM where two developmental models were proposed: cleavage historydependent; and stochastic gene activation [3].
The cleavage history-dependent model reveals that ICM cells are poised towards the
epiblast or PrE fate depending on when these cells arise. ICM cells are created at the 8- to
16-cell (wave 1), the 16- to 32-cell (wave 2), and the 32- to 64-cell (wave 3) stages. Lineage
tracing analysis has revealed that cells generated from wave 1 are primarily destined to the
epiblast fate while cells generated from wave 2/3 are biased towards PrE [56]. However,
another study using a Cre/Lox lineage tracing approach reached a different conclusion,
where all cells of the ICM have an equal chance of adopting either cell fate regardless of
their timing [57]. Nonetheless, these experiments highlight the developmental plasticity of
the mammalian embryo, and more research is required to elucidate the signaling
mechanisms and gene regulatory networks involved in epiblast-PrE specification.
The stochastic gene activation model considers that the profile of gene expression in cells
fated as ICM arise randomly, and independent of cellular divisions. Several studies using
single-cell PCR analysis have implicated the FGF signaling pathway in PrE specification
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where a subset of cells within the ICM stochastically express varying levels of either the
ligand FGF4 or its receptor FGFR2 [11,58]. Epiblast cells express Fgf4 during blastocyst
formation [11] while Fgfr2 is widely expressed in all ICM cells at E3.25, but becomes
restricted to PrE cells at E3.5 [11,52,59,60]. Disrupting FGF signaling results in only
epiblast cell [57,59,61] while supplementing with exogenous FGF4 is sufficient for all ICM
cells to adopt a PrE fate [57]. Thus, while the FGF/MAPK signaling pathway is responsible
for the specification of epiblast versus PrE fate (Figure 1-3), downstream effectors also
play important roles in this fate decision.
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Figure 1-3: FGF-MAPK signaling in the late blastocyst.
EPI cells express and secrete FGF4, which signals in paracrine to PrE cells where it
binds FGFR1 and FGFR2 activating ERK resulting in the increase in GATA6 and
downregulation of NANOG. EPI cells express NANOG and FGF4 with low levels of
FGFR1, while PrE cells express GATA6 and FGFR1 and FGFR2. EPI (EPI cells) and
PrE (primitive endoderm cells), FGF4 (fibroblast growth factor 4), FGFR1 (fibroblast
growth factor receptor 1), and FGFR2 (fibroblast growth factor receptor 2). This
diagram was adopted and modified from (59).
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The role of these effectors is evident when Grb2, encoding a SH2 domain-containing
adaptor protein downstream of FGF/MAPK signaling pathway, is knocked out [53,62] or
when the pathway is disrupted chemically [53,57,61], causing cells to express NANOG.
FGF/MAPK signaling pathway also ensures the repression of Sox2 and Nanog in the PrE
[13]; however, key pluripotency markers are also required for specification of these cells.
For example, embryos that lack Sox2 have reduced expression of PrE markers Gata6 and
Sox17 [13]. Pou5f1, another pluripotency marker is also required for PrE formation as the
translated protein promotes the expression of Gata4 and Sox17 downstream of MAPK; it
also promotes Gata6 expression and reduces Nanog expression in an POU5F1-independent
manner [63]. In this model, POU5F1 in the epiblast cells is required to secrete FGF4, which
interacts with FGFR2 on PrE cells to transduce the signal and upregulate key PrE markers.
When Pou5f1 is deleted, embryos have normal NANOG and GATA6 levels; however,
Gata6 expression declines drastically, which is partially attributed to the reduction in FGF4
[63]. Therefore, pluripotency markers in the epiblast cells are required for PrE
specification.
Once the epiblast and PrE are specified, the next step is to ensure the maturation of these
respective lineages. Particularly for PrE cells, mature markers such as SOX17, PDGFRα,
GATA4 and SOX7 levels increase, and as described below, their temporal regulation relies
on GATA6. At these later stages, genetic or chemical manipulation to alter cell number of
either epiblast or PrE cells does not result in compensation by an increase in the other cell
type since cells are committed. GATA6, whose message is expressed in cells from the 8cell stage becomes restricted to PrE cells at E3.75. While it is considered a master regulator
of the endodermal lineage; it does so together with other factors and signaling pathways
[53,64]. Prior to E3.75, Gata6 expression is independent of FGF signaling, but at later
stages it requires FGF [53,57,59-61]. GATA6 is expressed in all ICM cells of Nanog-/embryos, however, the levels of mature PrE markers GATA4 and SOX17 is significantly
downregulated [65,66], implying other players are required for their expression. More
importantly, the decline in FGF4 secreted by epiblast cells results in the reduction of Gata6
expression in PrE cells [13,63]. Incidentally, Gata6 nulls die at E6.5-E7.5 [67] and the ICM
cells of these embryos have detectable NANOG levels [50,51].
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GATA6, as noted above, is the initial transcription factor in PrE specification, followed by
the expression Sox17, Pdgfrα, Gata4 and lastly Sox7 [64]. Sox17 expression overlaps with
other markers including Nanog, Pou5f1 and Gata6 at E3.5 [56,68], but by E4.5, Sox17 is
expressed only in PDGFRA-expressing cells [49,64,68]. Nevertheless, Sox17-/- embryos
generate PrE but die at midgestation due to improper development of the gut endoderm
[68,69]. Similarly, the loss of the PDGFRα in PrE cells results in cell death [70]. Sox7,
which is normally expressed at preimplantation, maintains its expression in Sox17 null
embryos [64,69], and its compensation may explain the mild phenotype observed in Sox17
mutants [64,69]. Regardless, overwhelming evidence indicates that a hierarchy in gene
regulation is required for PrE formation.
Other growth factors and signaling pathways are also involved in specifying PrE, including
BMP where embryos treated with pathway inhibitors, including NOGGIN and
dorsomorphin, have a reduced number of PrE cells [71]. Interestingly, the number of
NANOG-positive cells is not altered and the epiblast versus PrE fate decision is not
affected. Together these studies highlight the importance of transcription factors and
signaling molecules implicated in lineage specification, and despite embryos being an
excellent platform to decipher the mechanisms involved, technical difficulties limit the
elucidation of these pathways. To overcome some of these shortfalls stem cells can be
cultured in vitro and directed into various lineages.
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1.3 « In vitro models of cells within the inner cell mass »
1.3.1

Mouse naïve and primed embryonic stem cells

Since pluripotency is a transient state in vivo, researchers can capture various stages of
development and maintain them indefinitely under defined culture conditions. These
culture conditions either maintain cells in an undifferentiated state or induce differentiation
towards a specific lineage. Pluripotent stem cells have been isolated from various
vertebrates, with each cell type requiring defined conditions to ensure their maintenance.
For instance, naïve embryonic stem (ES) cells of the preimplantation ICM can be isolated
and maintained indefinitely [72,73]. Morphologically, these cells grow in domed-like
colonies, have a high proliferation rate and clonogenicity, and can incorporate into the
blastocyst and give rise to ectoderm, endoderm and mesoderm [74]. These cells were first
isolated from ICM of 129 mouse strain and maintained on mitotically inactive mouse
embryonic fibroblast cells (MEFs) and fetal bovine serum (FBS). While MEFs are still
used today, potential contaminants resulting in confounding data limit the potential use and
application of these ES cells, specifically in regenerative medicine. It is also challenging
to pinpoint the factors secreted by MEFs and more importantly, even more difficult to
ensure consistency from batch to batch; the latter also applies to FBS. To maintain ES cells
feeder-free, leukaemia inhibitory factor (LIF) in combination with FBS was found to
maintain proliferation and pluripotency of ES cells [75,76]. LIF causes its receptor and
gp130 to dimerize, activating JAK and causing the phosphorylation of the LIF receptor and
gp130. In turn, STAT3 is recruited to the complex where it is phosphorylated by JAK,
causing homodimerization and translocation to the nucleus where it activates gene
expression [77,78]. STAT3 is key as its ectopic expression can maintain pluripotency in
the absence of LIF [79], while inactivating it compromises pluripotency and induces
spontaneous differentiation [80]. The first serum-free and feeder-free system to culture ES
cells and maintain them in the undifferentiated state relied on LIF and low doses of BMP4
to inactivate the MAPK pathway [81]. The LIF-2i system has since been employed, and
uses LIF alongside small molecule inhibitors of glycogen synthase kinase 3 (GSK3) and
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the mitogen-activated protein kinase (MEK) pathway [82]. Overall, culturing naïve ES
cells under LIF-2i system reduces heterogeneity in culture whilst maintaining pluripotency.
Further down the developmental timeline, primed epiblast stem cells (EpiSCs) can be
isolated from the post-implantation epiblast, and they differ morphologically from naïve
ES cells by growing as flat colonies. EpiSCs possess low clonogenicity and are unable to
form chimeras, but can give rise to all three lineages in a teratoma assay [74]. EpiSCs also
differ from naïve ES cells in having one inactivated X chromosome [83], and while they
express the core markers of pluripotency like naïve ES cells (OCT4, SOX2 and NANOG),
they downregulate naïve-specific markers including KLF2/4, ESRRβ, REX1 and DPPA3
and upregulate primed markers OTX2, T and ZIC2 [84]. The epigenetic landscape is also
distinct between the two cell types, with higher global DNA methylation [85]. Primed
EpiSCs are cultured under FGF2/Activin A to maintain their undifferentiated state [86,87],
and while FGF2-MAPK signaling does not directly promote the epiblast lineage, it does
suppress KLF2 and the neuroectodermal lineage [88]. In contrast, Activin A supports
pluripotency by activating NANOG while suppressing mesodermal lineages by inhibiting
SMAD2/3 levels [89].
While naïve-primed cells differ on many levels, including the expression profile of
pluripotency core genes, DNA methylation, histone modification status, clonogenicity and
chimera contribution [74], it is the culture conditions that contribute to this heterogeneity.
For example, naïve ES cells cultured under LIF-2i system maintain high degree of
hypomethylation on promoter regions. However, when cells are transitioned into naïve
serum-LIF system, an increase in DNA methylation is observed, which is more prominent
in the FGF2/Activin A system [90]. Conversely, transitioning naïve serum-LIF ES cells
into the 2i-LIF system induces changes in the promoter occupancy of key naïve markers
and downregulation of DNA methyltransferases and a reduction in global methylation [91].
To fully exploit this in vitro system, ES cells can be converted interchangeably between
the naïve and primed state using chemical agents or genetic means. Chemically, culturing
primed EpiSCs under naïve conditions with LIF-2i results, albeit inefficiently, in
reprogramming towards the naïve state. Genetically, however, overexpressing naïve

15

markers such as KLF4 promotes the conversion of EpiSCs to a naïve state, and these
reprogrammed cells can contribute to chimeras and germline transmission [82,92]. Other
naïve factors, including NANOG, ESRRβ and PRDM14 can also enhance the
reprogramming efficiency of EpiSCs into naïve ES cells [93]. Alternatively, naïve ES cells
can be converted into EpiSCs by culturing them in FGF2/Activin A [82,92,94]. Overall,
obvious differences exist between the two populations of stem cells, and despite both being
excellent tools to study early mammalian development, it is imperative to address culturing
conditions when elucidating the mechanisms instructing cell fate.

1.3.2

Mouse extraembryonic endoderm cells

In addition to naïve ES cells, cells can be isolated and cultured indefinitely from the PrE,
termed extraembryonic endoderm (XEN) cells. Morphologically, XEN cells are
heterogenous being round and refractile or epithelial-like in culture [95]. While pluripotent
stem cells have the ability to repopulate the ICM and give rise to chimeras, at least with
naïve ES cells [74], XEN cells can only repopulate the parietal endoderm and not the
visceral endoderm, suggesting that these cells are more reminiscent of the former.
However, XEN cells isolated from the post-implantation blastocyst do contribute to the
visceral endoderm [96]. More recently, XEN cells have been shown to contribute to the
endoderm proper, mainly in the gut [97]. Although there are several methods to establish
XEN cells, they were first isolated from the mouse blastocyst [95]. Other methods,
however, are available including differentiating ES cells using exogenous factors [98-100],
reprogramming fibroblast cells [101,102], or by overexpressing Gata4/6 [103,104] or
Sox17 [105]. Regardless of their origin or derivation, XEN cells, typically cultured in the
presence of serum without exogenous factors retain the ability to self-renew and
differentiate when prompted. Identifying the extrinsic and intrinsic factors is key to
understanding self-renewal and differentiation of XEN cells. For instance, naïve ES cells
require the inactivation of MAPK signaling, but XEN cells rely on this signaling in vitro
and in vivo [61]. Treating these cells in vitro with a MEK inhibitor leads to reduced
proliferation and differentiation towards visceral endoderm [70,106]. Other players
including LIF, Activin A and retinoic acid [100,107], are also involved in XEN cell
differentiation in vitro.
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Exogenous agents influence intrinsic mechanisms that are linked to transcription factors
and epigenetic regulators that play a role in self-renewal and differentiation of XEN cells.
Potent transcription factors such as GATA4, 6 and SOX17 differentiate ES cells towards
the PrE fate [103-105,108] and are required as Gata6 nulls fail to differentiate when these
cells are treated with retinoic acid and Activin A [98]. GATA6 promotes XEN induction
by directly binding to the promoter region of endodermal markers thereby enhancing their
expression, while also binding to regulatory regions of pluripotency genes to repress their
expression [108]. In addition to these transcription factors, epigenetic modifications
including DNA methylation, histone modifications and microRNAs play an intrinsic role
in XEN induction. Genes associated with the PrE lineage are hypomethylated while those
involved in pluripotency are hypermethylated [109]. Histones are also affected by
methylation, and while XEN cells have low levels of the repressive H3K27me3, ES cells
have high levels due to the expression of members of the Polycomb Repressive Complex
2 [110]. Thus, both intrinsic and extrinsic mechanisms play a role in the maintenance and
differentiation of XEN cells in vitro and a better insight into those mechanisms may help
us understand how mouse and human development occurs in vivo.

1.3.3

Mouse embryonal carcinoma cells

While most of the studies today are focussed on induced, embryonic and cancer stem cells,
much of the pioneering work arose from studies with embryonal carcinoma (EC) cells
derived from teratocarcinomas [111]. EC cells share three distinct features: (1) they are
malignant; (2) they can differentiate into any of the three germ layers or extraembryonic
tissue; and (3) they can contribute to the development of chimeras, however, not reliably
[112,113]. Although EC cells can be propagated indefinitely without supplementation of
exogenous factors, the ability to culture them in vitro and their loss of “multipotentiality”
was of paramount importance, leading to many studies that followed [114]. In fact, the
suggestion that the study of EC cells would uncover genes involved in stem cell selfrenewal and pluripotency only serves to underscore the importance of EC cells [115].
Nevertheless, these lines have been and continue to be studied extensively [116-119].
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F9 teratocarcinoma cells, one widely used mouse EC cell line that can give rise to tumours
consisting almost exclusively of undifferentiated cells, exhibit a pseudodiploid karyotype
[112,120,121]. Once considered nullipotent, studies would later reveal that F9 cells
differentiate into XEN-like cells [122,123], and evidence indicates that they share many
characteristics of ES cells [124]. In fact, F9 cells can be induced to form XEN-like cells by
all-trans retinoic acid (RA) [125], a natural derivative of vitamin A (retinol), or by
activating numerous signaling pathways involving canonical WNTs [126]. Thus, like ES
cells, extrinsic [127] and intrinsic factors can influence the maintenance and differentiation
of F9 cells.
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Table 1: Key features of various cell lines used in this thesis
F9
ES*
XEN
Species
Mouse
Mouse
Mouse
Strain
N/A
129P2/OlaHsd
ICR
Colony morphology
Compact
Compact
Single cells
Homogeneity
Yes
Yes
No
DNA methylation
Low
Low
High
X inactivation
Partial
No
Yes
Germ cell
None
Low
None
competence
Teratoma formation
High
High
Low
Chimera
High
High
Low
contribution
Marker expression
OSKM, Rex1, Klf4 OSKM, Rex1, Klf4, Gata4/6 and Dab2
Esrrb
LIF requirement
No
Yes
No
RA responsiveness
Yes
Yes
No
FGF/MAPK
No
No
Yes
dependence
*
ES cell line used in this thesis is the E14Tg2a, which is a feeder-free parental line.
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1.3.3.1

Retinoic acid: lessons from the inducer

RA is a potent teratogen and an important endogenous regulator of proper and
extraembryonic endoderm [128]. RA signaling has many diverse roles in the differentiation
of EC cells [99,129], most often leading to XEN-like lineages. RA-induced differentiation
is accompanied by changes in gene expression in F9 cells [130-135] include c-Myc
[136,137] and Wnt1, which have caught the attention of subsequent cancer-related studies.
In the case of c-Myc in F9 cells, its levels decline with RA-induced differentiation [130]
comparable to ES cells [138]. c-Myc is downstream of the WNT targetome [139], and its
expression including other Wnt target genes has been reported during RA-induced
differentiation in F9 cells [126,130,140]. These discoveries not only led to the assembly of
complex cell signaling pathways and gene networks linked to EC cell differentiation but
were the platform that many have since used to identify the crosstalk and autoregulatory
loops that exist within and between EC and ES cells [141-147]. It is interesting to note that
while many of these studies revealed that RA must repress certain genes during
differentiation, little discussion has linked these genes to self-renewal and stemness in EC
cells. In fact, despite the irony that stemness genes including c-Myc [136,148-151], Oct3/4
[152-154] and Sox2 [155-157] had already been identified in EC cells, their specific roles
in self-renewal and pluripotency would not be elucidated until later [115,158]. Meanwhile,
studies showing expression of genes such as K-fgf and Hst-1 [159-161] provided the
framework that gene activity was sufficient and necessary to keep EC cells in the
pluripotent state. In addition to these studies and others involving c-Myc [148,162-166],
Pou5f1 [154,167-169], and Sox2 [155,156], further evidence that pluripotency genes must
be developmentally regulated in the early embryo came from reports that Nanog [170,171],
and Foxm1 [172] are down-regulated in F9 cells in response to RA treatment. Foxm1, a
member of the Forkhead box of transcription factors, is an interesting example as we know
it plays pivotal roles in cell proliferation, differentiation, and self-renewal, and acts
downstream of canonical Wnt/b-catenin signaling [173,174]. Thus, while much of the
focus was initially on ways to differentiate EC cells, subsequent efforts are underway to
identify pluripotency factors that would attenuate differentiation, thereby maintaining
stemness.
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1.4 « Metabolism, pluripotency and differentiation »
1.4.1

Overview of glycolysis and oxidative phosphorylation

Stem cells possess long-term capacity to self-renew, thereby replenishing aged or damaged
cells in an organ. Thus, the immense demand for energy production and metabolites to act
as building blocks for substrates and co-factors has driven the field to investigate the role
of metabolism in pluripotency and differentiation. Metabolism is a process of anabolic and
catabolic reactions that take place in an organism to ensure survival. All mammalian cells
generate ATP as an energy molecule through catabolic reactions of macromolecules
(carbohydrates, proteins, and lipids). In the case of glycolysis, ATP is generated in an
oxygen-independent pathway in the cytoplasm, while oxidative phosphorylation
(OXPHOS) yields ATP from an oxygen-dependent mitochondrial pathway. Glycolysis is
a series of enzymatic reactions that convert glucose into pyruvate to generate a net of 2
ATP molecules per molecule of glucose. Cells that are exclusively glycolytic further
convert pyruvate into lactate, which is either used intracellularly or excreted
extracellularly. Alternatively, when oxygen is abundant, pyruvate is taken up into the
mitochondria and is oxidized into acetyl-CoA, which yields 34 ATPs per molecule of
glucose, thereby making it a more efficient process. Despite being less efficient, ATP
generated from glycolysis occurs at a faster rate than from OXPHOS [175], and when
glucose supply is sufficient, glycolysis is the preferred bioenergetic pathway for highly
proliferative cells.
Glycolysis is divided into three phases: 1) energy investment; 2) splitting; and 3) energy
production [176]. During the energy investment phase, glucose is phosphorylated by
hexokinase (HK) into glucose-6-phosphate (G6P). This first step of glycolysis requires
ATP and is irreversible. G6P isomerizes and is phosphorylated by the phosphofructokinase
(PFK) enzyme into fructose-1, 6-bisphosphate. In the splitting phase, fructose-1, 6bisphosphate is separated by an aldolase into glyceraldehyde-3-phosphate (G3P) and its
isomer, dihydroxyacetone phosphate. Finally, triose phosphate isomerase converts
dihydroxyacetone phosphate into G3P, which is used in energy production. In this last
phase, G3P is converted into 1,3-bisphosphoglycerate by glyceraldehyde-3-phosphate
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dehydrogenase (GAPDH), also yielding NADH2. ATP is produced by phosphoglycerate
kinase acting on 1, 3-bisphosphoglycerate to generate 3-phosphoglycerate, which
isomerizes into 2-phosphoglycerate by phosphosphoglycerate mutase. Enolase then
converts 2-phosphoglycerate into the high energy molecule phosphoenolpyruvate, which
is catalyzed by pyruvate kinase to form pyruvate and a second molecule of ATP. Pyruvate
is reduced by lactate dehydrogenase A (LDHA) into lactate, and this requires NADH2,
which gets oxidized to NAD+ and as a result, NAD+ is recycled and reused in glycolysis.
Incidentally, lactate can be converted back into pyruvate by the LDHB enzyme, to
participate in OXPHOS metabolism.
OXPHOS is an oxygen-dependent means to generate ATP. In the presence of oxygen,
pyruvate enters the mitochondria to be processed in the Tricarboxylic Acid Cycle (TCA),
also called the Citric Acid or Krebs cycle [177]. The mitochondrial pyruvate
dehydrogenase complex (PDC) catalyzes the oxidative decarboxylation of pyruvate into
acetyl-CoA, and oxaloacetate is added by the enzyme citrate synthase to generate citrate.
Citrate isomerizes and oxidatively decarboxylated into α-ketoglutarate through isocitrate
dehydrogenase, which is also oxidatively decarboxylated into succinate. In the process of
generating succinate, ATP, CO2 and NADH are produced. Succinate is oxidized by
succinate dehydrogenase into fumarate and FADH2, with fumarate being hydrated into
malate, which is oxidized by malate dehydrogenase to regenerate oxaloacetate and NADH.
The TCA cycle does not generate sufficient ATP, instead, electrons are removed and used
to generate NADH and FADH2. These molecules, however, flow through the electron
transport chain (ETC) creating a proton gradient that powers an ATP synthase to generate
ATP (Figure 1-4).
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Figure 1-4: An overview of the conversion of glucose through glycolysis and
OXPHOS.
Glucose enters the cells through glucose transporters where it is phosphorylated into
G6P by the activity of the HK enzyme in non-reversible manner. Following various
steps, phosphoenol pyruvate is generated, which is converted into pyruvate and ATP is
generated. Pyruvate has two fates, it can be reduced into lactate via LDHA, and reversed
back into pyruvate through the activity of LDHB. Alternatively, pyruvate is pumped
into the mitochondria through MPCs where PDC catalyzes the oxidative
decarboxylation of pyruvate into acetyl-CoA, which in turn is broken down to generate
reducing power though the Krebs cycle. The generated NADH and FADH2 are used the
ETC to eventually result in the production of ATP.
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1.4.2

Metabolic profile of the blastocyst and pluripotent stem cells

Recently, interest has focussed on understanding how metabolism can influence cell fate
commitment in the developing embryo; specifically, the interplay between metabolism and
the epigenome to drive changes in pluripotency and differentiation. Pioneering work
identified conditions that allowed the culturing and maintenance of blastocysts ex vivo
[178,179], and results show at the 1-2 cell stage the embryo requires pyruvate, while shortly
afterwards either pyruvate or lactate can be used [180]. Interestingly, neither glucose nor
glutamine alone can support development at these early stages. The inability to utilize
glucose is largely due to the high ratio of ATP-to-ADP, which allosterically inhibits the
activity of PFK, thereby inhibiting glycolysis [181]. As development progresses, an
increase in the demand for ATP occurs, and there is an increase in oxygen consumption
[182], and the ATP is primarily used for blastocoel expansion [183]. In addition, HK and
PFK inhibition also plays a role in the reduced reliance on glycolysis in the early embryo
[181]. The blastocyst converts half of its glucose into lactate, despite sufficient oxygen
levels for OXPHOS, known as the “Warburg Effect” named after Otto Warburg [184]. The
lactate generated is secreted through monocarboxylic acid transporters (MCTs) out of the
cell suggesting that lactate, acting as one of the extrinsic factors, may play a role in
mammalian development.
LDHB, which preferentially converts lactate into pyruvate, is highly expressed at the
preimplantation stage [185], and when glucose is depleted in culture the metabolically
flexible blastocyst can compensate by an increase in pyruvate uptake. Pyruvate is used as
an energy source, but it also serves as an antioxidant to sequester reactive oxygen species
(ROS) that can be detrimental to the embryo. Furthermore, both pyruvate and lactate
regulate metabolic function by controlling the redox state of the cell [186].
Mechanistically, pyruvate is required for zygotic genome activation at the 2-cell stage,
where pyruvate-mediated translocation of the PDC to the nucleus is required to generate
the acetyl-CoA essential for epigenetic modifications required for genome activation [187].
However, LDHA, which converts pyruvate into lactate is enriched in the late blastocyst
and as the embryo prepares for implantation, this lactate creates a low pH environment as
it is secreted by MCTs, which aid in breaking down the uterine lining [188]. In addition,
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this acidosis acts to induce VEGF recruitment, which promotes angiogenesis, further
facilitating development [189]. These studies highlight the few roles of glucose-derived
lactate in embryonic development.
Glucose is typically used as an energy source, but alternatively it is also used for the
synthesis of precursors for macromolecule biogenesis. Glucose can be redirected into the
hexokinase biosynthesis pathway (HBP) to synthesize the UDP-O-GlcNAc moiety that
plays a role in ICM-TE specification [190] or XEN differentiation (Appendix-Section 2).
In the apical cells, which later become TE, YAP1 must be O-GlcNAcylated to translocate
into the nucleus and activate the transcription of Cdx2. Blocking either O-GlcNAcylation
or treating embryos with 2-deoxyglucose, which inhibits glycolysis and HBP, blocks
YAP1 activation and Cdx2 expression. Tead4-/- embryos fail to form a blastocoel or implant
under oxidative stress conditions [191]. Specifically, Tead4-/- embryos develop properly
when cultured under 5% oxygen tension, and this was abrogated when glucose, amino acids
and glutamine were supplemented, thereby driving OXPHOS metabolism and ROS
production. The pentose phosphate pathway (PPP) uses glucose to generate the ribose
moiety for nucleic acid synthesis and the NADPH for lipid and other macromolecule
synthesis [192]. Nucleotide synthesis and sphingolipid signaling activate mTOR allowing
for the translation of Tfap2c [190]. Collectively, YAP1-TEAD4-TFAP2C complex binds
and upregulates TE-specific genes in apical cells. Finally, results show glucose and
glycolysis are preferentially utilized in the developing embryo to ensure low levels of ROS
are generated to maintain genomic integrity and reduce the chance of lipid and protein
oxidation [193]. Although previous studies have used the embryo as a model in order to
understand the role of metabolism in development, it remains technically challenging and
data can be confounded by culture conditions and the scarcity of tissue [194]. Again, to
circumvent these problems there has been a transition to using stem cells as an in vitro
model to study the interplay between metabolism, epigenetics, and fate decision.
Differences between naïve and primed stem cells were discussed earlier with reference to
morphology, culture conditions, gene regulatory networks, and epigenetic signatures
(Section 1.3.1). Indeed, metabolic differences also exists between naïve and primed stem
cells with naïve ES cells exhibiting a metabolic profile reliant on both glycolysis and
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OXPHOS [195]; while, EpiSCs are exclusively dependent on glycolysis, largely due to
increased glucose uptake through various transporters [196]. The high proliferation rate of
pluripotent stem cells and an extended S-phase imposes the demand for macromolecule
generation. The high glycolytic flux in pluripotent cells also provide substrates for the PPP.
These metabolic preferences reflect substrate utilization and are regulated by key
pluripotency factors. During early stages of development, low levels of HK2 and
dependence on pyruvate reduces the reliance on glycolysis [185]. However, in ES cells,
OCT4 directly binds to the Hk2 and Pkm2 promoter regions upregulating their expression
thereby increasing their glycolytic rate [197]. More importantly, overexpressing Hk2 or
Pkm2 maintains high glycolytic rates and hampers ES cell differentiation, suggesting that
metabolism influences cell fate. Similarly, OCT4, SOX2 and NANOG bind the enhancer
region of the Glut1 gene, thereby increasing glucose uptake in ES cells [198]. Furthermore,
the regulation of many metabolic enzymes does not have to rely solely on key transcription
factors. One example is the miR-290 cluster that represses MBD2, a “reader” of methylated
CpGs, resulting in an increase in c-Myc expression and its downstream targets Pkm2 and
Ldha, which encode essential glycolytic enzymes [199]. RNA-binding proteins including
LIN28a/b also play roles in regeneration and development [200] as they are known to
repress OXPHOS related transcripts, thereby enhancing the naïve-to-primed transition
[201]. Incidentally, the Lin28a/b locus is regulated by c-MYC, which is known to be an
important factor that enhances glycolytic metabolism [199].
Many reports have detailed how cell fate changes are influenced by glucose metabolism
[202,203], but other than substrate availability and enzymes level, hypoxia, and the
transcription factors hypoxia-inducible factor 1α and 2α (HIF1α and HIF2α, respectively)
are major regulators. At atmospheric levels referred to as normoxic conditions (21% O2),
HIF1α and HIF2α are hydroxylated by an oxygen-dependent prolyl hydroxylase, and
subsequently ubiquitinated by the von Hippel-Lindau tumour suppressor protein resulting
in their degradation [204-206]. However, under hypoxic conditions, HIF1α and HIF2α are
stabilized and form heterodimers with HIF1β [207]. This HIF complex accumulates in the
nucleus where it activates response genes, some of which are involved in glycolytic
metabolism such as members of the pyruvate dehydrogenase kinase (PDK) family and
LDHA [195,208]. Thus, the fate of pyruvate is indirectly regulated by HIF1α, as evident
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in EpiSCs where under normoxic conditions HIF1α is stabilized, PDKs are upregulated,
and the pyruvate dehydrogenase complex is phosphorylated and inactivated [195,209].
Concomitantly, pyruvate is converted into lactate by increased levels of LDHA in these
cells [195]. In addition, stabilized HIF1α or overexpressing an oxygen-insensitive form of
the protein that mimics hypoxic conditions reduces OXPHOS metabolism and promotes a
glycolytic phenotype that enhances the transition of naïve ES cells to the primed-like state
[195]. While the low level of mitochondrial respiration in EpiSCs is partially explained by
the HIF1α stabilization, deregulation in ETC components is also seen [195]. Most genes
encoding the ETC components, most notably from complex IV (cytochrome c oxidase),
are significantly downregulated in EpiSCs relative to naïve ES cells and this may be the
result of low levels of peroxisome proliferator-activated receptor-γ coactivator-1β and
ESRRβ [195]. Collectively, the action of ESRRβ and HIF1α play integral role in regulating
the metabolism in the naïve and primed states, respectively.
Although studies have focused on the role of metabolism in the specification of naïve to
the primed state, few reports detail how metabolism is involved in XEN differentiation.
Choi and colleagues characterized the metabolic profile of all three lineages of the
blastocyst using Seahorse XF technology to measures metabolic rate of energy producing
pathways, such as glycolysis and mitochondrial respiration [210]. This group found that
basal mitochondrial respiration was significantly lower in XEN cells when compared to ES
cells, and when challenged with a mitochondrial uncoupler, respiration of XEN cells was
higher and suggested they may have the ability to use OXPHOS metabolism. Despite this
finding, the derivation method and cell culture conditions may have confounded their
results leading to the reported metabolic discrepancies. For example, XEN cells
reprogrammed from fibroblasts have elevated Hk2 and Glut1 levels [101], but Gata4induced ES cells display a gradual reduction in the above targets [211]. Nonetheless these
studies highlight the metabolic complexity and plasticity of XEN cells.
While the role of glycolysis is crucial, the mitochondria is involved in fatty acid oxidation,
glutamine and amino acid metabolism, calcium homeostasis, and waste management, to
name a few [212], but specifically its ETC is the primary source of cellular ROS. One of
the most important determinants of mitochondrial activity is its structure with naïve ES
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cells exhibiting round to circular shaped mitochondria with irregular cristae [195]. Primed
EpiSCs and XEN cells, however, have oval mitochondria with prominent cristae [195,210].
The dynamic process of mitochondrial fission and fusion are tightly regulated and is
usually balanced to maintain a healthy mitochondrial population. During fission,
mitochondrial fission factor (MFF) recruits dynamin-related protein 1 (DRP1) from the
cytosol to constrict the mitochondrial tubules. Chemical inhibition or genetic ablation of
Drp1 is sufficient to induce mitochondrial remodelling and enhance fusion, which is also
as seen in iPSCs where it results in blocking reprogramming [213]. Conversely,
mitochondrial transmembrane GTPases mitofusion-1 and 2 (MFN1 and MFN2,
respectively) enhance fusion of the outer mitochondrial membrane while optic atrophy 1
(OPA1) augments the process on the inner mitochondrial membrane and cristae folds. It is
important to note that MFN1, 2 and OPA1 are all required for viable embryonic
development [214,215], while differentiation requires Ca2+ signaling facilitated by MFN2,
which tethers the mitochondria to the endoplasmic reticulum [216]. Overall, mitochondrial
structure is proxy for its activity, but despite its immature structure in pluripotent stem
cells, it still possesses the ability to modulate metabolism and thus play a pivotal role
instructing lineage-specific decisions.

1.4.3

ROS, NADPH oxidases and development

ROS can have positive and negative consequences on development. The mitochondria and
OXPHOS are major sources of ROS, which are typically classified as by-products of the
incomplete reduction of oxygen from metabolic processes. There are various forms of ROS
such as superoxide anion (O2−), hydrogen peroxide (H2O2) and hydroxyl radical (HO•).
When concentrations are above physiological levels, ROS puts the cell in a state of
oxidative stress [217]. However, at physiological levels, ROS act as a signaling molecule
[218]. In mouse embryos, H2O2 levels increase during the first cleavage, and this continues
to hatching [219], but culturing embryos under exogenous H2O2, exceeding normal levels,
impacts their development and results in embryo arrest [220]. In fact, ES cells cultured for
short periods in 150μM H2O2 undergo a transient G2/M cell cycle arrest but recover due to
the upregulation of scavenging machinery to combat oxidative stress [221]. However, longterm exposure caused growth arrest and apoptosis due to an exhaustion of the antioxidant
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defense system. Pluripotency markers, including Pou5f1, Nanog, and Sox2, are
downregulated in ROS-treated ES cells, triggering the upregulation of mesoderm and
endoderm markers [222] that can be attenuated when antioxidants are supplemented to the
culture media. Results showing the exposure to ROS impacts pluripotency and chronic
exposure to hypoxic conditions can induce apoptosis [223] underscore the importance of
tightly regulating ROS levels to ensure proper embryonic development.
In addition to mitochondrial ROS and its role in physiological processes, cells modulate
and fine-tune oxidative bursts involving ROS released by the NAPDH oxidase (NOX)
family of membrane-associated proteins. Activity and amount of ROS released by NOX is
constitutively active or regulated by cytosolic factors including calcium ions [224].
Regulation dictates what form of ROS is produced, but in general the NADPH-dependent
reduction of oxygen forms O2−, which can be converted by other enzymes into H2O2 [225].
In humans seven NOX proteins are present, NOX1-5, DUOX1 and 2; mice lack a NOX5
homologue [226]. Different NOX isoforms are expressed in specific subcellular
compartments thereby leading to compartmentalized redox signaling: NOX1-5 are tethered
to the plasma membrane, NOX4 is the only isoform present in the mitochondria, NOX2,
4, and 5 are ER-specific, and NOX4 and 5 are tethered to the nuclear membrane. To be
functional, various combinations of these subunits including p22phox, p47phox, NCF2
(p67phox), p40phox, NOXO1, NOXA1 and RAC 1/2, must assemble for the NOX complex
to generate ROS. Although the exception is NOX4, which only requires p22phox to make it
the only constitutively active isoform, the question remains as to what NOX is responsible
and how does ROS influence differentiation?
Nox gene expression in ES cells is generally low relative to various tissues, yet significant
ROS levels generated by these NOXs were detected [227]. Interestingly, pan-NOX
inhibitors diphenyleneiodonium (DPI) and apocynin impaired stem cell proliferation with
apocynin reducing NANOG levels through PI3K/AKT inhibition and the activation of the
canonical WNT/b-catenin signaling. However, DPI enhanced both PI3K/AKT and MAPK
signaling with no effect on WNT/b-catenin signaling. In favour of differentiation,
embryoid bodies derived from ES cells were found to express high levels of p67phox, a
cytosolic activator of NOX2, and a significant amount of intracellular ROS was detected
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[228]. Furthermore, directed differentiation of ES cells towards cardiomyocytes requires
NOX2 [229]. Similarly, F9 cells treated with H2O2 induced differentiation in the absence
of RA, and when F9 cells were treated with RA and DPI this differentiation was blocked
[230]. Together, these findings highlight the role ROS generated from these enzymes play
in maintaining pluripotency and/or inducing differentiation.
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1.5 « Hypothesis and Study Aims »
Broadly, changes in metabolism precede fate commitment and are active in dictating fate.
In this thesis, I used mouse non-stem cell (F9 cells) and stem cell (ES and XEN cells)
models to showcase their ability to recapitulate and shed light on many aspects of in vivo
development. Initially, I hypothesized that undifferentiated F9 cells have a distinct NOX1/4
expression profile and metabolic phenotype when compared to their differentiated XENlike cells. Furthermore, I employed the ES-XEN stem cell model to decipher the metabolic
changes between the two populations. This research investigates the role metabolism, and
its by-products play in differentiation towards the XEN lineage through the following
objectives:
Chapter 2: Identify a transcription factor that regulates Nox1 and Nox4 expression and
determine if the activity of these two enzymes is necessary and/or sufficient for F9 cell
differentiation.
Key finding: ROS generated by NOX1 and NOX4, which are regulated by the
GATA6 transcription factor, is necessary but not sufficient for F9 cell differentiation
towards XEN-like lineage.
Chapter 3: Characterize the metabolic profile of differentiated F9 cells and assess if
metabolism can influence cell fate. In addition, comment on whether cell passage
influences metabolism and cell fate.
Key finding: Differentiated F9 cells exhibit a reliance on glycolytic metabolism,
and despite having structurally mature mitochondria this is largely due to disruption in ETC
complex II components. Extensive passaging altered metabolic profile of F9 cells without
influencing differentiation potential.
Chapter 4: Determine the bioenergetic profile of embryo-derived XEN cells and elucidate
the role of lactate in XEN differentiation in vitro.
Key findings Feeder-free XEN cells maintain high lactate levels by increased
LDHA activity and re-routing pyruvate away from the mitochondria. Exogenous lactate
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supplementation or promoting intracellular lactate accumulation enhances XEN
differentiation in vitro.
Overall, my results highlight how ROS and metabolism contribute to XEN differentiation
in vitro and may serve to better understand how in vivo development occurs.
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Chapter 2

2

« NOX1 and NOX4 are required for the differentiation of
mouse F9 cells into extraembryonic endoderm »
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2.1 « Introduction »
Mouse primitive endoderm formation can be recapitulated in vitro using F9
teratocarcinoma cells, which are chemically differentiated to form extraembryonic
endoderm (XEN)-like cells when treated with retinoic acid (RA) [1] or to parietal
endoderm (PE)-like cells when treated with RA and cAMP analog [2]. F9 cell
differentiation is accompanied by the appearance of molecular markers, and morphological
changes, many resulting from the activation of the canonical WNT/β-catenin pathway [1].
When WNT is absent, a destruction complex serves to phosphorylate β-catenin marking it
for ubiquitination and proteasomal degradation. When present, WNT binds to a Frizzled
receptor causing Dishevelled (DVL) to move towards the plasma membrane, where it
recruits AXIN out of the destruction complex making it non-functional and allowing βcatenin to accumulate and translocate to the nucleus where it binds to and activates the Tcell-factors-Lymphoid enhancer factors (TCF-LEF) family of transcription factors. We
previously reported that differentiation is also accompanied by a burst of reactive oxygen
species (ROS), which is necessary as F9 cells treated with antioxidants or when treated
with a non-specific NADPH oxidase inhibitor failed to differentiate [3]. H2O2 treatment
alone induces XEN-like differentiation indicates that ROS are sufficient to initiate this
process [3]. To explore this further, we recently reported that DVL in undifferentiated F9
cells associates with nucleoredoxin (NRX) a redox sensitive protein that scavenges ROS,
and is known to play a role in differentiation [4]. This association and regulation of the
WNT/β-catenin pathway occurs in other systems [5-8], and we propose that this inhibition
prevents aberrant canonical Wnt signaling when WNT is absent as DVL in this state cannot
recruit AXIN away from a destruction complex. Thus, in the presence of ROS, NRX
dissociates from DVL and the Wnt pathway is primed awaiting the ligand.
The source of the ROS when F9 cells are treated with RA was investigated and the
candidates identified are members of the NADPH oxidase (NOX) family, which are
sources of superoxide anions and H2O2 [9]. In F9 cells Nox1-4 and Duox2 are upregulated
following RA treatment [3]. Duox1 is not RA-responsive and may not be involved in XENlike differentiation. Nox1 and Nox4 are upregulated to the greatest extent following RA
treatment and given the previous reports suggesting a link differentiation, we specifically
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selected NOX1 and NOX4 to interrogate as the candidates involved in the ROS production
during RA-induced differentiation in F9 cells.
To address that the activity of NOX1 and/or NOX4 is/are responsible for producing the
ROS that is necessary and sufficient to induce F9 cells to differentiate, we first tested and
found Nox1/4 genes are under the control of GATA6, the master regulator of endoderm
differentiation [10]. Inhibiting all NOX activity, or specifically inhibiting NOX1 blocked
differentiation, and knocking down Nox1 or Nox4 expression using an siRNA approach
complemented the chemical inhibitor data. Confident from these studies that both NOX
proteins were necessary for differentiation, we expected that their overexpression would
induce XEN-like differentiation. However, despite the overexpression of each having
increased ROS levels, no significant difference in β-catenin-dependent TCF activity
relative to controls was seen and neither would induce XEN-like differentiation. Together,
these results indicate that RA-induced differentiation of F9 cells requires a coordinate
increase in NOX activity that is due in part to the upregulation of the Nox genes by GATA6.
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2.2 « Materials and Methods »
2.2.1

Cell culture conditions and transfections

Mouse teratocarcinoma F9 cells (ATCC) were cultured in Dulbecco’s modified Eagles
medium (Lonza) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillinstreptomycin (Lonza) and incubated at 37°C and 5% CO2. Cells were treated with 10−7 M
retinoic acid (RA all-trans; Sigma Aldrich) or dimethyl sulfoxide (DMSO; Caledon) as a
negative control. Cells were co-treated with 1μM VAS2870 (Sigma) and RA 24 hours after
seeding and grown for 3 days or co-treated with 250nM ML171 (Tocris) and RA and grown
for 4 days as described above. F9 cells were reverse transfected using Lipofectamine 2000
(Thermo Fisher Scientific). Freshly passaged cells were added to a 35mm dish already
containing a total of 4μg of DNA plasmid. Culture media was replenished 6–8h posttransfection and transfected cells were selected using antibiotics.

2.2.2

Plasmids

The following plasmids were used: pCMV-Gata6 (Provided by Dr. E. E. Morrisey,
University of Pennsylvania); pcDNA-mNox4 (Gift from Dr. M. Jaconi, University of
Geneva), pcDNA3.1-mNox1 (Addgene #58340), pRL-TK (Gift from Dr. R. DeKoter,
University of Western Ontario), piLenti-siRNA-GFP against Nox1 and Nox4 (abm; Table
2). Plasmids were transiently expressed and are under a constitutively active promoter.
Table 2: siRNA sequences against mouse Nox1 and Nox4
Target

Sequence (5’ to 3’)

piLenti-siRNA-GFP-Nox1 #1

CTATTTAACTTCGAACGCTACAGAAGAAG

piLenti-siRNA-GFP-Nox1 #2

TGCTTCCATCTTGAAATCTATCTGGTACA

piLenti-siRNA-GFP-Nox4 #1

ACATTTGGTGTCCACTTTAAAGTAGTAGG

piLenti-siRNA-GFP-Nox4 #2

TCCAGTGGTTTGCAGATTTACTCTGTGTG
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2.2.3

Immunoblot analysis

Protein lysates were collected in RIPA buffer containing 150mM sodium chloride, 1.0%
Triton X-100, 0.5% deoxycholate, 0.1% SDS and 50mM Tris pH 8.0. Protein
concentrations were determined using the DC™ Protein Assay (Bio-Rad), and 20–50μg of
protein lysate was mixed 2:1 with 3X SDS loading buffer containing 10% βmercaptoethanol and separated on 10% polyacrylamide gels by electrophoresis for 2h with
100V

at

4°C.

Following

electrophoresis,

the

proteins

were

wet-transferred

electrophoretically to Immunoblot PVDF membrane (Bio-Rad) for 16 h with 20V at 4°C
using a Tris-glycine transfer buffer containing 20% methanol. Membranes were incubated
in Tris buffered saline with 0.1% Tween-20 (TBS-T) containing 10% w/v skim milk
powder for 1h shaking at room temperature, then incubated with primary antibody
overnight at 4°C. Following 3 washes 5 min each in TBS-T, membranes were incubated
with secondary antibody for 2 h at room temperature, followed by 3 washes for 10 min
each in TBS-T. SuperSignal West Pico Chemiluminescent Detection Kit (Thermo Fisher
Scientific) was used to detect the presence of secondary antibodies conjugated to
horseradish peroxidase (HRP). Signals were captured using a Molecular Imager Gel Doc
XR system (Bio-Rad) with Quantity One Software. The primary antibodies used were
directed against KERATIN-8 (1:10; 55 kDa, Developmental Studies Hybridoma Bank),
OCT4 (1:1000; 45 kDa, Cell Signaling Technology), DAB2 (1:10000; 96 kDa, BD
Transduction Laboratories), NOX1 (1:10000; 65 kDa, Thermo Fisher Scientific), NOX4
(1:10000; 67 kDa, Novus Biologicals) and β-ACTIN (1:10000; 43 kDa, Santa Cruz; βACTIN levels do not change significantly between cell types or treatments.) dissolved in
3% Bovine Serum Albumin w/v in TBS-T. Secondary anti-rat (1:1000), anti-mouse
(1:1000) and anti-rabbit (1:1000) antibodies were HRP-conjugated and dissolved in 3%
skim milk w/v in TBS-T.

2.2.4

Quantitative reverse transcription polymerase chain reaction

Total RNA from treated and/or transfected cells was isolated and collected using the
RNeasy Mini Kit (Qiagen). RNA was reverse transcribed into first strand cDNA using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and the
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manufacturer's recommendations. The CFX Connect Real-Time PCR Detection System
(Bio-Rad) was used for qRT-PCR analysis. Each reaction contained 500nM of each primer,
SensiFAST SYBR Mix (FroggaBio), and 1μL of cDNA. Primers were designed to Gata6,
Dab2, Nox1, Nox4 and L14 (Table 3). Analysis of gene expression was determined using
the comparative cycle threshold method. Gene expression was normalized to the
constitutively expressed L14 gene and relative values were normalized by comparing
treatments to DMSO-treated and/or control plasmid transfected control cells to determine
fold change. L14 expression does not change significantly between cell types or treatments.

2.2.5

TCF reporter assay

Cells were transfected with pGL3-BARL and pRL-TK (transfection control) and then
treated with DMSO (vehicle control), RA, or co-transfected with Nox1 or Nox4 plasmids
in equal amounts of DNA. Protein lysates were collected 3 days post-treatment or posttransfection using the Dual-Glo Luciferase Assay System and the manufacturer's
recommendations (Promega). Luciferase expression was quantified using the GloMax
Multi Detection System (Promega). Values were presented as relative luminescence
derived from the quotient of firefly luminescence (pGL3-BARL) and Renilla luminescence
(pRL-TK).

2.2.6

ROS detection

Intracellular ROS was detected using both an Amplex Red Assay and CM-H2DCFDA
(Thermo Fisher Scientific). Briefly, Amplex Red was prepared in DMSO, and cells were
treated following manufacturer’s instructions with slight modifications. Following
treatment or transfection, cells were detached and resuspended in 100μM Amplex Red in
measurement media buffer (120mM KCl, 5mM KH2PO4, 5mM EDTA, 10mM HEPES,
5mM MgCl2 at pH 7.40) supplemented with 40μg/mL Saponin (Sigma) and 0.2units/mL
HRP (Thermo Fisher Scientific). Immediately after incubation, cells were seeded onto an
opaque 96-well plate and florescence was measured at Ex/Em of 530/590nm using the
GloMax Multi Detection System (Promega). Values were normalized to protein
concentration. For CM-H2DCFDA staining cells following treatment with DMSO or RA
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were incubated in Hank’s Balanced Salt Solution for 15 min at 37°C and 5% CO2 with
2μM CM-H2DCFDA dissolved in DMSO and 10μg/ml Hoechst 33342 (Thermo Fisher
Scientific). Immediately after incubation, cells were rinsed twice with PBS and images
were captured using a Zeiss Axio Observer A1 inverted microscope with a QImaging
Retiga CCD.
Table 3: Primer sequences for mouse qRT-PCR target genes
Target

Forward sequence (5’ to 3’)

Reverse sequence (5’ to 3’)

Gata6

ATGGCGTAGAAATGCTGAGG

TGAGGTGGTCGCTTGTGTAG

Dab2

GGAGCATGTAGACCATGATG

AAAGGATTTCCGAAAGGGCT

Nox1

AATGCCCAGGATCGAGGT

GATGGAAGCAAAGGGAGTGA

Nox4

GATCACAGAAGGTCCCTAGCA

GTTGAGGGCATTCACCAAGT

L14

2.2.7

GGGAGAGGTGGCCTCGGACGC GGCTGGCTTTCACTCAAAGGCC

MTT assay

F9 cells were cultured and treated with DMSO, RA, VAS2870 or ML171 for 4 days
followed by incubation in MTT reagent (Sigma) for 2–4 hours at 37°C and 5% CO2. Media
was removed and DMSO was added to solubilize crystals, and then plates were incubated
overnight in the dark. Absorbance values were measured at 570nm with a reference
wavelength at 650nm using the GloMax®-Multi Detection System (Promega).

2.2.8

Statistical analysis

Data from qRT-PCR, densitometric analysis of immunoblots and Luciferase assays were
gathered format least three independent biological replicates. qRT-PCRs were run in
technical duplicates. Comparisons of data between control and experimental groups were
performed using a one-way ANOVA with Tukey’s honest significant difference (HSD)
post-hoc test or a Student’s t-Test (SPSS Statistics for Windows Version 19.0, IBM Corp.
Released 2010, Armonk, NY). Student’s t-Test was used for statistical analysis of data
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when comparing control to only one experimental data set and (*) was used to denote
significant difference. All other data were analyzed using a one-way ANOVA followed by
Tukey’s HSD test and letters were used to indicate significant differences. P-values were
considered statistically significant at the 0.05 level. Statistical data are presented as the
mean ± SEM.
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2.3 « Results »
2.3.1

RA increases NOX1 and NOX4 levels and ROS production

F9 cells treated with RA for 4 days showed a significant increase (P < 0.05) in the
expression of Nox1 (Figure 2-1A) and Nox4 (Figure 2-1B), as we have shown previously
[3]. Furthermore, NOX1 and NOX4 protein levels also increased after RA treatment
(Figure 2-1C), however, the levels of accessory subunits required for NOX protein
function, including NOXA1, NOXO1 and p22PHOX (Figure 2-1D), or the transcripts
encoding Rac1 (Figure 2-1E), did not appear to change during differentiation. Thus, the
subunits to generate functional NOX1 and NOX4 were present in undifferentiated F9 cells.
More importantly, elevated ROS production accompanying differentiation was detected
visually by CM-H2DCFDA (Figure 2-1F), and the significant increase in levels were
validated quantitatively using Amplex Red (Figure 2-1G). When F9 cells were
differentiated towards a PE-like lineage, Nox1 (Figure 2-2A) and Nox4 (Figure 2-2B)
transcript levels decreased significantly (P < 0.05) when compared to DMSO- and RAtreated F9 cells. It should be noted, however, that a significant oxidative state (P < 0.05;
Figure 2-2C) was maintained, thus suggesting another potential source of ROS,
mitochondrial, when cells differentiate to PE-like lineage.
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Figure 2-1: RA increases NOX1 and NOX4 levels and ROS production.
Total RNA and protein were harvested from F9 cells treated with either DMSO or
RA for 4 days. (A) Nox1 and (B) Nox4 expression following DMSO or RA treatment.
(C) NOX1 and NOX4 protein levels following DMSO and RA treatment. (D) Protein
levels of NADPH oxidase complex accessory subunits NOXA1, NOXO1, and
p22Phox following DMSO and RA treatment. (E) Rac1 expression following DMSO
or RA treatment. (F) ROS detection using CM-H2DCFDA or (G) Amplex Red in F9
cells treated with either DMSO or RA. β-ACTIN was used as a loading control. A
total of 3-5 independent experiments were analyzed and results presented as mean ±
SEM. * denotes significance (P < 0.05) tested by a Student’s t-Test.
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Figure 2-2: F9 cells show reduction in Nox1 and Nox4 expression yet maintain
high oxidative state at PE.
Total RNA was collected from F9 cells induced to differentiate into XEN-like and
PE-like cells. Expression of Nox1 (A) and Nox4 (B) following DMSO, RA, and RA
with db-cAMP treatment. (C) Oxidative state of F9 cells following treatment with
DMSO, RA, RA with db-cAMP. A total of 4 independent experiments were
analyzed and results are presented as mean ± SEM. Letters denote groups of
significance (P < 0.05) tested by a One-Way ANOVA followed by a Tukey’s test.
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2.3.2

Gata6 induction results in increased NOX1 and NOX4 levels

Gata6, a master regulator of PrE formation, is significantly upregulated (P < 0.05) in F9
cells treated with RA (Figure 2-3A). This evidence, together with the presence of GATAbinding sites in the Nox1 promoter [11], and that GATA6 is responsible for increased Nox1
transcription in Caco-2 cells [12] led us to propose that GATA6 might be responsible for
the upregulation of Nox1 and Nox4 in F9 cells. To address this, we overexpressed Gata6
and then analyzed Nox1 and Nox4 expression and protein levels using qRT-PCR and
immunoblot analysis, respectively. When Gata6 was overexpressed alone (Figure 2-3B),
it induced XEN-like differentiation [10], as evident by the increase in the differentiation
markers DAB2 and KERATIN-8, and the decrease in the pluripotency marker OCT4
(Figure 2-3C). Gata6 overexpression also induced a significant increase (P < 0.05) in Nox1
(Figure 2-3D) and Nox4 (Figure 2-3E) expression. These changes were also associated with
an apparent increase in the levels of NOX1 and NOX4 protein (Figure 2-3F), which were
comparable to those seen in RA-treated F9 cells. Together, results indicate that changes in
NOX1 and NOX4 levels accompany F9 cell differentiation and would suggest that the
increase in ROS is due in part to these changes. Thus, studies were conducted to determine
if the activity of NOX1 and/or NOX4 is/are required for XEN-like differentiation.
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Figure 2-3: Gata6 induction results in increased NOX1 and NOX4 levels.
Total RNA and protein were collected from F9 cells treated with DMSO or RA or
transfected with pcDNA3.1-EV (EV) and treated with either DMSO or RA or transfected
with pcDNA3.1-Gata6 (Gata6) and cultured 4 days. (A) Gata6 expression of F9 cells
treated with DMSO or RA. (B) Gata6 expression of F9 cells transfected with EV or
Gata6. (C) Immunoblot analysis for DAB2, KERATIN-8 and OCT4 in F9 cells
transfected with EV and treated with DMSO or RA or F9 cells ectopically expressing
Gata6. (D) Nox1 and (E) Nox4 expression in F9 cells transfected with EV and treated
with DMSO or RA, or F9 cells ectopically expressing Gata6. (F) Immunoblot analysis
for NOX1 and NOX4 in F9 cells transfected with EV and treated with DMSO or RA, or
F9 cells ectopically expressing Gata6. β-ACTIN was used as a loading control. A total
of 3 independent experiments were analyzed and results are presented as mean ± SEM.
* denotes significance (P < 0.05) tested by a Student’s t-Test, whereas letters denote
groups of significance (P < 0.05) tested by a One-Way ANOVA followed by a Tukey’s
test.
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2.3.3

Pan-NOX inhibition blocks RA-mediated differentiation

Our previous study revealed that Diphenyleneiodonium chloride (DPI), an inhibitor of
flavoenzymes that produce ROS attenuates RA-induced XEN-like differentiation [3]. DPI
is used frequently to inhibit ROS production, but since it acts on numerous
oxidoreductases, including the NOX proteins [13] the source of the ROS may not be
completely NOX-dependent. To test the hypothesis that the activity of the NOX proteins
is necessary for XEN-like differentiation, F9 cells were treated with NOX inhibitors.
First, the pan-NOX inhibitor, VAS2870 [14,15] was used to determine specifically if
members of the NOX family were necessary for F9 cells to differentiate to XEN-like cells.
VAS2870 inhibits NOX1, NOX2 [15] and NOX4 [14], and although it can inhibit all NOX
isoforms it does not serve as an antioxidant because it has no O2- scavenging effect [14].
VAS2870 treatment showed no significant effect on cell viability relative to the DMSO
control (Figure 2-4A), but it did cause a significant reduction (P < 0.05) in the amount of
ROS produced in cells co-treated with RA (Figure 2-4B). Cells treated with DMSO-, RA-,
VAS2870-, or co-treated with VAS2870 and RA were examined using qRT-PCR for Dab2
(Figure 2-4C), and immunoblot analysis for DAB2, KERATIN-8 and OCT4 (Figure 24D). Results show that Dab2 expression was not significantly different between DMSO
and VAS2870. The expression of Dab2 in F9 cells treated with RA alone was, as expected,
significantly higher (P < 0.001) from the DMSO treatment, but surprisingly dramatically
reduced in cells treated with RA and VAS2870 (Figure 2-4C). Immunoblot analysis
showed comparable results with elevated DAB2 levels following RA treatment alone
(Figure 2-4D). A similar increase was seen with the KERATIN-8 marker, while OCT4
levels decreased with RA treatment. The OCT4 signal, however, remained elevated in
VAS2870 and RA-treated cells, and was comparable to that seen in DMSO-treated cells
(Figure 2-4D). Thus, inhibiting NOX activity attenuates RA-mediated differentiation,
which suggests strongly that NOX complexes are necessary for F9 cell differentiation.
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2.3.4

NOX1-specefic inhibition attenuates RA-induced
differentiation

F9 cells were treated with 250nM of ML171, the IC50 of this NOX1-specific inhibitor [16].
ML171 has no ROS scavenging effects [16], and at this concentration it did not influence
F9 cell viability (Figure 2-4A). Co-treatment with RA, however, showed significantly
lower ROS levels than those seen in RA-treated F9 cells alone (Figure 2-4B). qRT-PCR
analysis revealed that Dab2 expression in DMSO- and ML171-treated F9 cells were not
significantly different from each other, but both were significantly different (P < 0.001)
from that in RA-treated F9 cells, and F9 cells co-treated with RA and ML171 (P < 0.05)
(Figure 2-4E). Since Dab2 expression in cells co-treated with RA and ML171 was
significantly lower (P < 0.05) than that in RA-treated F9 cells (Figure 2-4E), but not as low
as that in cells co-treated with RA and VAS2870 (Figure 2-4C) this suggest that inhibiting
NOX1 alone was not sufficient in completely attenuating XEN-like differentiation.
Immunoblot analysis for DAB2 and KERATIN-8 showed no signals in DMSO- or ML171treated F9 cells (Figure 2-4F). F9 cells co-treated with ML171 and RA, however, showed
DAB2 and KERATIN-8 signals (Figure 2-4F), but they appeared to be of less intensity
than that seen in the RA alone lane. OCT4 signals were seen in DMSO-, ML171 and RAand ML171-treated F9 cells, but again the intensity appeared reduced in RA-treated F9
cells with or without ML171 (Figure 2-4F). Since NOX4 was not targeted chemically, as
there are no known specific inhibitor(s) that do not have ROS scavenging effects or
additionally target other NOX proteins [16], we can only conclude that NOX proteins are
required for XEN-like differentiation, and that NOX1 specifically plays a role in this
process.
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Figure 2-4: Chemical inhibition of NOX proteins attenuates RA-mediated
differentiation of F9 cells.
(A) MTT cell viability assay of F9 cells treated with DMSO, RA, VAS2870 or ML171.
(B) F9 cells were treated with DMSO, RA, VAS2870 and RA, or ML171 and RA and
assayed for ROS production using Amplex Red. (C) Dab2 expression of F9 cells treated
with DMSO, RA, VAS2870, or VAS2870 and RA. (D) Immunoblot analysis for DAB2,
KERATIN-8, and OCT4 in F9 cells treated with DMSO, RA, VAS2870, or VAS2870
and RA. (E) Dab2 expression of F9 cells treated with DMSO, RA, ML171, or ML171
and RA. (F) Immunoblot analysis for DAB2, KERATIN-8 and OCT4 in F9 cells treated
with DMSO, RA, ML171, or ML171 and RA. β-ACTIN was used as a loading control.
A total of 4 independent experiments were analyzed and results are presented as mean
± SEM. Letters denote groups of significance (P < 0.05) tested by a One-Way ANOVA
followed by a Tukey’s test.
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2.3.5

Nox1 and Nox4 knockdown decreases ROS production

To corroborate the chemical inhibitor data, F9 cells were transfected with a siRNA vector
to knockdown Nox1, Nox4 expression or a scrambled siRNA and treated with DMSO or
RA as negative and positive controls, respectively. Since there is a significant increase (P
< 0.05) in Nox1/4 expression after RA treatment (Figure 2-1A, B), F9 cells were treated
with RA and the siRNA knockdown efficiency was compared to that seen with the RAtreated scrambled siRNA control. F9 cells containing Nox1 (Figure 2-5A) and Nox4 (Figure
2-5C) siRNAs showed significantly less expression of the respective Nox genes (P < 0.05)
when compared to the RA-treated scrambled control. The levels of NOX1 (Figure 2-5B)
and NOX4 (Figure 2-5D) were examined to test if the knockdown effects were seen at the
protein level. Results show that levels were significantly lower (P < 0.05) in cells
containing the targeting siRNAs and treated with RA, compared to RA-treated F9 cells
transfected with the scrambled siRNA. Furthermore, knocking down NOX1 and NOX4 in
F9 cells treated with RA showed a significant reduction (P < 0.05) in ROS levels compared
to those seen in cells transfected with the scrambled siRNA and treated with RA (Figure
2-5E).
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Figure 2-5: Nox1 and Nox4 knockdown reduces ROS production.
Total RNA was collected from F9 cells transfected with scrambled (scr) si-RNA, siNox1 and/or si-Nox4 siRNA and cultured 4 days with RA treatment. (A) Expression
of Nox1 and (B) NOX1 protein levels following transfection with scr or si-Nox1 and
RA treatment. (C) Expression of Nox4 and (D) NOX4 protein levels following
transfection with scr or si-Nox1 and RA treatment. (E) ROS production detected using
Amplex Red of F9 cells transfected with scr, si-Nox1, or si-Nox4 and treated with RA.
β-ACTIN was used as a loading control. A total of 3 independent experiments were
analyzed and results are presented as mean ± SEM. * denotes significance (P < 0.05)
tested by a Student’s t-Test, whereas letters denote groups of significance (P < 0.05)
tested by a One-Way ANOVA followed by a Tukey’s test.
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2.3.6

Nox1 and Nox4 knockdown attenuates RA-induced
differentiation

qRT-PCR and immunoblot analysis were used to determine if the knockdowns would
affect Dab2 (Figure 2-6A) or levels of DAB2, KERATIN-8, and/or OCT4 protein (Figure
2-6B-D). Analysis showed that compared to RA treatment, a significant reduction (P <
0.05) in Dab2 expression (Figure 2-6A) was seen when either Nox1 or Nox4 expression
was knocked down. Also, there was no significant difference between the individual
knockdowns compared to that due to the knockdown of both genes together. As expected,
DAB2 and KERATIN-8 levels were low or not detected in cells transfected with the
scrambled siRNA and treated with DMSO, however they did increase significantly in cells
treated with RA (Figure 2-6B, D). Also, it is interesting to note that DAB2 levels in cells
transfected with the targeted siRNAs and treated with RA were not significantly different
between those transfected with the scr siRNA and treated with either DMSO or RA.
However, KERATIN-8 levels were significantly lower in cells transfected with targeted
siRNAs and treated with RA than RA treated cells transfected with scr siRNA (P < 0.05)
(Figure 2-6D). OCT4 levels were high in the DMSO-treated scr siRNA control cells, but
these were significantly reduced (P < 0.05) in F9 cells transfected with either the scr siRNA
and treated with RA or those transfected with the siRNA targeting vectors and treated with
RA (Figure 2-6B, C). Together with the inhibitor data, these results would indicate that
NOX1 and NOX4 play a role in XEN-like differentiation.
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Figure 2-6: Nox1 and Nox4 knockdown attenuates RA-induced differentiation.
RNA was collected from F9 cells transfected with scrambled (scr) si-RNA, si-Nox1
and/or si-Nox4 siRNA and cultured 4 days with RA treatment. (A) Dab2 expression of
F9 cells transfected with scr, si-Nox1, or si-Nox4 and treated with RA. (B) Immunoblot
analysis for DAB2, KERATIN-8, and OCT4 in F9 cells transfected with scr, si-Nox1,
or si-Nox4 and treated with RA. (C) Densitometric analysis for OCT4, and (D) DAB2,
KERATIN-8 in F9 cells transfected with scr, si-Nox1, or si-Nox4 and treated with RA.
β-ACTIN was used as a loading control. A total of 3 independent experiments were
analyzed and results are presented as mean ± SEM. Letters and symbols denote groups
of significance (P < 0.05) tested by a One-Way ANOVA followed by a Tukey’s test.
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2.3.7

Overexpressing Nox1 and Nox4 increases ROS production

Since the inhibitor and genetic knockdown studies attenuated differentiation, and our
earlier study showing F9 cells treated with H2O2 differentiate into XEN-like cells [3], it
seemed logical to propose that Nox overexpression should induce F9 cell differentiation.
Towards that end, F9 cells were transfected with pcDNA3.1-EV and treated with either
DMSO or RA or transfected with pcDNA3.1-Nox1 or -Nox4. The relative degree of
overexpression was determined by qRT-PCR, and results showed an approximate 700 and
1800-fold increase for Nox1 (Figure 2-7A) and Nox4 (Figure 2-7B), respectively.
Similarly, NOX1 and NOX4 protein levels were higher in F9 cells transfected with the
respective Nox construct (Figure 2-7C, D). Having established that transfection resulted in
elevated NOX1 and NOX4 levels, we examined if this would affect ROS levels. For the
positive control, F9 cells transfected with pcDNA3.1-EV and treated with RA showed a
significant increase (P < 0.05) in ROS levels over those seen in transfected cells treated
with DMSO (Figure 2-7E). Note that the levels seen following RA treatment were
comparable to those in cells transfected with either Nox1 or Nox4.
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Figure 2-7: Overexpressing Nox1 and Nox4 increases ROS production.
Total RNA was collected from F9 cells transfected with an empty vector (EV) control,
pcDNA3.1-Nox1 or pcDNA3.1-Nox4 and cultured 4 days. (A) Nox1 and (B) Nox4
expression

following

transfection

of

pcDNA3.1-Nox1

or
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respectively, and relative to EV transfected cells. (C) NOX1 and (D) NOX4 protein
levels following transfection of pcDNA3.1-Nox1 or pcDNA3.1-Nox4, respectively,
relative to EV transfected cells. (E) ROS production using Amplex Red in F9 cells
transfected with EV and treated with DMSO or RA or transfected with pcDNA3.1-Nox1
or pcDNA3.1-Nox4. β-ACTIN was used as a loading control. A total of 3 independent
experiments were analyzed and results are presented as mean ± SEM. * denotes
significance (P < 0.05) tested by a Student’s t-Test, whereas letters denote groups of
significance (P < 0.05) tested by a One-Way ANOVA followed by a Tukey’s test.
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2.3.8

Nox overexpression activates canonical Wnt signaling, but
does not promote differentiation

The overexpression results and those from earlier studies [3,4] suggested that the increased
levels in ROS due to ectopic Nox1 or Nox4 expression would activate canonical WNT/βcatenin signaling. To test this F9 cells were co-transfected with Nox1 or Nox4, and the
firefly luciferase pGL3-BARL reporter that is used as readout for active WNT/β-catenin
signaling [17]. All cells were transfected with the Renilla luciferase construct, TK-RL to
normalize for luciferase expression. RA-treated F9 cells transfected with pcDNA3.1-EV
showed a significant increase (P < 0.05) in TCF activity compared to the DMSO control
(Figure 2-8A). F9 cells overexpressing Nox1 or Nox4 also showed increased TCF activity,
however, this increase was less than that seen in RA-treated F9 cells and was not significant
from either RA or DMSO treatments (Figure 2-8A). Nevertheless, F9 cells overexpressing
Nox1 or Nox4 were analyzed for XEN-like differentiation, and as expected Dab2
expression relative to the L14 loading control was significantly higher (P < 0.001) in RAtreated F9 cells than that in DMSO treated cells (Figure 2-8B, C). Dab2 expression
resulting from either the overexpression of Nox1 (Figure 2-8B) or Nox4 (Figure 2-8C) was
not significantly different from that in DMSO-treated F9 cells, suggesting that
differentiation had not occurred. Similarly, DAB2 protein was only present in RA-treated
cells, and this evidence of differentiation was seen in the corresponding increase in
KERATIN-8 and concomitant decrease in OCT4 levels (Figure 2-8D). KERATIN-8
signals were not seen in DMSO-treated, Nox1-, Nox4-, or Nox1 and Nox4-overexpressing
cells, and the appearance of OCT4 in the same samples was indicative that cells had not
differentiated because of Nox1 and/or Nox4 overexpression (Figure 2-8D). Thus, even
though overexpressing Nox1 or Nox4 in F9 cells increased ROS levels, there was no
significant activation of Wnt/β-catenin signaling or XEN-like differentiation. Therefore,
NOX1 and NOX4-derived ROS is not sufficient to induce XEN-like differentiation.
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Figure 2-8: Nox overexpression activates canonical Wnt signaling but does not
promote differentiation.
(A) Dual-luciferase assay of TCF activity in F9 cells transfected with EV and treated
with DMSO or RA or transfected with pcDNA3.1-Nox1 or pcDNA3.1-Nox4. Dab2
expression in F9 cells transfected with EV and treated with DMSO or RA or transfected
with (B) pcDNA3.1-Nox1 or (C) pcDNA3.1-Nox4. (D) Immunoblot analysis for DAB2,
KERATIN-8, and OCT4 in F9 cells transfected with EV and treated with DMSO or RA,
or transfected with pcDNA3.1-Nox1, pcDNA3.1-Nox4 or both vectors. β-ACTIN was
used as a loading control. A total of 3 independent experiments were analyzed and
results are presented as mean ± SEM. Letters denote groups of significance (P < 0.05)
tested by a One-Way ANOVA followed by a Tukey’s test.
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2.4 « Discussion »
ROS, which are by-products of metabolic processes produced through the incomplete
reduction of oxygen, create oxidative stress on cells, and damage nucleic acids, proteins,
and lipids. Although this damage is linked to age-related and other human disease
pathogenesis, recent studies now show cells benefitting from ROS as a second messenger
to modulate biological processes such as differentiation, apoptosis, and proliferation
[18,19]. F9 cells are induced to form XEN-like cells when treated with RA, an in vitro
process that mimics a very early event in mouse embryogenesis. Differentiation is
accompanied by numerous changes in gene expression and morphology and requiring
several signaling pathways. One of these pathways involves canonical WNT/β-catenin
signaling [1], where Wnt6 is induced by GATA6 [10] a master regulator of PrE formation.
Regulation of this WNT pathway occurs in a redox-regulated manner [3] involving NRX
and DVL, the latter serving as a lynchpin in the three major WNT signaling pathways [4].
We have shown previously that cytosolic ROS plays a role in F9 cell differentiation [3].
ROS impact positively on the canonical WNT/β-catenin signaling pathway, and the Nox
genes that are upregulated in response to RA were identified as candidates responsible for
this cytosolic ROS [3].
The expression profiles of the six mouse Nox genes led us to interrogate Nox1 and Nox4,
which were the most upregulated in differentiated F9 cells [3]. In addition to RA (Figure
2-1A-D), both genes are upregulated, and the level of the corresponding proteins increase
in response to GATA6 (Figure 2-3D-F). Previous studies provide evidence for a link
between GATA6 and Nox genes, specifically Nox1, which is activated directly by GATA6
[11,12]. NOX1 impact on WNT signaling occurs in colonic and intestinal epithelial cells
[8,20], and it is known to post-transcriptionally increase the levels of Keratin-8 [21], a
cytokeratin encoded by transcripts that increase during RA-induced F9 cell differentiation
[22]. Furthermore, NOX1 and NOX4 activate the p38 MAPK pathway in mouse and
human cells [23,24], which is also required to inhibit GSK-3β thereby maintaining WNT
in the on-state during XEN-like differentiation [25]. Evidence for NOX4 interacting with
WNT signaling or regulated by GATA transcription factors is not as compelling as NOX1.
However, it is interesting to note a study showing the opposite scenario exists in
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cardiomyocytes, where NOX4 increases Gata4 expression [26]. Other reports have linked
NOX4 to cell proliferation, cytoskeletal reorganization, migration and differentiation [2730], which incidentally are processes that F9 cells participate in during differentiation [31].
Having identified that NOX1 and NOX4 were under the regulation of GATA6, we next
used chemical inhibitors to test whether the activity of both NOX proteins was required for
differentiation. A previous study from our lab using the non-specific flavoenzyme inhibitor
DPI, demonstrated the necessity for ROS in the differentiation of F9 cells [3]. Since DPI
acts on other non-NOX flavoenzymes [13], we refined the approach and used a pan-NOX
and NOX1-specific inhibitor to test their effects on differentiation (Figure 2-4). Both
inhibitors affected differentiation at the gene and protein levels, but VAS2870, the panNOX inhibitor was more potent than ML171, the selective inhibitor of NOX1 activity
(Figure 2-4). Although there could be many reasons to explain this, the fact that all the
NOX proteins were being inhibited by VAS2870 would suggest that multiple NOX
proteins contribute to the ROS required for differentiation. This argument would be tested
later as these chemical inhibitor studies proved informative but required a genetic approach
to corroborate the data. Mouse knockout models exist for all 6 Nox genes [14,32,33], but
disrupting any one of them individually or in combination does not appear to have obvious
effects in embryos. Therefore, an alternative strategy was to use siRNAs, which have had
some success in knocking down the expression of specific Nox genes [14]. This approach
was used to knockdown Nox1 and/or Nox4 gene expression, and it resulted in reduced
expression and protein levels of NOX1 and NOX4 (Figure 2-5A-D). Knockdown led to the
attenuation of differentiation, as evident by the decrease in the markers of differentiation,
and the maintenance of pluripotency as noted by the persistence of the OCT4 signal (Figure
2-6A-D). Together with the inhibitor results, this data adds support that NOX activity,
specifically from NOX1 and NOX4, is necessary for XEN-like differentiation. While
encouraged by these results, the contribution to the differentiation process by the two other
Nox genes and Duox2 that are upregulated by RA in F9 cells needs to be considered and is
currently under investigation.
Although NOX1 and NOX4 are members of the NOX subfamily that require p22phox, the
former generates primarily superoxide, while the major product of the latter is H2O2 [34].
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Nox4 is widely expressed in human, while Nox1 is much more restricted [32]. Nevertheless,
there is overlap in places where functional redundancy might explain why the in vivo
knockout models do not show obvious phenotypes. This does not appear to be the case for
the F9 in vitro cell model as there was a common effect seen when knocking down either
Nox1 or Nox4. Thus, it is possible that attenuating the activity of one NOX isoform in vitro
reduces the total amount of ROS required for differentiation, and this cannot be
compensated by the other members. The overexpression of either Nox1 and/or Nox4
(Figure 2-7A-D) in F9 cells nevertheless resulted in increased ROS levels (Figure 2-7E),
and what appeared to be a modest increase in canonical WNT signaling (Figure 2-8A).
However, these increases were not sufficient to induce differentiation as seen following the
application of exogenous H2O2 [3]. Although there is much debate centered on the recently
reported Nox1, Nox2 and Nox4 triple knockout mouse model [33], our data would indicate
that ROS produced individually by at least two of the NOX isoforms is necessary in the F9
cell model, suggesting that other sources of ROS such as mitochondrial may be required
for F9 cell differentiation and must be elucidated (Chapter 3).
Building from previous studies our model now adds to the signaling hierarchy and crosstalk
within these networks where RA induces Gata6 expression, which in turn regulates several
genes including Wnt6 [10], Nox1 and Nox4 (this study). The subsequent increase in ROS
permits NRX to dissociate from DVL, thereby priming the WNT pathway [4] prior to the
appearance of the WNT6 ligand that is sufficient to promote XEN-like differentiation [1].
WNT6 signaling is attenuated in a negative feedback loop involving Dickkopf-1 [35], and
this is required for XEN-like cells to complete their differentiation to PE-like cells [36].
Given the report showing canonical WNT signaling activates RAC1 and this in turn
increases RAC1-dependent NOX1 activity that produces the ROS needed to oxidize NRX
and dissociate it from DVL in order to keep the pathway in the on-state [8], it is tempting
to speculate that a similar mechanism occurs in F9 cells in response to RA. However, since
NOX4 is not RAC1-dependent [9], and is required for XEN-like differentiation (this
study), canonical WNT signaling must be stimulating NOX4 activity in another manner.
Given that the production of ROS is increased as a direct result of increased NOX4
expression [37], the possibility exists that increased NOX4 activity is the result of an
upregulation in the Nox4 gene by active WNT signaling. Towards that end, experiments
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are underway to test if the Nox genes are WNT target genes or simply downstream in the
pathway. Whatever the case, that aberrant WNT signaling is prevalent in cancer biology
[38,39] underpins the importance of better understanding the crosstalk imparted by NOX
proteins and ROS on the WNT/β-catenin signaling pathway in both development and
cancer research.
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Chapter 3

3

« Metabolic profile and differentiation potential of
extraembryonic endoderm-like cells »
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3.1 « Introduction »
Metabolism provides substrates for energy expenditure [1-3], and can modulate the
epigenome thereby influencing cell fate [4-6]. Typically, somatic cells rely on oxidative
phosphorylation (OXPHOS) to generate ATP, while proliferative cancer and stem cells use
glycolysis [7-11]. ATP requirements in proliferative cells are high and although OXPHOS
is more efficient in generating ATP, sufficient glucose flux in glycolysis compensates for
the rate of ATP production [12-14]. This categorization of metabolic profiles is distinct in
early mammalian embryos [15]. Naïve embryonic stem (ES) cells use glycolysis and
OXPHOS, whereas primed epiblast stem cells (EpiSCs), having structurally mature
mitochondria capable of OXPHOS, transition from bivalent metabolism to glycolysis
[16,17]. Studies show that trophoblast stem cells preferentially use OXPHOS to produce
ATP [18]. However, the metabolic profile of extraembryonic endoderm (XEN) stem cells,
which can be recapitulated using F9 cells, remains unknown [19-21]. We reported that F9
cells require increased levels of cytosolic reactive oxygen species (ROS) to differentiate
into XEN-like cells [22-24], but the role of the mitochondria, a major source of ROS, has
not been investigated.
Mitochondria and metabolism play a key role in the reprogramming of somatic cells to
induced pluripotent stem cells (iPSCs). These events require a metabolic transition from
OXPHOS to glycolysis for cells to sustain proliferation and to reset the epigenetic
landscape [25-27]. The acquisition of pluripotency is not immediate as iPSCs that have
undergone few passages share a molecular and epigenetic signature reminiscent of their
somatic counterparts, whereas prolonged passaging resets their profile closer to ES cells
[28-30]. However, and although not universal [31,32], ES cells passaged extensively
develop abnormal karyotypes, yet maintain pluripotency and differentiation potential [33].
While studies have focused on the metabolic status of stem cells or the effects of passaging
on their ability to differentiate, an understanding of how the two are linked is limited.
In this report, we aim to characterize the metabolic profile of differentiated F9 cells and
assess if metabolism can influence cell fate. In addition, investigate whether cell passage
influences metabolism and cell fate. To address this, two populations of F9 cells were
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investigated and results show that early and late passage cells had similar differentiation
potential, but each have dramatically different metabolic profiles. These differences
observed were due to changes in the expression and protein levels of pyruvate
dehydrogenase kinases (PDKs), which regulate the activity of pyruvate dehydrogenase
(PDH) complex thereby influencing the metabolic profile of cells. Additionally, genes
encoding mitochondrial fusion proteins were upregulated in early passage F9 cells, while
relative levels of mitochondrial electron transport chain (ETC) proteins were disrupted in
late passage cells. Surprisingly, culturing either cell population under their preferred
metabolic conditions enhanced the exit from pluripotency and promoted XEN-like
differentiation. More importantly, late passage cells possessed an abnormal karyotype,
resulting in increased proliferation rates, which were correlated to significant increases in
the expression of cell cycle regulators.
First, we demonstrate that early versus late passage F9 cells retain their ability to
differentiate into XEN-like cells, however, this ability to occur in cells that have different
metabolic profiles and chromosomal composition. Second, differentiated F9 cells exhibit
a metabolic profile reliant on glycolytic metabolism. Together our work underpins the
importance of monitoring the physiology of stem cell populations to ensure their quality as
a tool for regenerative medicine.
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3.2 « Material and Methods »
3.2.1

Cell culturing conditions

F9 cells (Sigma) were cultured at 37°C and 5% CO2 on 0.1% gelatin coated plates in
DMEM (Lonza) supplemented with 10% heat inactivated FBS (Thermo Fisher Scientific)
and 1% penicillin-streptomycin (Thermo Fisher Scientific). All cultures were tested and
were negative for mycoplasma [34] and cells under 20 passages were classified as being
early. To induce XEN-like differentiation, cells were treated daily for 72h with 100nM Alltrans retinoic acid (RA; Sigma) or treated daily with 100nM RA and 10mM db-cAMP
(RDB; Sigma) to induce parietal endoderm-like cells. Cells treated with DMSO served as
a negative control.

3.2.2

Generation of PDK1-stable cell lines

F9 cells were plated as described above and reverse transfected using Lipofectamine 2000
(Thermo Fisher Scientific). Briefly, 200,000 cells were seeded in 35mm gelatin-coated
plates already containing 4μg of DNA plasmid. Culture media was replaced 6h post
transfection and cells were allowed to grow for 24h. Following incubation, media was
changed, and cells were selected with 2mg/ml G418 (Gemini Bio-Products) for 2 weeks.
Cells were trypsinized and seeded at low density allowing single colony formation. Single
clones were selected and propagated for downstream analysis. pcDNA 3.1 plasmid was
generously
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Robert
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Cumming

(UWO)

and DDK-MYC-

mPDK1 overexpression construct was purchased from Origene. Plasmids were integrated
randomly in the genome as validated by sequencing and are under a constitutively active
promoter.

3.2.3

RNA isolation and quantitative reverse-transcription PCR
analysis

Total RNA, isolated at 72h from cells using a RNeasy Mini kit (Qiagen), was reverse
transcribed into first strand cDNA using the High-Capacity cDNA Reverse Transcription
kit (Applied Biosystems). Quantitative reverse transcription-PCR (qRT-PCR) reactions,
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containing 500nM of each primer (Table 4), SensiFAST SYBR Mix (FroggaBio), and
cDNA, were carried out using a CFX Connect Real-Time PCR Detection System (BioTable 4: qRT-PCR primer sequences for mouse targets
Rad). Results were analyzed using the comparative cycle threshold (2−ΔΔCt) method
with L14 serving as the internal control.

qRT-PCR primer list for mouse target genes
Primer Name
Ldha
Ldhb
Thbd
Oct4
Gata6
Dab2
Glut1
Glut2
Glut3
Glut4
Glut8
Glut9
Mt-co1
Ndufb8
Sdhb
Pdk1
Pdk2
Pdk3
Pdk4
Pdp1
Pdp2
Mfn1
Mfn2
Opa1
Drp1
Fis1
Cdkn1a
Cdkn1b
Ccnd1
Cdk4
Cdk6
Rb1
Cdkn2a
Cdkn2c
Cdkn2d
P53
L14

3.2.4

Forward sequence

Reverse sequence

TGG CGA CTC CAG TGT GCC TG
AGG CAC TGT CCA CCA CCT GCT
GGG AAA GTC TCT GGC TGA TGA A
CTG TCA CAG AGT AAT CTT TAT CGG C
GGA GCA CGA ATG AAC CCA GA
CTT GCA CAC GAA CGT CCA TC
CCC AAT GCC GTG AAG TTG GA
GCT TTC ATG TCC TGG GAC TCC T
ATG GCG TAG AAA TGC TGA GG
TGA GGT GGT CGC TTG TGT AG
GGA GCA TGT AGA CCA TGA TG
AAA GGA TTT CCG AAA GGG CT
CTT CAT TGT GGG CAT GTG CTT C
AGG TTC GGC CTT TGG TCT CAG
TTCCAGTTCGGCTATGACATCG
CTGGTGTGACTGTAAGTGGGG
TCATCAATGCACCTGAGACAATC
GTCCCTCACTTGGTAGGTCTT
CTG TAA CTT CAT TGT CGG CAT GG
AGG CAG CTG AGA TCT GGT CAA AC
CCC TTC GTG ACT GGC TTT G
TGG GTA GGC GAT TTC CGA GAT
TTG CTT TAG CTT CCC TGA TGT G
GAG AGG TTG TAC CCG TAG AGG
CAG TCT AAT GCT TAC TCA GC
GGG CAG TTA CGA TAA CAT TG
TGT TGC CGG GGT CAT ATC CTA
AGC ATC GGG TAG TCG CCA TA
CGA AAG CGA CAT GGC GGT TC
GGT CCT GGA GAA ATG CTG ACA C
GAC TGT GAA GAT GAG TGA CCG GGG
CGT TTC AAC ACG AGG CCG GG
AGG GGC ACC CAA GTA CAT C
TGC CGG AGG AAA GTG AAT GAC
TCC TGG ACT TCG GAA GGG ATA
GAA GGG CGG TTC AAC AAG TTA
GGA TTA CTG ACC GCC TCT TTA GTT
GCA TTC CGG GAA TTG TCC ATC
ATGCCAGCACCAACTCAACT
GGGTGTGTACCTCAGACGATT
CAGCCCTCAAGTGTGGTTCTC
CTCTTCCTCGGTTGATGTGTG
CCT ACT GCT CCT TCT AAC CCA
AAG GAC GCC AAT CCT GTG A
AGA ACT GGA CCC GGT TAC CA
CAC TTC GCT GAT ACC CCT GA
TGG AAA ATG GTT CGA GAG TCA G
CAT TCC GTC TCT AGG TTA AAG CG
CAG GAA TTG TTA CGG TTC CCT AA
CCT GAA TTA ACT TGT CCC GTG A
AGA GCA CGC AAT TTG AAT ATG CC
ATA GTC CCG CTG TTC CTC TTT
AAG TGT GCC GTT GTC TCT TCG
AGT CAA AGT TCC ACC GTT CTC G
TCA AAC GTG AGA GTG TCT AAC G
CCG GGC CGA AGA GAT TTC TG
GCG TAC CCT GAC ACC AAT CTC
CTC CTC TTC GCA CTT CTG CTC
ATG GCT GCC ACT CGA TAT GAA
TGC TCC TCC ATT AGG AAC TCT C
GCT TCG TGG CTC TGA AGC GCG
TGG TTT CTG TGG GTA CGC CGG
TTG GAG TCC GAT TGT ATT ACC GT
AGC ACA GGC CAG TAA AGA CAT
CGC AGG TTC TTG GTC ACT GT
TGT TCA CGA AAG CCA GAG CG
GGG GAC CTA GAG CAA CTT ACT
AAA TTG GGA TTA GCA CCT CTG AG
CTG GAA GAA GTC TGC GTC GG
GTC TTG CCA AAG CGG TTC AG
CAC GTA CTC TCC TCC CCT CAA T
AAC TGC ACA GGG CAC GTC TT
GGG TGG CCT ACA TTT CCT TCG
GAG TAC AGG GTC CAT CCA CTA AA

Immunoblot analysis

Protein lysates were harvested using RIPA buffer (10mM Tris-HCl pH 8.0, 1 mM EDTA,
0.5mM EGTA, 1% Triton X−100, 0.1% sodium deoxycholate, 0.1% SDS, and 140mM
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NaCl) supplemented with HALT™ protease cocktail inhibitor (Thermo Fisher Scientific).
Protein concentrations were determined using a DC™ Protein Assay (Bio-Rad) and 5–
40μg of lysates were prepared in 5X SDS loading buffer (300mM Tris-HCl pH 8.0, 10%
SDS, 20mM EDTA, 0.1% bromophenol blue, and 50% glycerol) and 10% βmercaptoethanol. Proteins were separated on 5–15% polyacrylamide gels for 2h at 100V
and then transferred onto polyvinylidene difluoride membranes (Bio-Rad) for 2h at 250mA
and 4°C. Membranes were placed in Tris-buffered saline with 0.1% Tween-20 (TBS-T)
containing 5% w/v skim milk powder and shaken at room temperature for 30 min.
Membranes were then incubated overnight at 4°C with a primary antibody (Table 5). After
extensive washing with TBS-T, membranes were incubated with secondary antibodies
(Table 5) for 2h at room temperature and signals were detected using a Immobilon Classico
Western HRP substrate (Milllipore Sigma). Images were collected using a ChemiDoc™
Touch Imaging System (Bio-Rad); for densitometric analysis, images were analyzed using
Image Lab™ (Bio-Rad).

3.2.5

Karyotype analysis

Early- and late-passage F9 cells were cultured on 0.1% gelatin-coated coverslips and
allowed to reach 80% confluency. Cells were treated with 0.2μg/ml colcemid (Cayman
Chemical) for 2h at 37°C, followed by trypsinization and suspension in pre-warmed
0.075M KCl solution for 20 mins at 37°C. Cells were fixed in acetic acid-methanol solution
and then transferred onto pre-chilled glass slides. Chromosomes were stained with 4′,6diamidino-2-phenylindole mounting media containing ProLong™ Gold Antifade
Mountant and examined using an Axio Imager A1 microscope (Carl Zeiss). Thirty
representative images were taken of each cell and chromosomes were counted manually
for statistical analysis.

3.2.6

Detection of mitochondrial ROS and membrane potential

Mitochondrial ROS and membrane potential were detected using MitoSOX™ Red
Mitochondrial Superoxide indicator (MitoSOX; Thermo Fisher Scientific) and
Tetramethylrhodamine, methyl ester perchlorate (TMRM; Thermo Fisher Scientific),
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respectively. Briefly, cells were seeded onto 0.1% gelatin-coated plates and allowed to
differentiate as described above. At 96h, cells were washed with phosphate-buffered saline
and incubated with 100nM MitoSOX or TMRM for 30 min at 37°C and 5% CO2. Images
were captured on an Axio Observer A1 Inverted microscope (Carl Zeiss) equipped with a
Retiga 1300 camera (QImaging). Relative fluorescence intensity was quantified using
ImageJ 1.48V software (NIH).
Table 5: List of reagents and antibodies used in this study

Reagents and antibodies
Reagent/Antibody

Source

Catalogue number

Thermo Fisher Scientific
Thermo Fisher Scientific

M36008
T668

Promega

G7570

Sigma
Santa Cruz
Sigma
Cayman Chemical
Cell Signaling Technology

R2625
sc-201567A
347795
16980
3582

1:1000

LDHB Mouse mAb
β-ACTIN Mouse mAb

abcam
Santa Cruz

ab85319
sc-69879

1:1000
1:10000

PDK1 Mouse mAb
PDK2 Mouse mAb

Santa Cruz

sc-293160

1:100

Santa Cruz
Santa Cruz
Santa Cruz

sc-100534
sc-365378
sc-28783

1:100
1:100
1:100

Sigma

AP1063

1:1000

Novus Biologicals

NB110-93479

1:1000

PDH-E1α Mouse mAb

abcam

ab110334

1:1000

Total OXPHOS Rodent
WB Antibody Cocktail Mouse mAb

abcam

ab110413

1μg/ml

DAB2 Rabbit pAb

Cell Signaling Technology

12906S

1:1000

OCT4 Rabbit pAb

Cell Signaling Technology

2750

1:1000

DSHB

TROMA-I-f

1:10

Novus Biologicals

NBP2-54490B

1:1000

Goat Anti-Rabbit IgG-HRP

Sigma

AQ132P

1:10000

Goat Anti-Mouse IgG-HRP

Sigma

A5278

1:10000

Goat Anti-Rat IgG-HRP

abcam

ab97057

1:10000

MitoSOXTM
TMRM
CellTiter-Glo® Lumeniscent
Cell Viability Assay
All-trans RA
Dibutyryl-cAMP
Dichloroacetate
UK5099
LDHA Rabbit mAb

PDK3 Mouse mAb
PDK4 Mouse mAb
PDH-E1αpSer232 Rabbit pAb
PDH-E1α

pSer293

Rabbit pAb

KERATIN-8 Rat mAb
THBD Mouse mAb

Dilution
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3.2.7

Measuring ATP levels, glucose uptake, and lactate
production

ATP levels were measured using a CellTiter-Glo® Luminescent Cell Viability Assay
(Promega). Briefly, cells were cultured and differentiated as described above. At 72h, cells
were trypsinized, suspended in 100µl of media, and added to a 96-well plate. After adding
100µl of CellTiter-Glo® reagent, cells were lysed for 2 min and incubated for 10 min in the
dark at room temperature. Luminance was recorded using a Modulus™ II microplate
multimode system (Promega) and an integration time of 1.0s. For glucose uptake and
lactate production, cells were cultured and differentiated as above, and at 72h media was
removed and centrifuged at 4°C for 10 min at 10,000 r.p.m. Media was analyzed for
glucose and lactate using a BioProfile®400 Chemical Analyzer (Nova Biomedical) at
GCRC Metabolomics Core Facility (McGill University). Protein concentration was used
to normalize values.

3.2.8

Cytotoxicity assay

F9 cells were cultured in 0, 2, 4, and 6 mM dichloroacetate (DCA) and assayed for viability
using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
(Sigma). Briefly, media was removed 24h post treatment and MTT reagent was added to
cells cultured for 6h at 37°C and 5% CO2. To dissolve formazan crystals, DMSO was added
to cells, which were shaken in the dark overnight at room temperature. Absorbance values
at 570nM with a reference wavelength at 650nM were collected using the Modulus™ II
microplate system described above.

3.2.9

Scanning electron microscopy

F9 cells were cultured and differentiated as mentioned above. Briefly, cells were washed
in 0.1M phosphate buffer and fixed with 2% glutaraldehyde for 30 mins, followed by
osmium tetroxide for 2h at 4°C. After fixation, cells were dehydrated in a graded series of
ethanol (50, 50, 75, 85, 95, and 100%) for 5 min each. Samples were air-dried and sputtercoated with gold particles for 10 mins. Samples were viewed and images collected on a
Hitachi S-3400N microscope.
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3.2.10

Statistical analysis

All values are presented as mean ± SEM from at least three biological replicates.
Comparisons between two groups were done using a Student’s t-test. Comparisons
between three or more groups were done using a one-way analysis of variance (ANOVA)
followed by a Tukey’s honest significant difference test. Chromosomal distribution
frequency was tested by χ2-test for the Goodness of Fit.
All data analyses were conducted using SPSS (Version 21.0, IBM Corp.) and graphs were
generated using Prism software (Version 7.0d, 2017). P-values were considered significant
at *P < 0.05, **P < 0.01, ***P < 0.001.
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3.3 « Results »
3.3.1

Late-passage F9 cells differentiate into XEN-like lineage

Undifferentiated late passage F9 cells grew in compact colonies while those induced to
form XEN-like or PE-like adopted a stellate-like phenotype (Figure 3-1A). Oct4 expression
in RA-induced cells was like controls (Figure 3-1B), but protein levels were reduced
significantly (Figure 3-1F, G). This was more dramatic in cells induced to PE by RA and
db-cAMP (RDB; Figure 3-1B, F, G). Increased expression of Gata6 and Dab2 (Figure 31C, D, respectively) and levels of DAB2 (Figure 3-1F, H) and KERATIN-8 (Figure 3-1F,
I) were evidence that F9 cells had differentiated into the XEN-like cells. Finally, significant
increases in Thrombomodulin (Thbd) expression (Figure 3-1E) and in THBD levels (Figure
3-1F, J) indicated that cells had differentiated to PE-like. Collectively, these results support
the findings that late passage F9 cells differentiate efficiently towards XEN-like and PElike lineages when treated with RA and RDB, respectively [20,21].

93

I
*

20

*

10

0

0.0

J
30

B

β-ACTIN

D

THBD

R

A

R

RA

B

*
*

200

100

0

OCT4
45kDa

DAB2
96kDa

KERATIN-8
55kDa

20

2.5
2.0
1.5
1.0
0.5
0.0

*

400

200

*

0

A
B

D

R

R

M
SO

D

D
Relative Thbd Abundance

B

600

D

A

800

R

R

C

D
M
SO

Relative Dab2 Abundance

B

D

A

*

D

1.0

R

RA

R

1.5

R

D
M
SO

300

A

*
400

R

G

SO

DMSO

M

D

0.0

SO

*

M

1.0

Relative DAB2 Abundance
normalized to β-ACTIN

1.5

Relative Gata6 Abundance

B

Relative THBD Abundance
normalized to β-ACTIN

B

D

B

D

R

A

R

D
M
SO

DMSO

D

30

B

40

R

A

R

SO

0.5

D

A

M

D

F

R

SO

Relative OCT4 Abundance
normalized to β-ACTIN

Relative Oct4 Abundance

0.5

R

M

D

Relative KERATIN-8
Abundance normalized
to β-ACTIN

A
RDB

E
30

20

*

10
0

RDB

105kDa

43kDa

H
*
*

10

0

*

94

Figure 3-1: Late passage F9 cells differentiate into XEN-like cells.
(A) Scanning electron micrographs of undifferentiated F9 cells (DMSO), XEN-like
(RA) and PE-like (RDB). White arrows indicate differentiated cells. Expression of
(B) Oct4, (C) Gata6, (D) Dab2 and (E) Thbd in F9 cells treated with DMSO, RA or
RDB for 72h. L14 was used a constitutive gene for qRT-PCR. (F) Representative
immunoblot and densitometric analyses of (G) OCT4, (H) DAB2, (I) KERATIN-8
and (J) THBD normalized to β-ACTIN during F9 cell differentiation. Values are
presented as mean ± SEM of at least 3 biological replicates. Significance was tested
using a One-Way ANOVA followed by a Tukey’s test. *P < 0.05.
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3.3.2

Mitochondrial activity during late-passage differentiation

Although ROS generated from cytoplasmic sources accompanies F9 cell differentiation
[22,35,36], mitochondrial sources were never examined thoroughly. To address this, late
passage F9 cells were treated with DMSO-, RA- or RDB and then stained with MitoSOX
to detect mitochondrial superoxide (Figure 3-2A-C) or with TMRM for mitochondrial
activity (Figure 3-2E-G). XEN-like cells showed a significant increase in mitochondrial
superoxide levels relative to controls (Figure 3-2D), but not mitochondrial activity (Figure
3-2H). Significant differences in superoxide levels and mitochondrial activity were also
noted in PE-like cells (Figure 3-2D, H, respectively). These changes suggested that
differentiation was accompanied by an increase in OXPHOS, which was supported by the
increase in ATP levels in these cells (Figure 3-2I). Cells were also assayed for changes in
metabolites in the media, and results showed that overall, a significant decrease in glucose
uptake (Figure 3-2J), but not lactate production (Figure 3-2K) occurred in XEN-like cells.
To examine if these changes were due to altered expression of glucose transporters [37],
cells were differentiated, and then assayed for Glut 1-4, 8 and 9 (Figure 3-2L). Glut1, 3
and 9 expressions increased significantly in XEN-like cells, while Glut3 and 9 were
significantly upregulated in PE-like cells. Conversely, Glut4 transcript abundance
decreased in XEN-like cells, while Glut2 and 8 expressions remained unchanged. These
results suggested that Glut4 is likely the key glucose transporter during RA-induced
differentiation of late passage F9 cells.
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Figure 3-2: Differentiated late passage F9 cells display increased
mitochondrial ROS production, membrane potential and ATP levels.
(A-C) Fluorescence images and quantification of F9 cells (D) stained with
MitoSOX to detect mitochondrial superoxide in undifferentiated F9 cells, PrE-like
(RA treatment) and PE-like (RDB treatment). (E-G) Fluorescence images and
quantification (H) of F9 cells stained with TMRM to detect mitochondrial
membrane potential during F9 cell differentiation. (I) ATP levels, (J) relative
glucose uptake, (K) and lactate production were also measured during
differentiation. (L) Differential expression of Glut1-4, 8 and 9 seen during the
differentiation of late passage F9 cells. L14 was used a constitutive gene for qRTPCR. Values are presented as mean ± SEM of at least 3 biological replicates.
Significance was tested using a One-Way ANOVA followed by a Tukey’s test. *P
< 0.05, ***P < 0.001. (Scale bar, 20μm).
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3.3.3

Metabolic changes accompanying late-passage
differentiation

To examine the metabolic profile, late passage F9 cells were differentiated and then
analyzed to detect transcripts encoding lactate dehydrogenase A (LDHA), which promotes
the conversion of pyruvate to lactate, and LDHB, which catalyzes the reverse reaction.
Ldha expression was significantly downregulated in differentiated F9 cells, but only in PElike cells at the protein level (Figure 3-3C, D). However, Ldhb transcripts were only
significantly downregulated in XEN-like cells (Figure 3-3A), and a similar trend was seen
at the protein level (Figure 3-3C, E). The expressions of Pdk1-4 (Figure 3-3B), which
encode PDK isoforms that phosphorylate and inactivate the PDH complex, were examined
(Figure 3-3B). Results show that Pdk1 was significantly downregulated during
differentiation, while Pdk2 was significantly upregulated relative to controls (Figure 3-3B).
Similar results were seen at the protein level (Figure 3-3F, G, H). Despite these increases,
PDH-E1αpSer232 (Figure 3-3F, I) and PDH-E1αpSer293 (Figure 3-3F, K) levels were reduced
significantly, suggesting that PDK1 likely regulates the activity of the PDH complex during
differentiation.
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Figure 3-3: Differentiated late passage F9 cells downregulate transcripts and
enzymes involved in inhibiting OXPHOS metabolism.
Relative transcript abundance of (A) Ldha and Ldhb and (B) Pdks during F9 cell
differentiation. L14 was used a constitutive gene for qRT-PCR. (C) Representative
immunoblot and densitometric analyses (D, E) of LDHA and LDHB, respectively, during
F9 cell differentiation. (F) Representative immunoblot showing PDK1, PDK2, PDHE1αpSer232, PDH-E1αpSer293, and PDH-E1α levels, and densitometric analysis of (G)
PDK1, (H) PDK2, (I) PDH-E1αpSer232 and (K) PDH-E1αpSer293 levels. β-ACTIN served
as a loading control. Values are presented as mean ± SEM of at least 3 biological
replicates. Significance was tested using a One-Way ANOVA followed by a Tukey’s test.
*

P < 0.05, **P < 0.01.
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To further examine the role of PDK1 in XEN-like differentiation, Pdk1-expressing stable
lines were generated (Figure 3-4). As expected, clones overexpressing PDK1 showed
significantly higher levels of Pdk1 expression (Figure 3-4A) and protein levels (Figure 34E, F) over controls. To test the functionality of the exogenous PDK1, PDH-E1αpSer232 was
assayed, and results show its levels were significantly higher than those in controls (Figure
3-4E, G). Next, Oct4 expression and protein levels were examined and found to be reduced
significantly in control cells treated with RA (Figure 3-4B, H, respectively), but neither
were affected by RA in PDK1-overexpressing cells (Figure 3-4B, H). Despite seeing
changes in OCT4 levels between the two clones, Gata6 expression did not differ (Figure
3-4C). However, while Dab2 expression was significantly upregulated in control XEN-like
cells, there was no significant difference when compared to Pdk1-overexpressing cells
(Figure 3-4D). In converse, DAB2 protein levels were significantly lower when Pdk1 was
overexpressed (Figure 3-4I). Lastly, overexpressing Pdk1 attenuated RA-induced
differentiation as evident by the levels of KERATIN-8, which were not significantly
different from controls (Figure 3-4J). Together, these results indicate that the
overexpression of Pdk1, and inactivation of the PDH complex in F9 cells, maintains
pluripotency, and reduces their differentiation potential.
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Figure 3-4: Overexpression of PDK1 attenuates RA-induced differentiation of late
passage F9 cells.
qRT-PCR of relative abundance of (A) Pdk1, (B) Oct4, (C) Gata6 and (D) Dab2 in
pcDNA 3.1 clone 1 (pcDNA C1) or DDK-MYC-mPDK1 clone 5 (DDK-MYC-mPDK1
C5)-overexpressing F9 cells treated with DMSO or RA for 96h. L14 was used a
constitutive gene for qRT-PCR. Representative immunoblot (E) and densitometric
analysis of (F) PDK1, (G) PDH-E1αpSer232, (H) OCT4, (I) DAB2, and (J) KERATIN-8 in
pcDNA C1 or DDK-MYC-mPDK1 C5-overexpressing F9 cells treated with DMSO or
RA for 96h. β-ACTIN served as a loading control. Values are presented as mean ± SEM
of at least 3 biological replicates. Significance was tested using a One-Way ANOVA
followed by a Tukey’s test. *P < 0.05.
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3.3.4

Passaging alters metabolism but not differentiation potential

Since passage number influences stem cell quality and fate [38-42], we asked whether F9
cells at early passages (<20) exhibited a differentiation and metabolic profile like that in
late passage cells. Examining markers of differentiation (Gata6, Dab2 and Thbd) showed
similar expression profiles between the two populations (Figure 3-5A-C). Similarly, OCT4
levels were higher in the undifferentiated state, and KERATIN-8 levels higher in the
differentiated state (Figure 3-5D-F). Thus, early, and late passage F9 cells exhibited similar
differentiation profiles, and it was expected that the metabolic profiles would be similar.
To test this, the expression of Ldh transcripts and the levels of protein were examined
(Figure 3-6A-C). No significant differences in the abundance of Ldha and Ldhb were
detected in early passage cells, and at the protein level, both levels were significantly
reduced in PE-like cells (Figure 3-6B, C). Differences were seen, however, in the
expression of Pdks, and while the decreasing Pdk1 trend with differentiation was
maintained between the two populations (Figure 3-7A and Figure 3-3B, respectively), Pdk3
and Pdk4 expression was upregulated significantly only in early passage cells (Figure 37A). No significant difference in the abundance of Pdk2 was evident in early passage cells
(Figure 3-7A), which contrasts that seen in late passage cells (Figure 3-3B). At the protein
level, PDK1 levels dropped significantly with differentiation (Figure 3-7B, C), while
PDK4 levels increased significantly in PE-like cells (Figure 3-7B, E). Despite the increase
in Pdk3 expression (Figure 3-7A), PDK3 levels remained unchanged in differentiated early
passage cells (Figure 3-7B, D). These differences in PDK profiles prompted further
investigation into the phosphorylation status of PDH-E1αpSer293, which in late passage F9
cells decreased with differentiation (Figure 3-3F, K). In early passage cells, PDH-E1αpSer293
levels increased significantly, but only in PE-like cells (Figure 3-7B, F). To explain the
increase, pyruvate dehydrogenase phosphatases (PDPs), which dephosphorylate serine
residues and subsequently activate the PDH complex, were examined (Figure 3-7G).
Results show Pdp1 and Pdp2 expression was significantly downregulated in response to
RA treatment, but only in early passage cells, suggesting that the increase in PDHE1αpSer293 levels is due to PDK4. To test whether the PDH complex was inactive, lactate
levels in the media and glucose uptake were measured in early passage undifferentiating
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and differentiated cells (Figure 3-7H and I, respectively). Media from PE-like cells showed
significantly more lactate (Figure 3-7H) when compared to controls, and this was
accompanied by a significant increase in glucose uptake (Figure 3-7I). The relative
abundance of Glut1-4, 8 and 9 in early passage F9 cells was also examined, and while
Glut1 and 3 expression was significantly upregulated in XEN-like, Glut2 and 4 expressions
were only upregulated significantly in PE-like cells (Figure 3-7J). Glut8 expression was
downregulated significantly in XEN-like cells (Figure 3-7J), unlike that seen in late
passage cells (Figure 3-2). Collectively, the results indicate that unlike late passage F9
cells, those that have not been passaged extensively transition from OXPHOS metabolism
towards glycolysis during differentiation, despite maintaining a similar differentiation
marker profile.
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Figure 3-5: Early passage F9 cells differentiate to extraembryonic endodermlike cells when treated with RA or RDB.
Relative (A) Gata6, (B) Dab2 and (C) Thbd expression in untreated (DMSO), PrElike (RA) and PE-like (RDB). L14 was used a constitutive gene for qRT-PCR. (D)
Representative immunoblot and densitometric analyses of (E) KERATIN-8 and (F)
OCT4 abundance normalized to β-ACTIN during F9 cell differentiation. Values are
presented as mean ± SEM of at least 3 biological replicates. Significance was tested
using a One-Way ANOVA followed by a Tukey’s test. *P < 0.05, **P < 0.01, ***P
< 0.001.
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Figure 3-7: Differentiated early passage F9 cells upregulate transcripts and
enzymes involved in glycolysis.
(A) qRT-PCR of Pdk1-4 expression, representative immunoblot (B) of PDK1, PDK3,
PDK4, PDH-E1αpSer293 and PDH-E1α, and densitometric analysis of (C) PDK1, (D)
PDK3, (E) PDK4 and (F) PDH-E1αpSer293 during F9 cell differentiation. β-ACTIN served
as a loading control. (G) qRT-PCR analysis of Pdp1 and Pdp2 transcripts, (H) lactate
production and (I) glucose uptake during F9 cell differentiation. (J) Differential
expression of Glut1-4, 8 and 9 seen during the differentiation of early passage F9 cells.
L14 was used a constitutive gene for qRT-PCR. Values are presented as mean ± SEM of
at least 3 biological replicates. Significance was tested using a One-Way ANOVA
followed by a Tukey’s test. *P < 0.05, **P < 0.01, ***P < 0.001.
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3.3.5

Mitochondrial dynamics in early- vs. late-passage cells

Since passage number influenced metabolism but not the differentiation potential of F9
cells, the focus turned to delineate if other metabolic-related changes exist between the two
populations, particularly in the electron transport chain (ETC) proteins. Analysis revealed
that undifferentiated and differentiated early passage cells express comparable levels of all
ETC subunits, except for succinate dehydrogenase complex iron sulfur subunit B (SDHB)
in complex II (Figure 3-8A, B). While differentiation of late passage cells to PE-like cells
caused a significant decrease in the levels of MTCO1 (complex IV), SDHB (complex II)
and NDUFB8 (complex I; Figure 3-8C, D). To explain the disruption in ETC protein levels,
the expression profiles of genes involved in mitochondrial fission and fusion were
examined. Early passage cells showed no significant change in Drp1, Opa1 and Fis1
expression, which encode proteins that promote mitochondrial fission; however, Mfn1 and
2 expression was significantly upregulated in PE-like cells (Figure 3-8E). No obvious
changes were detected in late passage cells (Figure 3-8F), and despite seeing elevated
mitochondrial ROS levels and increased activity in differentiated late passage cells (Figure
3-2A-H), the data suggests that the mitochondria in both early and late passage cells are
mature, fused, and capable of OXPHOS metabolism.
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Figure 3-8: ETC components and mitochondrial dynamics are deregulated in
differentiated late passage F9 cells.
Representative immunoblots and densitometric analyses of subunits in the ETC seen
during the differentiation of (A, B) early and (C, D) late passage F9 cells. Relative
transcript abundance of mitochondrial fusion proteins (Mfn1 and Mfn2), and
mitochondrial fission proteins (Drp1, Opa1 and Fis1) during the differentiation of (E)
early and (F) late passage F9 cells. L14 was used a constitutive gene for qRT-PCR.
Values are presented as mean ± SEM of at least 3 biological replicates. Significance was
tested using a One-Way ANOVA followed by a Tukey’s test. *P < 0.05, ***P < 0.001.
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3.3.6

Glycolysis promotes differentiation of early-passage F9 cells

If early passage F9 cells transition towards glycolysis during differentiation, then
promoting glycolysis in these cells should induce differentiation. To test this, early passage
cells were treated with UK5099, a non-competitive inhibitor of the mitochondrial pyruvate
uptake transporter. A 50µM concentration was selected, and results show that treatment in
combination with RA caused a significant reduction in the abundance of Oct4 relative to
RA alone (Figure 3-9A). Although these results suggested cells were exiting the pluripotent
state, treatment alone or in combination with RA showed no additive effects on Dab2
expression (Figure 3-9B). OCT4, DAB2, and KERATIN-8 levels were also analyzed, and
as expected OCT4 levels were significantly lower in RA-treated cells, and even lower in
the treatment with UK5099 (Figure 3-9C, D). DAB2 levels, like the corresponding
expression data were not significantly different between RA or RA and UK5099 treatments
(Figure 3-9C, E); however, under the same conditions, KERATIN-8 levels were
significantly higher (Figure 3-9C, F). Thus, culturing early passage cells under conditions
to promote glycolysis enhanced the exit from pluripotency and differentiation to XEN-like
state.
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Figure 3-9: Glycolysis promotes differentiation of early passage F9 cells.
qRT-PCR analysis of (A) Oct4 and (B) Dab2 in F9 cells differentiated without or with
UK5099 to inhibit mitochondrial pyruvate transport. L14 was used a constitutive gene
for qRT-PCR. (C) Representative immunoblot of DAB2, KERATIN-8 and OCT4,
and densitometric analyses of (D) OCT4, (E) DAB2 and (F) KERATIN-8 levels in
F9 cells treated with RA or RA and 50μM UK5099. β-ACTIN served as a loading
control. Values are presented as mean ± SEM of at least 3 biological replicates.
Significance was tested using a One-Way ANOVA followed by a Tukey’s test. *P <
0.05.
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3.3.7

OXPHOS enhances the exit from pluripotency in latepassage cells

Since promoting glycolysis in early passage F9 cells enhanced their ability to differentiate,
then promoting OXPHOS in late passage cells should augment differentiation. To test this
hypothesis, late passage cells were cultured in increasing concentrations of dichloroacetate
(DCA), a competitive PDK inhibitor, and then assayed for changes in metabolism and
differentiation (Figure 3-10). Cells cultured in the highest concentration of DCA (6mM)
showed a significant reduction in cell viability (88 ± 1%; Figure 3-10A); however, 6mM
DCA was selected as it caused the most significant reduction in PDH-E1αpSer232 and PDHE1αpSer293 levels (Figure 3-10B-D), resulting in significantly higher ATP levels (Figure 310E). As for differentiation, DAB2 and KERATIN-8 levels were significantly higher than
the controls, but only in cells co-treated with RA and DCA (Figure 3-10F-H). Since the
results would indicate that cell differentiation was augmented by DCA, OCT4 levels in the
cells should be dramatically decreased. This was tested, and results show OCT4 levels were
significantly reduced in RA-treated cells relative to controls (Figure 3-10F, I). As expected,
these levels were even more reduced in cells treated with RA and DCA (Figure 3-10F, I)
suggesting that promoting OXPHOS in late passage cells not only enhanced their exit from
pluripotency, but it also promoted their differentiation.
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Figure 3-10: OXPHOS promotes differentiation of late passage F9 cells.
(A) MTT viability assay, representative immunoblot (B) of PDH-E1αpSer232, PDHE1αpSer293 and PDH-E1α, and densitometric analyses of (C) PDH-E1αpSer232 and (D) PDHE1αpSer293 of F9 cells treated with 0, 2, 4 and 6mM DCA. (E) Relative ATP levels in
untreated and 6mM DCA-treated F9 cells. (F) Representative immunoblot of DAB2,
KERATIN-8 and OCT4, and densitometric analyses of (G) DAB2, (H) KERATIN-8 and
(I) OCT4 in F9 cells treated with RA or RA and 6mM DCA. β-ACTIN served as a loading
control. Values are presented as mean ± SEM of at least 3 biological replicates.
Significance was tested using a One-Way ANOVA followed by a Tukey’s test. *P < 0.05,
**

P < 0.01, ***P < 0.001.
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3.3.8

Genomic integrity and cell cycle regulation in early- vs. latepassage

Although metabolic changes can influence genomic integrity [43], reports have shown that
extensive passaging of adherent cells and ES cells can induce genetic abnormalities thereby
affecting cellular metabolism [44,45]. To address this, karyotyping was used to determine
whether chromosomal composition could explain the variations observed between early
and late passage cells. Analysis revealed approximately 60% of the early passage F9 cells
have the proper karyotype, while less than 5% of the late passage F9 cells had the optimal
chromosome number (Figure 3-11A). Furthermore, the chromosome frequency
distribution of early passage cells was significantly different from the late passage cells
(χ2=42.868, df=2, P < 0.001, Figure 3-11B). Cell proliferation was examined as this is
known to be affected by chromosomal abnormalities [46]. Results showed early passage
cells proliferated at a significantly lower rate than late passage cells (Figure 3-11C). An
examination of various cell cycle regulators including Cdkn1a, Cdkn1b, Cdkn2a, Cdkn2c,
Cdkn2d, Ccnd1, Cdk4, Cdk6, P53 and Rb1 revealed that except for Cdkn2a, the other cell
cycle markers were upregulated in late passage cells (Figure 3-11D). Together, this loss of
genomic integrity could account for the differences in the proliferation rates and metabolic
profiles seen between early versus late passage cells.
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Figure 3-11: Early passage F9 cells display a genetically stable karyotype and
proliferate slower than late passage F9 cells.
(A) Number of Chromosome, (B) chromosomal frequency, and (C) growth curve of
early and late passage F9 cells. (D) Differential expression of genes encoding proteins
involved in cell cycle regulation and progression between early versus late passage F9
cells. Values are presented as mean ± SEM of at least three biological replicates.
Significance was tested using a one-way ANOVA followed by a Tukey’s test.
Chromosomal distribution frequency was tested by χ2-test for the Goodness of
Fit. ***P < 0.001
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Figure 3-12: Differentiation potential, metabolic profile, and genomic integrity of
early versus late passage F9 cells.
F9 embryonal carcinoma stem-like cells differentiate towards a XEN-like lineage and
switch their metabolic profile depending on their passage. Early passage cells (less than
20) transition from OXPHOS towards glycolysis while late passage cells do the opposite.
Additionally, late passage cells accumulate more ROS and genetic abnormalities.
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3.4 « Discussion »
Stem cells hold great potential for regenerative medicine applications; however,
understanding their physiology in vitro is crucial to ensure the delivery of quality cells to
patients. We used F9 cells to determine the metabolic profile during XEN-like
differentiation, and how passaging may affect their metabolic profile and differentiation
potential. Two cell populations were examined and although each differentiated and
upregulated markers of XEN-like and PE-like lineages respectively (Figure 3-1, 3-5), their
metabolic profiles differed drastically. During differentiation, late passage F9 cells
transitioned from glycolysis to OXPHOS resulting in an increase in mitochondrial ROS
levels and mitochondrial activity, both correlated with increased ATP production (Figure
3-2). The increase in OXPHOS during differentiation is explained by the reduction in
PDK1 levels (Figure 3-3F, G), resulting in reduced PDH-E1αpSer232 (Figure 3-3F, I), and
PDH-E1αpSer293 (Figure 3-3F, K) levels. Conversely, overexpressing Pdk1 attenuated RAinduced differentiation in these cells (Figure 3-4). A similar trend occurs with iPSCs,
hESCs and MSCs, which are glycolytic in nature due to an inactive PDH complex shuttling
pyruvate to lactate [25,26], but employ OXPHOS when differentiated [27,47,48]. The
opposite scenario occurs in the mouse embryo as naïve ES cells exhibit bivalent
metabolism, while differentiated primed EpiSCs use glycolysis [16], similar to
differentiated early passage cells as they increased lactate production (Figure 3-7G), with
elevated levels of PDK4 (Figure 3-7B, E), and concomitant increased levels of PDHE1αpSer293 (Figure 3-7B, F). During the differentiation of adult stem cells, elevated lactate
levels and subsequent increased acetyl-CoA levels enhance histone H3K9 acetylation, a
prelude required for differentiation [49]. However, this is not universal, and the fact that
other stem cells transition towards OXPHOS when they differentiate [50], highlight cellspecific differences regulated by the intricacies of the metabolome.
The metabolome is directly affected by the mitochondria [51], whose activity is linked to
substrate availability and structure [52]. ETC protein stoichiometry dictates the flow of
electrons, which influences mitochondrial activity [53]. As described earlier, iPSCs
upregulate glycolytic enzymes during the early stages of reprogramming [26,27], and this
coincides with the downregulation of proteins in complex I and IV, and the upregulation
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of proteins in complex II, III and V [54]. Although the metabolic profile of iPSCs is similar
to differentiated early passage cells, there were no detectable changes to complex I and IV
in these cells (Figure 3-8A-B). In contrast, the reduction in protein levels in these
complexes were seen in differentiated late passage cells, which favor OXPHOS during
differentiation (Figure 3-8C-D). Nevertheless, the disruption of ETC stoichiometry in late
passage cells explains the elevation in mitochondrial ROS (Figure 3-2A-D). Surprisingly,
these elevated mitochondrial ROS levels were not accompanied by changes in the levels
of mitochondrial dynamic proteins (Figure 3-8F) that are typically associated with
mitochondria actively generating ATP [55]. Instead, an increase in the expression of Mfn1
and Mfn2, which encode mitochondrial fusion-promoting proteins, was seen in
differentiated early passage cells (Figure 3-8E). Similarities exist with primed EpiSCs and
hESCs, which possess oval-shaped mitochondria with dense matrix, prominent cristae, and
high mtDNA copy number, but have reduced mitochondrial respiration rates due to
deficiencies in in complex I and IV [16]. These inconsistencies in the literature confounded
the interpretation of our data, and details to explain the differences in metabolic profile
seen between early versus late passaged F9 cells led us to examine other possibilities.
Genomic integrity was one possible explanation, as long-term passaging of stem cells can
promote chromosomal abnormalities resulting in loss of pluripotency and low contribution
to chimeras [32]. In our report, early and late passage F9 cells shared similar pluripotency
and differentiation profiles (Figure 3-1, 3-5); however, based on a comparison with other
stem cell lines, we were unable to assign candidates that would implicate their involvement
in the metabolic differences seen in the two F9 cell populations. It is known that mouse ES
cell lines cultured for prolonged periods develop abnormal karyotypes yet maintain
pluripotency and differentiate when grown as embryoid bodies [33]. Our results revealed
dramatic differences in the karyotypes of early and late passage F9 cells (Figure 3-11A,
B), and these would have profound effects on the physiology of each population.
Differences included altered levels of ROS (Figure 3-2A-D) and elevated Cdkna1 and p53
levels (Figure 3-11D), the latter affecting the proliferation rate in late passage F9 cells
(Figure 3-11C). Interestingly, these characteristics are seen in late passage MSCs [47] and
hESCs [56], and although they are attributed to abnormal karyotypes, other cell lines retain
proper chromosomal composition and show no apparent change in cell proliferation rate or
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pluripotency potential [56]. Thus, like early and late passage F9 cells, stem cells have
properties that may or may not change with passaging, suggesting that culturing methods
and passage number are not the only factors promoting chromosomal degradation [57].
Overall, our results demonstrate that early versus late passage F9 cells can differentiate
into XEN-like lineages, while utilizing different metabolic profiles (Figure 3-12).
Moreover, culturing either population under conditions that favor their profile enhances
their exit from pluripotency and promoted differentiation. Although several reports have
documented the differentiation of F9 cells into XEN-like cells [58-63], none have
addressed the mechanisms in reference to metabolic profile or altered karyotypes that
accompany extensive passaging. Thus, the desired differentiation phenotype of cells may
come at a cost if genomic integrity is compromised. Future studies should investigate
whether embryo-derived XEN cells behave similarly to either early or late passage
populations. Furthermore, our findings underpin the importance of continually scrutinizing
a stem cell population and assessing metabolic phenotypes in addition to differentiation
potential and karyotypic analysis to ensure best practices for regenerative therapies.
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Chapter 4

4

« Lactate accelerates mouse ES cell differentiation
towards XEN in vitro»
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4.1 « Introduction »
The early mammalian blastocyst is comprised of two distinct layers: the inner cell mass
(ICM) and trophectoderm. The ICM houses pluripotent epiblast stem cells and primitive
endoderm cells, and the latter differentiate into parietal and visceral endoderm cells.
Various ES cells have been cultured at different developmental time-points [1], each
requiring specific conditions. For instance in mouse, ES cells isolated from the ground state
epiblast (preimplantation) represent a naïve pluripotent state and can be artificially
maintained under LIF and serum/BMP [2,3] or defined conditions of LIF-2i in N2B27
media where dual inhibition of glycogen synthase kinase 3 and mitogen-activated protein
kinase pathways maintain pluripotency [4]. However, shortly after implantation, epiblast
stem cells, which are the in vitro counterparts of the primed epiblast, require Activin A and
FGF2 in culture [5,6]. In addition to differences in culture conditions, both ES and epiblast
stem cells differ in their expression profile of pluripotency core genes, DNA methylation,
histone modification status, clonogenicity and chimera contribution [7]. XEN cells, which
contribute to both embryonic and extraembryonic endoderm tissue in mouse [8], have been
first derived by isolation from the blastocyst [9], differentiated using exogenous factors
[10-12], reprogrammed from fibroblast cells [13,14], or form after the overexpression of
Gata4/6 [15,16] or Sox17 [17]. In addition, evidence indicates that the metabolic state
between embryonic and extraembryonic lineages differs [18], suggesting that metabolism
may be sufficient to influence lineage commitment.
ES cells exhibit a bivalent metabolic profile, relying on glycolysis and oxidative
phosphorylation (OXPHOS) to generate energy, while epiblast stem cells are exclusively
glycolytic, despite displaying a mature mitochondrial ultrastructure [19]. Although the
majority of studies have focused on ES and epiblast stem cells, recent reports on
extraembryonic cells show they are reliant on OXPHOS metabolism [18], with a similar
mitochondrial ultrastructure to epiblast stem cells [19,20]. In addition, we have previously
shown that differentiated F9 cells, a model of XEN-like differentiation, rely on glycolytic
metabolism, produce high levels of lactate, and express of Mfn1 and Mfn2 (Chapter 3) [21].
However, details on the comprehensive intracellular profile of metabolites and their role
during differentiation remains unknown.
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Small metabolites have garnered attention with their role in maintaining pluripotency,
promoting differentiation, and enhancing reprogramming efficiency of induced pluripotent
stem cells [22-24]. These small compounds play integral roles in energy production and
epigenetic modifications. For instance, short-chain and saturated fatty acids can modulate
histone deacetylases and the epigenetic landscape and thus are implicated in enhancing the
efficiency of stem cell differentiation [25,26]. Also, the depletion of threonine or loss of
threonine dehydrogenase (TDH) impacts stemness [27], while supplementation of Lthreonine maintains pluripotency [28]. Therefore, naturally occurring metabolites play an
important role in regulating pluripotency and differentiation of stem cells by modulating
the metabolic and epigenetic landscape.
In this report we used a multi-omics approach to identify metabolic changes in mouse ES
and XEN cells and have further characterized the metabolic pathways involved in
regulating XEN differentiation in vitro. Overall, we observed a significant reduction in the
survival of feeder-free XEN cells following glycolytic inhibition. Transcriptomic and
proteomic profiling implicate lactate metabolism in regulating the differentiation towards
the XEN lineage. Strikingly, lactate was enriched intra- and extracellularly in feeder-free
XEN cells and promoting intracellular lactate accumulation or supplementing with
exogenous L-lactate enhanced XEN induction. Together our results elucidate an
unacknowledged role for lactate in XEN cell differentiation in vitro, which further our
understanding of the role metabolites play in stem cell differentiation with potential
applications in regenerative medicine.
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4.2 « Experimental procedures »
4.2.1

ES, XEN, and cXEN cell culture

The ES-E14TG2a embryonic stem (ES) cell line was obtained from the University of
California, Davis. ES cells were cultured feeder-free on 0.1% gelatin-coated tissue culture
plates in ES media (LIF-2i): 50/50 neurobasal/DMEM-F12 media (Thermo Fisher
Scientific), 1X N2 supplement (Thermo Fisher Scientific), 0.5X B27 (without retinoic acid;
Thermo Fisher Scientific), 2mM GlutaMAXTM (Thermo Fisher Scientific), 0.1mM βmercaptoethanol (Thermo Fisher Scientific), 100U/ml units of LIF (Millipore-Sigma),
3µM CHIR99021 (ApexBio) and 1µM PD 0325901 (ApexBio). ES cells were passaged
every 3–4 days using Accutase (Thermo Fisher Scientific) and used to passage 30. ES
media was changed daily to maintain optimal growth and reduce spontaneous
differentiation.
E4 extraembryonic endoderm (XEN) cells, generously donated by Cheryle Seguin, UWO
[9], were cultured in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with
15% fetal bovine serum (Thermo Fisher Scientific), 2mM GlutaMAXTM and 0.1mM βmercaptoethanol. XEN cells were passaged every 2–4 days using TrypLE Express (Thermo
Fisher Scientific) up to passage 20.
Chemically induced XEN (cXEN) differentiation was performed following a previously
established protocol [12]. Briefly, ES cells were seeded onto 0.1% gelatin-coated tissue
culture plates in base XEN media (RPMI 1640 media, 0.5X B27 without insulin, 2mM
GlutaMAXTM and 0.1mM β-mercaptoethanol) for 2 days. To induce XEN differentiation,
base XEN medium was supplemented with 100U/ml units of LIF, 3µM CHIR99021 and
20ng/ml Activin A (R&D Systems), which was replaced with fresh media every 2 days.
All lines were grown at 37°C and 5% CO2 and contained a normal chromosomal karyotype
and negative for mycoplasma [29] at the beginning of the project.
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4.2.2

RNA isolation, cDNA synthesis and qRT-PCR analysis

Cellular RNA was extracted from cells using QIAshredder/RNAeasy Mini kit (Qiagen)
and reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription
kit (Thermo Fisher Scientific). For quantitative RT-PCR, reactions contained 500nM of
forward and reverse primers [21], SensiFAST SYBR Mix (FroggaBio), and cDNA.
Reactions were run on a CFX Connect Real-Time PCR detection system (Bio-Rad), and
results presented using the comparative cycle threshold (2−ΔΔCt) method with Rpl14 serving
as the internal control.

4.2.3

RNA sequencing analysis

Total RNA was extracted as in section 4.2.2 and quantified using a NanoDrop 2000
spectrophotometer (Thermo Fisher Scientific) and Agilent 2100 bioanalyzer (Agilent
Technologies). Library construction and sequencing were performed using the BGISEQ500 platform (Beijing Genome Institute). Clean reads were mapped to a reference genome
(GRCm38-mm10) using Bowtie2 [30] and gene expression levels were calculated with
RSEM [31]. Differentially expressed genes were detected with DEseq2 [32] with fold
change ≥ 2.0 and P ≤ 0.0001, and GO-term enrichment and KEGG analyses were
conducted using David v6.8 [33,34]. Three independent biological replicates were used for
each line.

4.2.4

Protein extraction, quantification and immunoblot analysis

Total cell lysates were harvested using RIPA buffer supplemented with protease and
phosphatase inhibitors (Thermo Fisher Scientific). Protein concentrations were quantified
using a DCTM protein assay (Bio-Rad). Approximately 5–20µg of protein was separated on
5–15% polyacrylamide gels at 100V, then transferred onto PVDF membranes (Bio-Rad)
overnight at 4°C at 20V. Membranes were washed in TBS-T with 0.1% Tween-20 and
blocked with 5% skim milk powder for 30 minutes at room temperature with gentle
shaking. Membranes were probed with primary antibodies [21] overnight at 4°C followed
by washes with TBS-T and secondary antibody incubation for 2 hours at room temperature.
Images were captured using a ChemiDoc™ Touch Imaging System (Bio-Rad).
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4.2.5

Proteomic analysis

Sample preparation, handling and quantification were performed according to [35].
Briefly, cells were pelleted and 50μg of protein was quantified by ionic detergent
compatible Pierce 660nm Protein Assay Reagent (Thermo Fisher Scientific) in 8M Urea,
50mM ammonium bicarbonate, 10mM dithiothreitol, and 2% SDS lysis buffer. Lysates
were sonicated, reduced, and alkylated followed by precipitation in chloroform/methanol
[36], and digested samples were resuspended in 0.1% formic acid in preparation for LCMS/MS. One microgram of tryptic peptides was injected into a Waters nano-Acquity
HPLC system (Waters, Milford, MA) coupled to an ESI Orbitrap mass spectrometer
(Orbitrap Elite or QExactive, Thermo Fisher Scientiﬁc). MS raw files were examined using
MaxQuant (1.6.5.0) and the Human Uniprot database. Bioinformatic analyses were
performed in Perseus (1.5.8.5), and statistical analyses performed using multiple sample ttest with a permutation FDR set at 0.05. GO-term enrichment and KEGG analyses were
conducted using David v6.8 [33,34]. Three independent biological replicates were used for
each line.

4.2.6

Detection of total ATP levels

Total ATP levels were measured using the CellTiter-Glo® Luminescent Cell Viability
Assay (Promega). Cells were detached and re-suspended in media and aliquoted into 96well plate. Cells were lysed in CellTiter-Glo® reagent, incubated in the dark for 10 minutes,
and luminance recorded using a Modulus™ II microplate multimode system (Promega).

4.2.7

Detection of extracellular lactate levels

Cells were cultured under normal conditions until reaching 70% confluency. Media from
each cell population was collected, centrifuge at 14000g at 4°C for 10 minutes and analyzed
using a BioProfile®400 Chemical Analyzer (Nova Biochemical), at the GCRC
Metabolomics Core Facility, McGill University. Values were normalized to protein
concentrations.

135

4.2.8

Metabolomic analysis

Three million cells, cultured for 4 days under normal conditions, per sample were used for
extraction and analysis. Samples were analyzed for metabolites involved in glycolysis, and
TCA cycle, as well as amino acids, fatty acid, and lipids. Sample preparation, handling and
quantification were carried out as in [37] by The Analytical Facility for Bioactive
Molecules, The Hospital for Sick Children, Toronto, Canada. Briefly, cells were harvested
in 80% methanol (vol/vol) solution, centrifuged at 14,000g for 5 minutes at 4°C. Samples
were aliquoted and lyophilized prior to injection. Approximately 20μl of LC/MS grade
water was used to resuspend samples and 5–10μl was injected into a LC-MS/MS system
which was a SCIEX 5500 QTRAP mass spectrometer (SCIEX) coupled with an Agilent
1290 HPLC stack (Agilent Technologies). MultiQuant (v3.0; SCIEX) was used for
analysis. Three independent biological replicates were used for each line.

4.2.9

Data and code availability

Data files can be obtained from accession number GEO: GSE159855. Proteomic and
metabolomic datasets are underpowered and were not deposited for public access.

4.2.10

Statistical analysis

All values are presented as mean ± SEM from at least three biological experiments. In some
instances (TEM experiments), three technical replicates were also included. Comparisons
between two groups were performed using Student’s t-test, while comparisons between
three or more groups were done using one-way ANOVA test followed by Tukey’s honest
significant difference test. All graphs and statistics were generated using Prism (v8.4.3).
P-values were considered significant at *P<0.05, **P<0.01, ***P<0.001, or ****P<0.0001.
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4.3 « Results »
4.3.1

ES cells are less sensitive to glycolytic inhibition than XEN
cells

A recent report characterized the metabolic profile of XEN cells as reliant on OXPHOS
metabolism [18]. Albeit informative, this study derived and maintained XEN cells on
inactivated mouse embryonic fibroblasts, which are oxidative in nature [38] and are known
to reduce the reliance of pluripotent stem cells on glycolysis [39]. To address if culturing
methods influence the metabolic profiles, ES-E14TG2a embryonic stem cells (ES cells)
and embryo-derived extraembryonic endoderm cells (XEN cells) [9] were cultured under
feeder-free conditions in media containing 50mM 2-Deoxy-D-glucose (2-DG; glycolysis
inhibitor) or 2.5µM oligomycin (OXPHOS inhibitor), and results were compared with cells
grown under control conditions (LIF-2i for ES cells and RPMI 1640 with FBS for XEN
cells; Figure 4-2). ES cells displayed domed-homogenous colonies while XEN cells had
two distinct morphologies present in culture, spindle-like or round and refractile in nature
(Figure 4-1A). Both populations expressed the respective pluripotency or endodermal
genes as detected by qRT-PCR or immunoblot analysis (Figure 4-1B-H).
ES colony shape appeared to be insensitive to 2-DG or to oligomycin treatment; however,
XEN cells lost their distinct morphologies, particularly in the 2-DG treatment and adopted
a spindle-like morphology, suggestive of cell stress (Figure 4-2A). In contrast to a previous
report [18], XEN cells were more sensitive to glycolytic inhibition (5.87% ± 1.82) than
OXPHOS inhibition with oligomycin (41.3% ± 7.30; P < 0.01; Figure 4-2B). Since ES
cells are metabolically bivalent [19], the significant reduction in cell viability observed
under both treatments was expected (P < 0.01) and not significantly different between the
two treatments (2-DG: 45.3% ± 8.84 versus oligomycin: 62.7% ± 5.24; Figure 4-2B).
Despite this reduction in cell viability, no change in relative total ATP levels was observed
between the two populations and treatments (Figure 4-2C). Collectively, our findings
support the notion that feeder-free XEN cells are more sensitive to glycolytic inhibition
than feeder-free ES cells.
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Figure 4-1: Morphological and molecular analysis of ES and XEN cells in vitro.
(A) A representative phase contrast micrograph of ES and XEN cells cultured under
maintenance conditions under free-feeder conditions. (B) Immunoblot analysis of
OCT4 (pluripotency marker) and DAB2, GATA6, and KERATIN-8 (extraembryonic
endoderm markers). β-ACTIN served as a loading control. (C, D) Bar graph of
expression level of Oct4 and Nanog in ES and XEN cells under maintenance
conditions. Rpl14 was used a constitutive gene for qRT-PCR. (n = three biological
replicates, ***P <0.001). (E-H) Bar graph of expression level of Gata6, Sox7, Dab2,
and Foxa2 in ES and XEN cells under maintenance conditions. Rpl14 was used a
constitutive gene for qRT-PCR. (n = three biological replicates, *P <0.05, **P <0.01).
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Figure 4-2: XEN cells are more sensitive to glycolytic inhibition.
(A) Representative phase contrast images of ES and XEN cells cultured under control,
50mM 2-DG, and 2.5µM oligomycin. Solid arrows are indicative of round XEN
morphology. Dashed arrows are indicative of stellate XEN morphology. Scale bars =
100µm. (B) Relative cell viability of ES and XEN cells under control, 50mM 2-DG
and 2.5µM oligomycin conditions. (C) Total ATP levels in ES and XEN cells under
control, 50mM 2-DG and 2.5µM oligomycin conditions. (n = three biological
replicates, ns = not significant, **P < 0.01, ***P <0.001).
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4.3.2

Intracellular metabolomic profiling of ICM cells

Since feeder-free ES and XEN cells responded differently to metabolic inhibitors, we
exploited the feeder-free system to identify changes in intracellular metabolites between
the two populations. For metabolite identification, untargeted metabolomics was used to
measure the relative levels of intracellular metabolites (Figure 4-3). We identified 142
intracellular metabolites of which 18 were significantly enriched in ES cells and 68 in XEN
cells (Figure 4-3A). Next, targeted metabolomics was performed to quantify the levels of
amino acids (Figure 4-3B) and metabolites involved in glycolysis and the tricarboxylic acid
(TCA) cycle (Figure 4-3C). Several amino acids were significantly enriched in XEN cells,
including proline, serine, and threonine, which are reported to play a role in pluripotency
and differentiation [27,28,40,41]. While most metabolites involved in glycolysis and TCA
cycle were not statistically significant, intracellular lactate and 2-hydroxyglutarate were
significantly higher in XEN cells when compared with ES cells (P < 0.05; Figure 4-3C).
Together, our data indicate that XEN cells exhibit a unique metabolite profile that is distinct
from the ES population.
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Figure 4-3: Intracellular metabolomic analysis of ES and XEN cells.
(A) Volcano plots of differentially expressed metabolites from untargeted LC/GCMS/MS metabolomics of ES and XEN cells cultured under normal conditions. (Fold
change > 1 and P < 0.05). Metabolites enriched in ES cells are highlighted in purple
(38 metabolites) and metabolites enriched in XEN cells are highlighted in orange (105
metabolites). (B, C) Levels of key intracellular metabolites generated by glycolysis,
TCA cycle, and amino acid detected by targeted LC/GC-MS/MS analysis of ES and
XEN cells cultured under normal conditions. Metabolites are expressed in ng and were
normalized to cell number. (n = three biological replicates, ns = not significant, *P <
0.05, **P <0.01).
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4.3.3

Transcriptomic and proteomic analysis showcases the
importance of metabolic pathways during embryonic
development

Bulk transcriptomic and proteomic analyses were performed on three biological replicates
of ES and XEN cells to compare global gene expression and protein abundance patterns
and assign molecular pathway(s) to better our understanding of the landscape of each
population. I found that 2742 genes (Figure 4-4A) and 165 proteins (Figure 4-4B) were
significantly enriched in the ES population. In contrast, 1716 genes (Figure 4-4A) and 298
proteins (Figure 4-4B) were significantly enriched in XEN cells. As expected, markers of
pluripotency including Nanog, Sox2, OCT4 and ESRRB were enriched in the ES
population, while XEN markers such as Gata4/6, Sox7/17, Dab2, and PDGFRA were
significantly enriched in XEN cells (Figure 4-4A, B). Differentially expressed genes and
proteins enriched in either ES or XEN cells were selected and analyzed by gene ontology
to classify targets based on their associated biological process (Figure 4-5A-D), cellular
compartment (Figure 4-5E-H) and molecular process (Figure 4-5I-L). Targets from ES
cells were enriched for biological processes associated with multicellular organism
development and regulation of transcription (Figure 4-5A, B). Conversely, XEN cells
terms were associated with various signaling pathways, endodermal development, and
extracellular matrix organization (Figure 4-5C, D) to list a few.
Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was also
performed on genes and proteins to identify biological pathways specific to each
population (Figure 4-4C-G). XEN cells expressed targets primarily involved in
proteoglycan metabolism and endoplasmic reticulum processing (Figure 4-4F, G), as
reported previously [18]. However, targets involved in metabolism of xenobiotics by
cytochrome P450 and glucose/pyruvate metabolism were enriched in the ES population
and represent two common KEGG pathways between the RNAseq and MS datasets (Figure
4-4C, D). Notably, three targets that were highly enriched in both datasets and linked to
glucose metabolism were aldehyde dehydrogenase 1 family member B1 (ALDH1B1),
phosphoenolpyruvate carboxykinase 2 (PCK2) and lactate dehydrogenase B (LDHB,
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Figure 4-4E). Together, these data suggest that these targets and their metabolites may play
a role in either maintaining pluripotency or in the differentiation towards the XEN lineage.
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Figure 4-4: Bulk transcriptomic and proteomic analysis of ES and XEN cells.
(A) Volcano plots of differentially expressed genes from bulk RNA sequencing of ES
and XEN cells cultured under normal conditions. (Fold change > 2 and adjusted P <
0.01). Genes enriched in ES cells are highlighted in purple (2742 genes) and genes
enriched in XEN cells are highlighted in orange (1716 genes). (B) Volcano plots of
differentially expressed proteins from bulk proteomics of ES and XEN cells cultured
under normal conditions. (Fold change > 2 and adjusted P < 0.01). Proteins abundant in
ES cells are highlighted in purple (165 proteins) and proteins abundant in XEN cells are
highlighted in orange (298 proteins). (C) Dot plot representing enriched KEGG
pathways in ES cells from transcriptomic dataset. (D) Dot plot representing enriched
KEGG pathways in ES cells from proteomic dataset. (E) Venn diagram of common
targets from both transcriptomic and proteomic datasets for specific KEGG pathways.
(F) Dot plot representing enriched KEGG pathways in XEN cells from transcriptomic
dataset. (G) Dot plot representing enriched KEGG pathways in XEN cells from
proteomic dataset.
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Figure 4-5: GO term analysis of ES and XEN cells.
(A, B) Bar graph representing top 10 enriched GO biological processes terms in ES
cells from transcriptomic and proteomic datasets. (C, D) Bar graph representing top
10 enriched GO biological processes terms in XEN cells from transcriptomic and
proteomic datasets. (E, F) Bar graph representing top 10 enriched GO cellular
compartments terms in ES cells from transcriptomic and proteomic datasets. (G, H)
Bar graph representing top 10 enriched GO cellular compartments terms in XEN cells
from transcriptomic and proteomic datasets. (I, J) Bar graph representing top 10
enriched GO molecular functions terms in ES cells from transcriptomic and
proteomic datasets. (K, L) Bar graph representing top 10 enriched GO molecular
functions terms in XEN cells from transcriptomic and proteomic datasets.
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4.3.4

Enzymes involved in lactate homeostasis are upregulated in
XEN cells

Pyruvate is converted into lactate by the activity of LDHA and converted back by LDHB;
since the latter was enriched in the ES population (Figure 4-4A-E), and lactate was enriched
in XEN cells intracellularly (Figure 4-3C), we sought to further investigate the levels of
enzymes involved in lactate metabolism. qRT-PCR results showed significantly higher
Ldha/Ldhb mRNA abundance in XEN cells compared with ES cells (P < 0.01, Figure 46A), and this was confirmed at the protein level using immunoblot analysis (Figure 4-6B).
Extracellular lactate levels were also measured, and results showed significantly higher
levels in XEN cells (P < 0.05, Figure 4-6C). Furthermore, the expression of the lactate
transporter Mct1 (Figure 4-6D), but not Mct4 (Figure 4-6E), was significantly upregulated
in XEN cells (P < 0.0001) and is a prime candidate linked to these high extracellular lactate
levels.
Pyruvate can also be oxidized in the mitochondria by the pyruvate dehydrogenase complex
(PDC) to generate acetyl-CoA. This conversion is dependent on the activity of the PDC,
which is negatively regulated by phosphorylation of the E1α subunit by members of the
pyruvate dehydrogenase kinase (PDK) family. Expression analysis shows that Pdk1, 2 and
4, but not Pdk3, were significantly downregulated in XEN cells (Figure 4-6F-I). Similarly,
immunoblot analysis revealed low levels of PDC-E1αSer232/Ser293 in XEN cells (Figure 46J), indicating that the PDC is active and would suggest higher OXPHOS activity.
However, expression analysis of the mitochondrial pyruvate carriers Mpc1 (Figure 4-6K),
but not Mpc2 (Figure 4-6L), showed significantly reduced expression in XEN cells (P <
0.0001). Thus, despite having an active PDC, pyruvate in XEN cells fails to enter the
mitochondria, and instead is preferentially converted to lactate by the enhanced LDHA
activity (Figure 4-6A, B). These results suggest that lactate may participate in specifying
ES cells towards a XEN lineage.

155

C

ES

**

20

XEN

10

37kDa

15

LDHA

10

LDHB

37kDa

β-ACTIN

43kDa

5
0

ES

D

Extracellular
lactate production
(mM/μg/μl)

B
Relative Ldha/Ldhb Abundance

A

6
4
2
0

XEN

E

Mct1
****

ES

XEN

Mct4

25

400

*

8

20

FPKM

200
100
0

F

15
10
5

ES

0

XEN

Pdk1

G

25

ES
Pdk2

25

H
8

15

15

6

5

FPKM

20

FPKM

20

10

10

J

XEN

2.0

4

1.5
1.0
0.5
0.0

ES

ES

****

2.5

0

ES

Pdk4

****

2

5

0

I

Pdk3
10

**

****

FPKM

XEN

FPKM

FPKM

300

XEN

ES

ES

XEN

K

XEN

XEN

L
Mpc2

Mpc1

PDK4

48kDa

PDC-E1αpSer232

42kDa

PDC-E1αpSer293

42kDa

PDC-E1α

42kDa

40

15

***

30

10

FPKM

48kDa

FPKM

PDK1

20

5
10

0

0

ES

XEN

ES

XEN

156

Figure 4-6: Levels of enzymes involved in pyruvate metabolism in ES and XEN
cells.
(A) Bar graph of qRT-PCR analysis of Ldha/Ldhb ratio in ES and XEN cells. Rpl14
was used a constitutive gene for qRT-PCR. (n = three biological replicates, **P <0.01).
(B) Representative immunoblot analysis showing levels of LDHA and LDHB in ES
and XEN cells. β-ACTIN served as a loading control. (n = three biological replicates).
(C) Bar graph of extracellular quantification of lactate levels in ES and XEN cells by
BioProfile®400 Chemical Analyzer. (n = three biological replicates, *P < 0.05). (D, E)
Bar graph of expression level of Mct1 and Mct4 in ES and XEN cells. FPKM was used
for RNAseq data. (n = three biological replicates, ****P <0.0001). (F-I) Bar graph of
FPKM of Pdk1-4 in ES and XEN cells. (n = three biological replicates, ns = not
significant,

**

P <0.01,

****

P <0.0001). (J) Representative immunoblot analysis

showing levels of PDK1, PDK4, PDC-E1αpSer232, PDC-E1αpSer293, and PDC-E1α in ES
and XEN cells. (n = three biological replicates). (K, L) Bar graph of expression level
of Mpc1 and Mpc2 in ES and XEN cells. FPKM was used for RNAseq data. (n = three
biological replicates, ***P <0.001).
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4.3.5

Promoting intracellular lactate enhances XEN differentiation

Given the previous data highlighting a potential role for lactate in XEN cells, we sought to
directly assess whether modulating lactate metabolism influenced XEN induction in vitro
(Figure 4-8). We adopted a previously defined chemical cocktail [12] to induce naïve
mouse ES cells towards the XEN lineage. Exogenous supplementation with LIF, Activin
A and CHIR99021 (inhibitor of glycogen synthase kinase 3) in the absence of insulin
(Figure 4-7A) promotes differentiation towards the XEN lineage as evident by elevated
Gata6 and Dab2 transcript and low levels of Nanog and Oct4 (Figure 4-7B-E).
To test whether lactate metabolism plays a role in XEN differentiation, we used two
approaches. In the first, three inhibitors were selected, two of which would promote
intracellular lactate accumulation (UK5099 and AZD3965), while the other would promote
pyruvate uptake into the mitochondria (Dichloroacetate, DCA). In the second approach,
media was supplemented with exogenous L-lactate and cells were assessed for markers of
pluripotency and XEN differentiation. UK5099 is a potent pan MPC inhibitor that prevents
pyruvate uptake into the mitochondria [42,43], while AZD3965, a highly-specific MCT1
inhibitor, reduces lactate secretion in human stem cells [39] and cancer cells [44]. The latter
was used since MCT1 is the predominant transporter responsible for exporting lactate
extracellularly in XEN cells (Figure 4-6D). Neither UK5099, AZD3965 or L-lactate
affected Oct or Nanog expression (Figure 4-8C, F, G, J, K); however, Oct4 expression was
slightly but significantly downregulated (P < 0.05) in ES cells cultured under LIF-2i and
UK5099 (Figure 4-8B). In contrast, DCA-treated ES cells cultured with LIF-2i had slightly
elevated Oct4 and Nanog expression when compared to controls (Figure 4-8N, O).
Next, ES cells were induced towards the XEN lineage under control conditions or treated
with inhibitors or supplemented with L-lactate. ES cells treated with UK5099 in XEN
induction media were not viable after 48h post treatment (Figure 4-8D, E), while
surprisingly those cultured with either AZD3965 (Figure 4-8H, I) or supplemented with Llactate (Figure 4-8L, M) for 96h showed enhanced Gata6 and Dab2 expression when
compared to controls. Conversely, when ES cells were treated with DCA in XEN induction
media, thereby promoting pyruvate uptake into the mitochondria and reducing intracellular
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lactate, Gata6 and Dab2 expression were significantly downregulated when compared to
controls (P < 0.05, Figure 4-8P, Q). Therefore, promoting intracellular lactate
accumulation was associated with enhanced XEN induction in vitro, highlighting a novel
role for lactate as a signaling molecule involved in the differentiation of XEN cells.
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Figure 4-7: In vitro induction of ES cells towards the XEN lineage.
(A) Schematic diagram of the methodology of cXEN induction in vitro. (B, C) Bar
graph of expression level of Nanog and Oct4 in ES cells induced towards the XEN
lineage over 8 days. Rpl14 was used a constitutive gene for qRT-PCR. (n = three
biological replicates). (D, E) Bar graph of expression level of Gata6 and Dab2 in ES
cells induced towards the XEN lineage over 8 days. Rpl14 was used a constitutive gene
for qRT-PCR. (n = three biological replicates.
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Figure 4-8: Intracellular lactate enhances XEN differentiation in vitro.
(A) Schematic diagram of glucose metabolism and the metabolic enzymes involved.
Green is indicative of treatments that increase intracellular lactate and red is indicative
of treatment that decrease intracellular lactate. (B, C) Bar graph of expression level of
Oct4 and Nanog in ES cells in 2i-LIF with or without 50µM UK5099 for 48h. Rpl14
was used a constitutive gene for qRT-PCR. (n = three biological replicates, *P <0.05).
(D, E) Bar graph of expression level of Gata6 and Dab2 in ES cells induced towards
a XEN lineage with or without 50µM UK5099 for 96h. Rpl14 was used a constitutive
gene for qRT-PCR. (n = three biological replicates, *P <0.05). (F, G) Bar graph of
expression level of Oct4 and Nanog in ES cells in 2i-LIF with or without 250nM
AZD3965 for 48h. Rpl14 was used a constitutive gene for qRT-PCR. (n = three
biological replicates). (H, I) Bar graph of expression level of Gata6 and Dab2 in ES
cells induced towards a XEN lineage with or without 250nM AZD3965 for 96h. Rpl14
was used a constitutive gene for qRT-PCR. (n = three biological replicates, *P <0.05).
(J, K) Bar graph of expression level of Oct4 and Nanog in ES cells in 2i-LIF with or
without 5mM L-lactate for 48h. Rpl14 was used a constitutive gene for qRT-PCR. (n
= three biological replicates). (L, M) Bar graph of expression level of Gata6 and Dab2
in ES cells induced towards a XEN lineage with or without 5mM L-lactate for 96h.
Rpl14 was used a constitutive gene for qRT-PCR. (n = three biological replicates, *P
<0.05). (N, O) Bar graph of expression level of Oct4 and Nanog in ES cells in 2i-LIF
with or without 5mM DCA for 48h. Rpl14 was used a constitutive gene for qRT-PCR.
(n = three biological replicates, *P <0.05, **P <0.01). (P, Q) Bar graph of expression
level of Gata6 and Dab2 in ES cells induced towards a XEN lineage with or without
5mM DCA for 96h. Rpl14 was used a constitutive gene for qRT-PCR. (n = three
biological replicates, *P <0.05).
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Figure 4-9: Schematic representation of the role lactate plays in XEN
differentiation in vitro.
Schematic of ES cells (in purple) and XEN cells (in orange) displaying different
LDHA-to-LDHB and pyruvate-to-lactate ratios depending on the developmental stage.
In addition, supplementation with L-lactate or treatment with MCT1 inhibitor,
AZD3965, enhances intracellular lactate accumulation and therefore, XEN induction.
However, treatment with DCA, a PDK inhibitor, blocked XEN differentiation in vitro.
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4.4 « Discussion »
We have shown previously that F9 cells mimic the transition to a XEN-like lineage when
co-treated with retinoic acid and a cAMP analog, and more importantly, these cells
exhibited a metabolic phenotype reliant exclusively on glycolysis [21]. While recent
reports have expanded on the metabolic profiles observed in the early embryonic lineages
[18,19], a comprehensive analysis of the metabolites and their roles during development
remains lacking. Our data indicates that feeder-free XEN cells are sensitive to glycolytic
inhibition when compared with OXPHOS inhibition (Figure 4-2A, B). This phenomenon
is also observed in mouse primed stem cells, human stem cells [19] and canine epiblast
stem cells [45], suggesting that these characteristics are adaptive mechanisms linked to a
developmental stage. Furthermore, XEN cells possess altered glycolytic enzyme levels
involved in pyruvate and lactate homeostasis (Figure 4-6). Recent reports suggested that
XEN cells rely on OXPHOS metabolism for energetic needs [18]; however, the
developmental stage and culture condition of XEN cells may influence their metabolic
profile. For instance, primitive endoderm cells are present within the ICM at 3.5 days post
fertilization, and they further commit into parietal and visceral endoderm cells shortly after
implantation. A similar phenomenon is observed between preimplantation naïve versus
post-implantation primed ES cells, which display distinct metabolic profiles [19],
suggesting that XEN cells may exhibit a unique metabolic signature depending on their
developmental stage. In addition, the localization of XEN cells varies depending on the
stage of development, where primitive endoderm cells reside within the ICM, visceral
endoderm cells surround the epiblast while parietal endoderm cells interact with
trophoblast stem cells are along the inner surface of the trophectoderm [46]. Therefore, the
precise identity of these XEN cells and their interaction with the microenvironment may
influence their metabolic needs. Lastly, culture conditions vary between trophoblast, ES
and XEN cells, and it is known that the latter can be derived using various culture
conditions and supplements [9-13,15-17,47-49]. Together, the ability to derive XEN cells
by various means would contribute to their heterogeneity [9,48] and potentially affect the
metabolic profile of these cells. For example, XEN cells can be generated by the
overexpression of Gata4 in ES cells [15,49] or reprogramming fibroblasts using a chemical
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cocktail [13]. While both methods result in the establishment of XEN cells, Gata4-induced
ES cells display gradual reduction in hexokinase 2 (HK2) and glucose transporter 1
(GLUT1) levels [50], while XEN cells reprogrammed from fibroblasts display elevated
levels of those same markers [13]. Together, these differences highlight the metabolic
complexity and plasticity of all cells in the developing embryo, and of XEN cells
specifically.
As the embryo develops its metabolic needs shift to meet energetic demands for growth
and development and this metabolic rewiring is dependent on extrinsic and intrinsic cues.
The blastocyst resides in a hypoxic environment, with oxygen tension dropping
significantly during implantation [51]. This hypoxic environment results in the
stabilization of hypoxia-inducible factor one alpha (HIF1α), resulting in the increase in
enzymes shifting the metabolic profile towards glycolysis. During implantation, however,
angiogenesis promotes reoxygenation of the embryo triggering a switch to OXPHOS.
Despite residing in a similar environment, trophoblast stem cells rely on OXPHOS
metabolism, largely to fuel the sodium/potassium ion pumps required for blastocoel
expansion [52]. While extrinsic factors such as the microenvironment are important,
intrinsic factors play a key role in remodeling metabolic needs to meet developmental
programs. For example, naïve ES cells are metabolically flexible and utilize both glycolysis
and OXPHOS metabolism. However, the transition to a primed state is marked by a switch
to glycolytic metabolism, which is largely due to HIF1α stabilization within the cell [19].
While changes in the levels of metabolic enzymes play a role in remodelling cellular
metabolism, the metabolites resulting from the activity of these enzymes are instrumental
in regulating pluripotency and/or differentiation. Our study is the first to provide a
comprehensive snapshot of the intracellular metabolite profile of feeder-free XEN cells
and reveals how elevated levels of key metabolites, mainly lactate, influence
differentiation.
Lactate, the primary source of carbon for the TCA cycle in both normal and cancer tissues
[53], is generated by the activity of LDHA, reportedly enriched in XEN cells (Figure 46A, B). Since lactate can be converted to pyruvate by LDHB, the stoichiometric ratio
between the two isoforms dictates the fate of pyruvate and lactate. In addition, the oxidation
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of pyruvate by the PDC is required for its conversion to acetyl CoA, and the activity of the
complex is regulated by the PDK family. Despite detecting elevated intracellular (Figure
4-3C) and extracellular (Figure 4-6C) lactate levels in XEN cells, the PDC was not
phosphorylated and is therefore active in XEN cells (Figure 4-6J). While reduced
expression of Mpc1 was found in XEN cells (Figure 4-6K), which may explain the
rerouting of pyruvate to lactate, PDC is known to have moonlighting abilities and can
translocate to the nucleus where it generates acetyl CoA for acetylation of H3K9 and
H3K18 [54]. Thus, since total lysates were used to analyze the phosphorylation status of
the PDC in ES and XEN cells, it is possible that a higher proportion of the active complex
is nuclear and not mitochondrial. Nevertheless, since elevated intracellular lactate levels
were found in XEN cells (Figure 4-3C), it was hypothesized that lactate plays a crucial role
during XEN differentiation.
Chemical inhibition to promote intracellular lactate accumulation (Figure 4-8H, I) or
supplementation of XEN induction media with L-lactate (Figure 4-8L, M) showed
enhanced XEN differentiation. Surprisingly, blocking pyruvate uptake into the
mitochondria using UK5099 led to cell mortality (Figure 4-8D, E). Alternatively,
promoting pyruvate uptake into the mitochondria by inhibiting PDKs resulted in significant
reduction in XEN differentiation (Figure 4-8P, Q). Therefore, our results support the notion
that maintaining intracellular lactate levels potentiates ES cells towards a XEN lineage.
Since lactate can stabilize HIF1α and promote a glycolytic phenotype [55], the lactateHIF1α axis may provide a mechanism for XEN differentiation. In addition, lactate can also
inhibit histone deacetylases [56], and in conjunction with active PDC (Figure 4-8J),
promote hyperacetylation, which we observed in XEN cells (data not shown). Thus, it
appears lactate is a key player linking metabolism with epigenetic factors and transcription.
These links provide insight into the role lactate plays in directing the differentiation of
XEN cells, and together they underscore the importance of how the metabolic profile
directs lineage commitment within the mouse early embryo.
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Chapter 5

5

« General Discussion and Conclusions »

5.1 « Summary of findings »
The mammalian embryo undergoes coordinated cell divisions resulting in the formation of
the blastocyst, a structure comprised of three cell lineages: embryonic stem cells, primitive
endoderm cells and trophoblast stem cells. These three cell types can be isolated, derived
and maintained indefinitely in vitro, allowing for their exploitation to answer fundamental
questions pertaining to development. It is well-understood that manipulating signaling
pathways can alter cell fate decisions. More recently, metabolism and its downstream
products have garnered attention with their influence on pluripotency and differentiation.
Overall, I hypothesized that both undifferentiated F9 and ES cells have distinct metabolic
and Nox expression profiles compared to their XEN counterparts, and that changes in these
profiles direct cell fate determination.
In Chapter 2 using F9 cells, I observed a significant increase in Nox1 and Nox4 expression,
protein abundance and activity in differentiated XEN-like cells. However, no observable
changes were seen in the various accessory components of the NOX family. Since RA
induces Gata6 expression [1] and GATA6 is involved in the XEN identity [2-4] and the
Nox1 promoter region contains a GATA6 binding site [5], I tested if GATA6 regulates
Nox1 and/or Nox4 expression. Overexpressing Gata6 induced XEN-like differentiation and
notably, both Nox1 and Nox4 expression were significantly upregulated. Next, I examined
the necessity of NOX activity using chemical inhibitors and genetic perturbations where
both showed an attenuation in XEN-like differentiation. Alternatively, while Nox1 and
Nox4 overexpressing-cells produced ROS, no differentiation was observed, despite having
a mildly active canonical WNT/β-catenin signaling. I concluded that a secondary source of
ROS (potentially mitochondrial), in combination with NOX-derived ROS is required to
induce differentiation.
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In Chapter 3, I attempted to answer two biological questions: first, whether XEN-like cells
produce mitochondrial ROS sufficient to induce differentiation; and second, the effect
passaging has on the differentiation potential and bioenergetic profile of XEN-like cells.
Initially, I examined the transcript and protein abundance of key metabolic enzymes
involved in glycolysis and OXPHOS metabolism. Analysing the levels of LDHA, LDHB,
PDKs and the phosphorylation status of PDH-E1α subunits suggested that the
differentiation towards a XEN-like lineage is accompanied by a switch from OXPHOS to
glycolytic metabolism. To test whether the reliance on glycolysis is due to mitochondrial
defects, I examined the levels of ETC proteins, and the expression of various markers
involved in mitochondrial dynamics. The SDHB subunit in complex II was significantly
downregulated in XEN-like cells, inferring reduced mitochondrial activity; however, the
expression of mitochondrial fusion markers was significantly higher. Therefore, XEN-like
cells exhibit a molecular signature indictive of fused mitochondria, but it is possible that
they do not rely on OXPHOS metabolism due to the downregulation in ETC components.
To address whether this observation is reminiscent of in vivo development, a more
comprehensive multiomic analyses approach on embryo-derived XEN cells was taken
(Chapter 4).
With respect to passage number on the differentiation and metabolism of XEN-like cells,
surprisingly, both early and late-passage cells were able to differentiate by RA.
Unexpectedly, early- and late-passage cells, however, had a dramatically different
metabolic profile, signifying the importance of evaluating stem cell metabolism prior to
their utilization for regenerative medicine.
Though the data from the F9 model was compelling, I shifted focus to using feeder-free ES
cells and embryo-derived XEN cells (XEN cells), both of which are relevant models that
recapitulate either EPI or PrE lineage, respectively. While reports have documented the
metabolic profile of ES cells, little is known about the bioenergetics of XEN cells and
inconsistencies exist [6-9]. In Chapter 4, I started by testing the sensitivity of either
populations to glycolytic or OXPHOS inhibition. The inhibition of either glycolysis or
OXPHOS in ES cells resulted in a similar reduction in cell viability, namely due to their
equal reliance on either metabolic pathway [6]. However, XEN cells showed a stark
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reduction in cell viability when glycolysis was perturbed, indicating their dependence on
glycolytic metabolism. Targeted and untargeted metabolomics coupled with biochemical
assays was used to detail the intracellular metabolic composition of both populations.
Several amino acids were found to be enriched in the XEN population, but more
specifically lactate and 2-hydroxyglutarate, from glycolysis and the TCA cycle,
respectively, were highly enriched in XEN cells. To expand our understanding on how
these metabolites influence cell fate, I performed bulk RNA sequencing and proteomic
analysis followed by GO and KEGG analysis on differentially expressed targets. In short,
three targets were highly enriched and had a link to metabolism: ALDH1B1, PKC2 and
LDHB. Since a switch to glycolysis with XEN-like differentiation was observed (Chapter
3), with the intracellular enrichment of lactate, and sensitivity to glycolytic inhibition in
XEN cells (Chapter 4), my conclusions were that XEN cells preferentially rely on
glycolytic metabolism. This conclusion was further supported by analysis of transcript and
protein abundance of LDHA, LDHB and various lactate transporters. However, unlike that
in the F9 model, the PDH-E1αpSer232/pSer293 levels declined significantly in XEN cells,
indicative of an active complex, despite pyruvate preferentially being converted into
lactate. One explanation for the reliance on glycolysis may be due to the low abundance of
Mpcs, thus restricting pyruvate availability for acetyl-CoA production. Despite
observations being largely phenomenology, would altering lactate levels chemically
influence cell fate? Results revealed that inhibiting mitochondrial pyruvate uptake was
lethal, whereas inhibiting MCT1 or supplementing with exogenous L-lactate enhanced
XEN differentiation in vitro. Alternatively, blocking the phosphorylation of the PDC
reduced XEN differentiation, thus directly implicating lactate in cell fate specification.
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5.2 « Discussion and Significance of Research »
5.2.1

ROS is required for stem cell-like differentiation

The NOX family of enzymes catalyze the reduction of oxygen into ROS using NAPDH as
an electron acceptor. In the F9 teratocarcinoma model, all Nox family members are
expressed, and exogenous ROS supplementation induced XEN-like differentiation [10]. I
also showed significant enrichment at the transcript and protein levels of both NOX1 and
NOX4 in XEN-like cells (Chapter 2). Although no reports have analyzed in detail the
expression and protein levels of the NOXs in the mouse embryo during preimplantation
development, publicly available scRNA-seq datasets show that the expression of Nox4 is
exclusive to the PrE with p22phox and Rac1 present in both PrE and TE lineages (data not
shown). The focus was on both NOX1 and NOX4, because Nox1 expression is regulated
by GATA6 in colorectal adenocarcinoma cells [11] and in F9 cells (Chapter 2), NOX4
requires the least number of subunits (p22phox only) [12] and can produce H2O2 directly.
Since both chemical agents and genetic perturbations attenuated XEN-like differentiation
(Chapter 2), a link must exist between NOX proteins, ROS, and differentiation towards the
XEN lineage.
The canonical WNT/β-catenin pathway connects NOX-derived ROS to differentiation, and
our lab has shown that WNT6 activates the pathway [13] by recruiting disheveled (DVL)
to the plasma membrane thus disrupting the destruction complex. Active WNT signaling
allows the translocation of β-catenin into the nucleus where it binds to TCF/LEF to induce
the expression of WNT target genes. At the transcript and protein level, DVL and its
interactor nucleoredoxin (NRX) are expressed, albeit no change during differentiation [14].
However, the DVL-NRX complex is regulated post-translationally by redox signaling
[14,15] where NRX binds DVL when reduced while it dissociates under oxidative
conditions. Therefore, it is possible that the physiological levels of ROS generated by the
NOX proteins result in the disassociation of NRX from DVL, thereby activating the
WNT/β-catenin pathway and promoting XEN-like differentiation. This observation was
also seen in colonic epithelial cells where WNT alone was not sufficient to activate the
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pathway, but instead it required ROS produced by NOX1 for the dissociation of NRX from
DVL [16].
NOX proteins subunits also play an important role in ROS production and WNT/β-catenin
pathway activation. For instance, RAC1 is required for the oxidase activity of NOX1 and
NOX2 [17], but when a dominant negative RAC1 is expressed, ROS production is
significantly reduced resulting in the destabilization of β-catenin [16]. Similar observations
have been made regarding the WNT/β-catenin pathway and PrE formation in vitro as
treating mouse ES cells with WNT3A induces Gata6 and Dab2 expression [18]. In vivo
experiments also show that embryos lacking β-catenin display inappropriate visceral
endoderm organization and subsequent failure to form an anterior-posterior axis. However,
embryos injected with GSK3-insenstive β-catenin display high number of visceral
endoderm cells [19]. Whether NOX-derived ROS regulates WNT/β-catenin signaling in
the embryo remains unknown. One caveat is that Nox1 and/or Nox4 overexpression alone
did not promote XEN-like differentiation and failed to produce sufficient ROS to activate
the WNT/β-catenin pathway. Therefore, an additional source of ROS, including that from
the mitochondria, may also participate and/or in fact drive differentiation.
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5.2.2

Metabolic regulation of cell fate specification

It is widely accepted that metabolism plays an active role in modulating signaling pathways
and the epigenetic landscape to direct stem cell fate [20,21]. Evidence from the increase in
intra- and extracellular lactate levels would indicate XEN-like cells (Chapter 3) and XEN
cells (Chapter 4) display a metabolic signature dependent on glycolysis with lactate playing
a central role.
Lactate, once considered an end-product of glycolysis, is implicated in bioenergetic
demands, redox homeostasis, epigenetic modifications [22] and many more [23]. In mice,
glucose-derived lactate is the primary carbon source for the TCA cycle in all tissues apart
from the brain; a similar trend was seen in cancer cells [24]. With regard to in vivo
development and in preparation for implantation, glycolysis is favoured as the secreted
lactate creates an acidic environment activating matrix metalloproteinases [25], which aid
in the degradation of the uterine lining [26]. As the embryo begins to implant, the
environment becomes more hypoxic, thus more lactate is produced, which induces
angiogenesis and oxygenation of the embryo [27].
In addition to the abovementioned roles, recent evidence has implicated lactate in
epigenetic regulation [22]. Zhang and colleagues demonstrated that lysine residues on
histones can be modified with a lactyl group. This group was from glucose-derived lactate,
a modification sensitive to changes in lactate levels or perturbations to glycolysis. During
the reprogramming of fibroblasts into pluripotent stem cells, the high glycolytic flux
increases acetyl-CoA and lactate levels, which in turn enhance histone acetylation and
lactylation, respectively [28]. These modifications favour an open chromatin state,
particularly at loci of pluripotency genes. In addition, lactate inhibits histone deacetylases
(HDACs) in vitro with concentrations ranging from 10-40mM, in comparison to the more
potent inhibitors, including TSA (nanomolar range) and butyrate (micromolar range), with
all treatments resulting in hyperacetylation and similar changes in gene expression [29].
Based on these results I predict that a similar mechanism occurs in XEN specification,
where the lactate produced is involved in histone lactylation as well as inhibiting HDACs
thereby facilitating H3K27Ac.
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Lactate levels can be regulated by hypoxia through HIF1α. Under normoxic conditions,
HIF1α is synthesized and degraded rapidly through the PHD-VHL complex while under
hypoxic conditions, the oxygen-dependent activity of PHD is halted [30], thus allowing for
the stabilization and subsequent translocation of HIF1α into the nucleus to upregulate genes
involved in glycolysis [31]. In tumours, poor angiogenesis in masses larger than 1mm
creates hypoxic pockets that stabilize HIF1α. Additionally, HIF1α can be stabilized
through oncogenes such as v-src and HRAS or by inactivating tumour suppressors like p53
and PTEN [32,33]. EpiSCs, which are glycolytic in nature and express high levels of
glycolytic enzymes such as Ldha, Pdk1 and Pygl, stabilize HIF1α under normoxic
conditions [6]. HIF1α is also stabilized by the product of its transcriptional targets such as
LDHA [34]. Lactate and pyruvate compete with α-ketoglutarate, the latter being required
for PHD activity, thus inhibiting it [35]. ROS has also been implicated in HIF1α
stabilization through the oxidation of Fe2+ into Fe3+ thus blocking the hydroxylase activity
of the PHD enzyme [36].
Together, my working model begins upstream with GATA6 upregulating Nox1 and Nox4,
which in turn produce physiological levels of ROS that result in the activation of the
WNT/β-catenin pathway (Chapter 2). Simultaneously, the ROS stabilizes HIF1α, which in
turn upregulates enzymes involved in glycolysis such as LDHA and PDK1 (Chapter 3 and
4). LDHA converts pyruvate into lactate, which acts in a positive feedback loop to block
PHD activity thereby further stabilizing HIF1α. Consequently, the accumulation of
intracellular lactate (Chapter 4) acts as substrate for lactylation and inhibits HDACs
thereby enhancing acetylation and XEN specification in vitro (Figure 5-2).
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Figure 5-1: Model of the role ROS and lactate play in XEN cells.
In this working model, GATA6 binds and upregulates the expression of Nox1 and Nox4,
which in turn result in the production of ROS. First, NOX-derived ROS plays a central
role by stabilizing β-catenin by promoting the release of NRX from DVL, which results
in the activation of the WNT/β-catenin pathway. Second, ROS stabilizes HIF1α under
normoxic conditions by indirectly inhibiting PHD activity. Stabilized HIF1a promotes a
glycolytic phenotype by upregulating LDHA, thus increasing the levels of intracellular
lactate. Lactate then further stabilizes HIF1a by inhibiting PHD activity and participates
in epigenetic regulation by promoting histone lactylation (La) and acetylation (Ac).
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5.3 Study Limitations and Future Studies »
It is extraordinary how stem cells can be propagated indefinitely and directed towards
specific cell fates. To-date, ES cells have been established from a variety of species
including mouse [37], primate [38], human [39], pig [40], and canine [41] to name a few.
While the in vitro systems used in my thesis capture certain aspects of development and
are accepted tools, they remain limited due to their 2D nature and more importantly, lack
in vivo data. Thus, they are unable to reproduce the spatial patterning, shape, size and in
utero environment observed in vivo. Despite these limitations, several new methods exist
to improve the 2D system and recapitulate in vivo settings.
Recent reports have shown that culturing human [42] or mouse [43] ES cells on defined
micropattern surfaces under specific morphogens results in the self-organization and
formation of the three germ layers, which allows for the examination of signaling pathways
and its components. Various modalities such as single-cell resolution imaging and singlecell multi-omics provide a comprehensive understanding of aspects of development that
would be technically difficult to capture in vivo. In addition, generation of knockout lines
in ES cells is achievable thus allowing researchers to investigate the role of signaling
pathways during development. While the micropattern system does have its advantages,
the cells are limited to 2D, therefore, experiments should always be validated using an in
vivo system.
One of the earliest ways researchers used to recapitulate the 3D environment of the embryo
is to form embryoid bodies (EBs) from ES cells. Historically, EBs were first generated
using EC cells [44] and have been later adopted in ES cells [45,46]. The generation of EBs
from ES culture is done by the removal of self-renewal conditions and culturing cells in
suspension or on bacterial grade plates or as hanging drops. While this process is relatively
simple, the EBs generated are heterogenous in size and cellular composition, thus making
it difficult to reach experimental conclusions. To bypass these inconsistencies, ES cells can
be cultured in micro-well plates, which produce large EBs, with uniform size and shape,
making them a reproducible model to study differentiation with a 3D context. While EBs
are generated and differentiated spontaneously or under defined conditions, they remain
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limited in mimicking early embryonic development. Recently, Rivron and colleagues
established a method of mixing embryonic and trophoblast stem cells in vitro resulting in
their self-assembly into a structure, a blastoid, which morphologically and transcriptionally
resemble the E3.5 blastocyst [47]. Despite their ability to implant in a host, blastoids fail
to give rise to mature blastocysts in vitro and in vivo. Remarkably, co-culturing of ES, XEN
and TS cells in an extracellular matrix scaffold yielded a structure containing all three
lineages and mimic the gastrula with enhanced developmental potential [48,49].
Collectively, any of these systems can be used to help us better understand the role of ROS
and metabolism in embryonic development.
While the 2D and 3D models provide cues to embryonic development they do not mimic
the environment around the embryo seen in vivo. Specifically, oxygen tension plays an
important role in regulating metabolism and cell fate. However, many studies on
pluripotent stem cells have been conducted at atmospheric conditions (21% O2), while the
oxygen tension in the female reproductive tract is roughly 5% [50-52]. Embryos that
develop under 21% oxygen tension are developmentally compromised when compared to
their 5% counterparts [53,54]. Despite the high oxygen levels, these embryos show
significantly higher levels of pyruvate uptake, which not only acts as a substrate but as a
powerful antioxidant to reduce hydrogen peroxide levels [55]. The embryo can utilize its
antioxidant defense system but prolonged exposure to high oxygen levels exhausts the
system resulting in ROS buildup and arrest. Alternatively, hypoxia can regulate stem cell
fate [6], with HIF1α stabilization enhancing glycolytic metabolism and subsequently the
transition from a naïve to a primed state. However, chronic exposure to hypoxic conditions
can be lethal to the embryo [56]. Therefore, optimizing the culture condition environment
to recapitulate in utero setting would be crucial to capture a true glimpse of the role
metabolism plays during embryonic development.
Lastly, a major limitation of this thesis is the lack of genetic studies (except for Chapter 2).
While chemical inhibitors used in Chapter 3 and 4 do alter metabolism and cell fate, they
have the potential to do so through off targeting effects. For example, 2-DG, a chemical
used to inhibit glycolysis, can activate AKT signaling through PI3K [57,58]. To minimalize
this limitation, I used additional chemical agents that target different enzymes involved in
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glycolysis or OXPHOS. However, genetic approaches using CRISPR-Cas9 to knockout
various key enzymes, most notably LDHA and LDHB, are necessary to corroborate the
chemical data. Collectively, however, with the resources provided I implicated NOX1/4derived ROS in XEN-like differentiation and expanded on our knowledge of the metabolic
phenotype to XEN cells, particularly a role for lactate in XEN induction in vitro.
While these limitations serve as key points to consider in future experiments, corroborating
the data by other means would not only serve to better understand the role of ROS and
lactate in an in vivo model or synthetic embryo, but by examining the effects of hypoxia
and knocking out key metabolic enzymes would provide invaluable clues on how
metabolism influences primitive endoderm formation. Briefly, I will suggest specific
experiments pertaining to each chapter. In Chapter 2, GATA6 was suggested as being
responsible for upregulating Nox1 and Nox4 expression. Although a report exists pertaining
to GATA6-Nox1 interaction [11], no data supports this for Nox4. Thus, performing a ChIP
assay to identify whether GATA6 directly binds to the Nox4 promoter is required.
Although differentiated F9 cells are XEN-like, it is possible that NOXs play a different role
in embryo-derived XEN cells, hence it also necessary to test directly whether NOX1 and
NOX4 and the ROS generated by them, are required for PrE formation in vivo.
In Chapters 3 and 4, the metabolic profile in XEN-like cells and XEN cells were
characterized. While studies were extended in Chapter 4 and metabolomics was used to
identify specific intracellular metabolites in XEN cells, more detailed analyses are required
to identify the role lactate plays in XEN differentiation. For example, fluorescent-labeled
lactate could be used to track its localization (cytoplasmic versus nuclear). Typically,
cytoplasmic lactate participates as a signaling molecule or in metabolism [59], whereas
nuclear lactate was recently shown to modify histones, thus influencing the epigenetic
signature of a cell [22,28,60].
In addition to the abovementioned experiments, preliminary data showed basal
mitochondrial respiration was significantly lower in XEN cells when compared to ES cells
(See Appendix 1 for details). This reduced activity was not, however, due to structural
issues as immunoblot analysis of fission and fusion markers, corroborated by TEM and
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morphometric analysis, was indicative of mitochondrial fusion. Instead, immunoblot
analysis revealed the downregulation of various subunits in the electron transport chain
(ETC), namely from complex II, III and V. Therefore, in combination with the reduced
mitochondrial substrate availability (Chapter 4), deregulation in ETC stichometry may also
explain the reduced mitochondrial activity observed in XEN cells. In addition, one target
that was highly enriched in our transcriptomic and proteomic datasets is the estrogenrelated receptor beta (ESRRB; Chapter 4), which has been shown to play a role in
development and pluripotency [61-69], modulating cell cycle to drive ES cells towards
either EpiSCs or XEN cells in vitro (bioRxiv) and metabolism [70,71]. I predict that
ESRRB will act as a linchpin by regulating mitochondrial dynamics and metabolism, which
consequently influences cell fate decisions. In collaboration with Bedzhov lab, a tamoxifen
inducible Esrrb deletion and overexpression ES lines were derived and will be used to first
assess the effects Esrrb will have on mitochondrial morphology. Next, both ES lines
harboring either Esrrb deletion or overexpression will be differentiated towards the XEN
lineage and characterized based on a panel of pluripotency and differentiation markers.
Overall, these experiments will shed light on a novel role for ESRRB in modulating
mitochondrial dynamics during XEN cell differentiation in vitro.
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5.4 « Conclusion »
Embryonic development is a complex process of orchestrating various signaling pathways
and multiomic changes that ultimately establish cell fates. The first lineage specification
segregates the TE from the pluripotent ICM, which is subsequently followed by the
establishment of the EPI and the PE. While the focus has been on how transcription factors
and signaling pathways instruct cells to adopt either EPI or PE fate, my thesis has provided
insight on the role ROS and metabolism play during this fate decision. Specifically, the
ROS generated by NOX1 and NOX4, which themselves are regulated by the endoderm
master regulator GATA6, is necessary but not sufficient for XEN-like differentiation. I
hypothesized that mitochondrial ROS acts in conjunction with NOX-derived ROS to
induce XEN-like differentiation. Surprisingly, both XEN-like cells and XEN cells favour
glycolytic metabolism over OXPHOS and when interrogated the intracellular metabolome,
lactate was identified as a factor, which I later show is involved in enhancing XEN
differentiation in vitro. Furthermore, I found that XEN cells re-route pyruvate from the
mitochondria and despite having mature mitochondria, various ETC subunits were
downregulated. Overall, my work implicates both ROS and metabolism in the acquisition
of XEN fate in vitro and this work sets the stage to test whether these mechanisms are
employed by the developing embryo in vivo.
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Appendix
In this section, I showcase two studies that do not directly contribute to the thesis but are
relevant to the topic of metabolism and differentiation. Both studies are preliminary in
nature and are incomplete to be considered a full chapter in the thesis.
In appendix 1, we assessed mitochondrial activity and dynamics in both ES and XEN
populations to try and explain the reliance on glycolytic metabolism we observed in
Chapter 4. A portion of this has been accepted for publication in Stem Cells alongside a
version of Chapter 4.
In appendix 2, we uncovered a new role for the posttranslational modification OGlcNAcylation during extraembryonic endoderm differentiation in vitro. More
importantly, in collaboration with the lab of Dr. Alexander Timoshenko, we implicated
galectins in this process.
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Appendix 1

6

« Analysis of mitochondrial activity and ultrastructure in
XEN cells »

6.1 « Introduction »
The late preimplantation blastocyst consists of two structures, the inner cell mass, which
houses the pluripotent epiblast and primitive endoderm (PrE) cells and the trophectoderm
(TE, placenta precursor). Epiblast cells give rise to the embryo proper while the PrE cells
differentiate into parietal and visceral endoderm cells, which contribute to the yolk sacs
and gut endoderm later in development [1]. While studying these lineages in vivo is
advantageous, these specific lineages can be isolated from the blastocyst and maintained
indefinitely in vitro.
From the inner cell mass, embryonic stem (ES) cells or naïve ES cells are derived from the
preimplantation epiblast and can either be cultured under FBS and leukemia inhibitory
factor (LIF) [2,3] or under serum-free in LIF-2i (2i: inhibitors of GSK3 and MEK) [4].
Alternatively, ES cells can be isolated from the post-implantation epiblast as primed
epiblast stem cells (EpiSCs) and are maintained with Activin A and FGF2 in culture [5,6].
Naïve and primed stem cells are interconvertible in vitro and possess different profiles of
pluripotency markers, epigenetic signatures, clonogenicity, chimera contribution and
developmental potential in vivo [7]. In addition to these stem cells, extraembryonic
endoderm (XEN) cells can also be isolated from the pre- and post-implantation blastocyst
and maintained indefinitely in vitro in FBS without exogenous factors [8,9]. XEN cells are
morphologically heterogenous with the co-existence of round/refractile cells and
epithelial-like cells, and while ES cells can repopulate the inner cell mass and contribute
to chimeras, XEN cells mainly repopulate the parietal endoderm in vivo [8] with little
contribution to the visceral endoderm [9]. Nevertheless, XEN cells can be differentiated
chemically [10-12] or by overexpressing Gata4, Gata6 [13,14] and Sox17 [15]
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transcription factors in ES cells. Regardless of the derivation method, downstream effectors
activate the endoderm signaling program driving cells towards the XEN lineage in vitro.
A major question that has recently surfaced is the role mitochondrial metabolism plays in
influencing XEN, and other cell fate decisions. The mitochondrion is an important
organelle involved in energy production, but it also plays key roles in macromolecule
anabolism and catabolism, redox maintenance, Ca2+ signalling and waste management
[16]. Mitochondrial activity is intimately linked to its structure, and it is implicated in
directing cell fate decisions [17,18]. Mitochondrial morphology is altered by fission or
fusion in response to metabolic requirement, stress and pluripotency or differentiation cues
[19]. Fission is initiated by the mitochondrial fission factor (MFF), which recruits the
dynamin-related protein 1 (DRP1). Once recruited from the cytosol, it is then
phosphorylated on serine 616 making it active, thereby forming rings to constrict
mitochondrial tubules. In contrast, mitochondrial transmembrane GTPases mitofusion-1
and mitofusion-2 (MFN1 and MFN2, respectively) promote fusion of the outer
mitochondrial membrane, while optic atrophy 1 (OPA1) operates on the inner
mitochondrial membrane and cristae. Collectively, the relative levels of these players
dictate the morphology of the mitochondria and cristae structure, and hence its activity.
Differentiated F9 teratocarcinoma cells, a model that can recapitulate primitive endodermlike differentiation in vitro, express high levels of Mfn1 and Mfn2, yet have significantly
downregulated levels of the complex II protein succinate dehydrogenase B (Chapter 3),
indicative of reduced mitochondrial activity. More importantly, despite these high levels
of mitochondrial fusion markers, these cells exhibit a metabolic phenotype reliant on
glycolysis, as evident by elevated extracellular lactate levels in these cells. This
counterintuitive phenomenon of cells having high levels of mitochondrial fusion markers
but reliant on a glycolytic metabolism is also observed in pluripotent stem cells of the
epiblast [20]. Naïve ES cells exhibit a bivalent metabolic profile, relying on both glycolysis
and oxidative phosphorylation (OXPHOS), and possess a mitochondrial structure
reminiscent of inactive mitochondria, round with immature cristae. However, primed
EpiSCs are exclusively glycolytic, largely due to downregulation of complex IV proteins,
yet they possess an elongated mitochondrial morphology with prominent cristae. It has
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been suggested that the low levels of estrogen-related receptor beta (ESRRB) in EpiSCs
relative to naïve ES cells may contribute to the deregulation in complex IV components
resulting in low mitochondrial respiration [20]. Recently, Choi and colleagues
characterized the metabolic profile of all three lineages of the blastocyst and found that
basal mitochondrial respiration was significantly lower in XEN cells when compared to ES
cells [21]. When cells were challenged with a mitochondrial uncoupler, respiration of XEN
cells was higher, suggesting that they can use OXPHOS metabolism.
In addition, one target that was highly enriched in our transcriptomic and proteomic
datasets is the estrogen-related receptor beta (ESRRB; Chapter 4), which has been shown
to play a role in development and pluripotency [22-30], modulating cell cycle to drive ES
cells towards either EpiSCs or XEN cells in vitro (bioRxiv) and metabolism [31,32]. I
predict that ESRRB will act as a linchpin by regulating mitochondrial dynamics and
metabolism, which consequently influences cell fate decisions.
In this report, we examined mitochondrial activity using flow cytometry and mitochondrial
ultrastructure with transmission electron microscopy (TEM), which was corroborated by a
detailed morphometric analysis on mouse ES and XEN cells in vitro. Results showed basal
mitochondrial respiration was significantly lower in XEN cells when compared to ES cells.
This reduced activity was not, however, due to structural issues as immunoblot analysis of
fission and fusion markers, corroborated by TEM and morphometric analysis, was
indicative of mitochondrial fusion. Instead, transcriptomic, and biochemical analysis
revealed the downregulation of various subunits in the electron transport chain (ETC),
namely from complex II, III and V. Despite these findings, the mechanism(s) for XEN cells
having reduced mitochondrial activity remains unknown.
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6.2 « Materials and Methods »
ES and XEN cell culture, in vitro XEN differentiation, protein extraction, quantification
and immunoblot analysis and RNA isolation, cDNA synthesis and qRT-PCR analysis are
as previously described in Chapter 4.

6.2.1

Mitochondrial copy number by digital droplet PCR (ddPCR)

RNA extraction and cDNA synthesis were as in Chapter 4 and ddPCR performed according
to the manufacturer’s instructions (Bio-Rad). Briefly, reactions were with 50pg–50ng of
cDNA, 100nM of forward and reverse primers and QX200TM ddPCRTM EvaGreenTM
supermix (Bio-Rad). Samples and oil were loaded onto a DG8TM cartridge (Bio-Rad) and
used in a QX200 droplet generator (Bio-Rad). Sample-oil mixtures were transferred into a
96-well plate and processed using a C1000 Touch thermocycler (Bio-Rad). PCR steps were
as follows: enzyme activation for 5 minutes at 95°C, denaturation for 30s at 95°C,
annealing/extension for 1 minute at 58°C, and signal stabilization for 5 minutes at 4°C.
Once complete, data acquisition was performed on QX200 Droplet reader using
QuantaSoftTM Software (Bio-Rad).

6.2.2

Transmission Electron Microscopy and Mitochondrial
Morphometric Analysis

Samples were prepared, fixed, and imaged as described previously [33]. Briefly, cells were
seeded onto 0.1% gelatin-coated Nunc™Thermanox™ coverslips (Thermo Fisher
Scientific) and grown for 48h at 37°C and 5% CO2. Cells were rinsed with pre-warmed
PBS solution and fixed in a 1:1 mixture of Karnovsky’s fixative (2.5% glutaraldehyde and
2% paraformaldehyde in 0.1M cacodylate buffer, pH 7.4) and maintenance media for 15
minutes at 37°C. Cells were then fixed with 100% Karnovsky’s fixative for 2h at room
temperature followed by four washes with cacodylate buffer for 10 minutes. Post-fixation
was carried out with 0.5% osmium tetroxide in 0.1M cacodylate buffer for 1h followed by
en-bloc staining overnight with 2% aqueous uranyl acetate at 4°C. Samples were
dehydrated in an ascending series of ethanol solutions and embedded in Spurr’s resin at
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60°C for 48h and sectioned (70nm) using an ultramicrotome (Reichert-Jung Ultracut E;
Leica Microsystems, Wetzlar, Denmark). Images were examined and captured using a
Philips CM10 TEM (Philips). Mitochondrial morphometric analysis was conducted using
ImageJ software (Version 1.51).

6.2.3

Mitochondrial membrane potential

Cells were cultured under normal conditions to 70% confluency, followed by dissociation
with Accutase and resuspension in 1X HBSS. Cells were counted and incubated with 5nM
Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM; Thermo Fisher Scientific) for
30 minutes at 37°C and 5% CO2 in the dark, with gentle mixing every 5 minutes. Samples
were washed three times with 1X HBSS and 20,000 events were analyzed by flow
cytometry using a FACSCanto SORP (BD Biosciences). Once a basal mitochondrial
membrane potential was established, 50µM of carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) was added to each sample and reanalyzed. Data was analyzed using FlowJoTM
(v10.7) and presented as mean florescence intensity (MFI).

6.2.4

Statistical analysis

All values are presented as mean ± SEM from at least three biological experiments. In TEM
experiments, three technical replicates were also included. Comparisons between two
groups were performed using Student’s t-test, while comparisons between three or more
groups were done using an ANOVA test followed by Tukey’s honest significant difference
test. All graphs and statistics were generated using Prism (v8.4.3). P-values were
considered significant at *P<0.05, **P<0.01, ***P<0.001, or ****P<0.0001.
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6.3 « Results »
6.3.1

Reduced mitochondrial activity in feeder-free XEN cells in
vitro

Differentiated F9 cells, which resemble XEN cells, exhibit a higher oxidative state and
more reactive oxygen species (ROS) production than their undifferentiated counterparts
[34]. Towards that end, we examined the oxidative state and mitochondrial activity in ES
and XEN cells (Figure 6-1A). To assess the oxidative state of ES and XEN cells, we
employed a modified MTT assay where the percentage of formazan crystals formed
relative to the control were normalized to total protein concentration [35]. No significant
difference was found in the oxidative state between the two populations. However, when
mitochondrial copy number was analyzed using ddPCR, lower levels of mitochondrial
copy number were detected in XEN cells relative to ES cells (P < 0.05; Figure 6-1B). Since
mtDNA copy number is a strong indicator of mitochondrial function and because
mitochondria contain their own genome where mutations are common due to the proximity
of ROS generated from the ETC [36], the possibility existed that respiration in XEN cells
was directly correlated to the fewer mitochondria present in these cell and hence less ROS.
To investigate this, we employed flow cytometry to measure mitochondrial membrane
potential using TMRM stain on ES and XEN cells cultured under basal conditions or
treated with a mitochondrial uncoupler, CCCP (Figure 6-1C). Basal respiration was
significantly higher in ES cells when compared to XEN cells (P < 0.001; Figure 6-1C),
which was reported previously [21]. A significant reduction in mitochondrial membrane
potential was observed when either population was treated with CCCP, but it was lowest
in XEN cells (P < 0.001; Figure 6-1C). Together, the data indicates that feeder-free XEN
cells exhibit reduced basal mitochondrial activity relative to ES cells.
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Figure 6-1: XEN cells exhibit low mitochondrial activity relative to ES cells.
(A) Relative oxidative state of ES and XEN cells. (B) ES and XEN cells assessed for
mitochondrial copy number. Nd5 was used as a mitochondrial gene and Rpl14 as a
nuclear gene. (C) Flow cytometric analysis of untreated and CCCP-treated ES and XEN
cells. A total of at least 3 independent experiments were analyzed and results are
presented as mean ± SEM. Asterisks denote groups of significance tested by a either
Student’s t-Test or One-Way ANOVA followed by a Tukey’s test. *P < 0.05,

***

P<

0.001.
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6.3.2

XEN cells exhibit mature mitochondrial morphology

Another mechanism to explain why mitochondrial activity was significantly lower in XEN
cells (Figure 6-1C) when compared to ES cells, might involve the lack of substrate uptake
and utilization of pyruvate. When the status of the pyruvate dehydrogenase complex
(PDC), which is responsible for the oxidative decarboxylation of pyruvate into acetyl-CoA
in the mitochondria, was examined it was found to be de-phosphorylated and hence active
(Chapter 4). Since mitochondria can utilize pyruvate and mitochondrial morphology is
linked to activity [17,18], morphological identity may explain the reduced activity
observed in XEN cells. Protein levels of fission and fusion markers were examined, and
results show the mitochondrial fission marker, MFF was not significantly different between
the two populations (Figure 6-2A, B). However, DRP1pSer616, which promotes
mitochondrial fission, was significantly higher in ES cells (Figure 6-2A, C; P < 0.05).
Alternatively, the mitochondrial fusion marker MFN2 was significantly higher in XEN
cells (Figure 6-2A). TEM and morphometric analysis to corroborate the molecular analysis
(Figure 6-2E-I) showed no significant difference in overall size of mitochondria between
cell populations (Figure 6-2F). The mitochondria of XEN cells, however, appeared
significantly more elongated (Figure 6-2E, G) with lower mean incident cristae angle
(Figure 6-2E, H), which agrees with elevated MFN2 levels (Figure 6-2A, D). In contrast,
the mitochondria in ES cells were round with bent cristae (Figure 6-2E). Lastly, the
quantification of cristae length to overall surface area, an indirect indicator of
mitochondrial activity, was significantly lower in XEN cells (Figure 6-2I; P < 0.05). Thus,
the reduced activity seen was not due to mitochondrial structure but could be also explained
by the surface area for ETC components being significantly lower in XEN cells.
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Figure 6-2: XEN cells exhibit mature mitochondria with prominent cristae.
(A) Immunoblot analysis and (B-D) densitometric analysis of fission markers MFF and
DRP1pSer616 and fusion marker MFN2 in ES and XEN cells. TOM20 was used a
mitochondrial loading control. (E) Representative TEM micrograph of mitochondria
from ES and XEN cells cultured under maintenance conditions. Scale bars is 400nm
and images were captured at 11000x magnification. Mitochondrial morphometric
analysis such as (F) area, (G) mean aspect ratio, (H) mean incident cristae angle and
(I) cristae length-to-area ratio in ES and XEN cells. For image analysis 105 and 95
mitochondria were analyzed from ES and XEN cells, respectively. A total of 3
independent experiments were analyzed and results are presented as mean ± SEM.
Asterisks denote groups of significance tested by a Student’s t-Test. *P < 0.05, ***P <
0.001, ****P < 0.0001.
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6.3.3

ETC complex II, III and V are reduced in XEN cells

Previous reports indicate that the reduced mitochondrial activity in EpiSCs is largely due
to reduction in complex IV cytochrome c oxidase levels and activity [20]. Using publicly
available RNA sequencing data of ES and XEN cells [12], the expression profile of various
components from the ETC were examined (Figure 6-3A). Surprisingly, most of the targets
from complex I-IV were downregulated in XEN cells when compared to ES cells.
Specifically, 23 out of 38 targets from complex I, 3 out of 8 targets from complex II, 4 out
of 6 targets from complex III, and 12 out of 19 targets from complex IV were significantly
downregulated in XEN cells. A total OXPHOS rodent westernblot antibody cocktail, which
probes for complex I subunit (NDUFB8), complex II subunit (SDHB), complex III subunit
(UQCRC2), complex IV subunit (MTCO1) and complex V subunit (ATP5A) was used to
validate the transcriptomic data and immunoblot analysis showed a significant reduction
in complex II, III and V subunits in XEN cells relative to ES cells (Figure 6-3B, C).
Together, this data indicates that the reduction in mitochondrial activity in XEN cells is
also due, in part, to the downregulation of various ETC subunits.
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Figure 6-3: Downregulation of ETC components in XEN cells.
(A) Expression heatmap of components in the ETC complexes from ES and XEN cells.
The data was adopted from Anderson and colleagues (12). (B) Immunoblot analysis
and (C) densitometric analysis of ETC components in ES and XEN cells using the
MitoProfile antibody. TOM20 was used a mitochondrial loading control. A total of 3
independent experiments were analyzed and results are presented as mean ± SEM.
Asterisks denote groups of significance tested by a One-Way ANOVA followed by a
Tukey’s test. **P < 0.01, ***P < 0.001.

204

6.4 « Discussion »
We have previously shown that differentiated F9 cells (Chapter 3) [37] and embryo-derived
XEN cells (Chapter 4) rely on glycolytic metabolism by uncovering a mechanism where
the expression of mitochondrial pyruvate carrier (Mpcs) is downregulated thereby
restricting substrate availability for the active PDC. Despite this finding, we were interested
in examining whether mitochondrial activity was altered due to reduced substrate
availability and if mitochondrial structure was a culprit in this process. XEN cells exhibited
a significant reduction in mtDNA (Figure 6-1A) and activity when assessed by flow
cytometry using TMRM (Figure 6-1C). Surprisingly, biochemical analysis, TEM, and indepth morphometric analysis of the mitochondria in both populations demonstrated mature
and elongated mitochondria with prominent cristae in XEN cells (Figure 6-2). Previous
reports have shown similar observations regarding mitochondrial remodelling when
transitioning from naïve-to-primed states, with naïve being more globular and primed more
elongated with complex cristae network [20,38]. However, mechanistic studies have yet to
explain whether the changes in mitochondrial structure between naïve and primed states is
due to fission and fusion stoichiometry or mitophagy. In XEN cells, we observed a
significant decrease in the levels of DRP1pSer616 (Figure 6-2A, C) coinciding with an
increase in MFN2 levels (Figure 6-2A, D), which was corroborated by imaging and
morphometric analyses (Figure 6-2E-I). Therefore, XEN cells undergo mitochondrial
remodelling by tipping the scale towards mitochondrial fusion.
Mature mitochondria with complex cristae networks are expected to produce energy
efficiently mainly due to the increased space for intermembrane proteins for energy
production [39]. However, in XEN cells, despite having mature mitochondria with
prominent cristae, the reduced cristae length-to-area ratio in XEN cells (Figure 6-2I)
alluded to the fact that less space is available for ETC proteins and their reactions to take
place. We analyzed levels of various ETC subunits at the transcript and protein level and
like the F9 model, deregulation in ETC stoichiometry was observed in XEN cells, namely
in complex II, III and V subunits (Figure 6-3). Notably, cytochrome c oxidase family in
complex IV were largely downregulated in EpiSCs when compared to ES cells, and a
similar observation was made in human ES cells, suggesting that reduced mitochondrial
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activity due to deregulation in ETC components may be conserved in cells of the inner cell
mass [20]. Mechanistically in EpiSCs, the low levels of estrogen-related receptor beta
(ESRRB) may contribute to the deregulation in complex IV components resulting in the
low mitochondrial respiration observed in these cells [20], while we observed a similar
reduction in ESRRB levels during XEN differentiation (unpublished data), we predict that
ESRRB may play an analogous role in XEN cells and this work is currently under
investigation.
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6.5 « Future Directions »
ESRRB is part of the nuclear receptor family characterized by a weak transactivation
domain at the N-terminus, a zinc finger DNA-binding region in the centre of the
polypeptide and a ligand-binding domain at the C-terminus of the protein. Esrrb is
expressed in the oocyte and the zygote [40] and declines until the morula stage and inner
cell mass at 3.5dpf where it is restricted to the epiblast [25]. Esrrb expression is abruptly
downregulated in the epiblast and is turned on in the extraembryonic ectoderm, where it is
involved in trophoblast development [30]. Knocking out Esrrb in mouse results in
embryonic lethality at E10.5 due to placental abnormalities [29]. In addition to its role in
vivo, ESRRB also maintains pluripotency of ES cells in vitro, and can bind NANOG and
OCT4, but is significantly downregulated when they are disrupted [25,28]. Knocking down
Esrrb in ES cells impacts their self-renewal [22,28] and induces the upregulation of TE
markers [26,28]. Conversely, overexpression of Esrrb enhances the primed-to-naïve
transition [23] and blocks embryoid body-induced differentiation with the exception of the
endodermal lineage [27]. Other than its role in regulating pluripotency, ESRRB is also
implicated in metabolism. Generally, estrogen-related receptors (ERRs) are involved in
promoting OXPHOS metabolism by recruiting the coactivators peroxisome proliferatoractivated receptor-γ coactivator-1 α and β (PGC-1α and PGC-1β, respectively).
Interestingly, this ERR-PGC-1α/β complex promotes an OXPHOS to glycolysis metabolic
transition [31], which is necessary for the reprogramming of fibroblasts into induced
pluripotent stem cells (iPSCs) [32]. Collectively, we predict that ESRRB acts as linchpin
by regulating mitochondrial dynamics and metabolism, which consequently influences cell
fate decisions.
In collaboration with Bedzhov lab, a tamoxifen inducible Esrrb deletion and
overexpression ES lines were derived and will be used to first assess the effects Esrrb will
have on mitochondrial morphology. Next, both ES lines harboring either Esrrb deletion or
overexpression will be differentiated towards the XEN lineage and characterized based on
a panel of pluripotency and differentiation markers. Overall, these experiments will shed
light on a new role for ESRRB in regulating metabolism through modulating mitochondrial
dynamics and influencing XEN cell differentiation in vitro.
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Appendix 2

7

« O-GlcNAcylation and regulation of Galectin-3 in
extraembryonic endoderm differentiation »

7.1 « Introduction »
Many proteins in vertebrates are regulated through the addition of 𝛽-N-acetylglucosamine
(GlcNAc) to the hydroxide moiety of serine or threonine residues, known as OGlcNAcylation [1,2]. The addition of O-GlcNAc acts in competition with phosphorylation
at the same, or nearby amino acids [3-5], demonstrating its integral function in protein
regulation. Unlike protein phosphorylation and dephosphorylation, which are carried out
by a variety of kinases and phosphatases, respectively, O-GlcNAcylation is regulated by
only two enzymes: O-GlcNAc transferase (OGT), which transfers GlcNAc to proteins from
a donor UDP-GlcNAc derived from the hexosamine biosynthesis pathway [6], and Nacetyl-𝛽-D-glucosaminidase (O-GlcNAcase, OGA), which removes GlcNAc from
proteins [7].
O-GlcNAcylation is a dynamic process that is regulated through multiple mechanisms. As
UDP-GlcNAc is derived through the hexosamine biosynthesis pathway, the availability of
GlcNAc is highly regulated by glucose metabolism [8,9] and insulin [10]. This posttranslational modification is also sensitive to free fatty acids [11], thermal stress [12] and
oxidative stress [12-14]. The addition or removal of O-GlcNAc in response to nutrients
and stress is not universal as the O-GlcNAcylated proteome during oxidative stress is
dynamic where many proteins have increased O-GlcNAcylation, while many others have
decreased O-GlcNAcylation despite an overall increase in global O-GlcNAc in the cell
[14]. O-GlcNAc is also differentially regulated during development and differentiation.
High levels of O-GlcNAc are known to be important in pluripotency in mouse embryonic
stem (ES) cells by regulating the activity of OCT4 and SOX2, transcription factors
necessary in maintaining pluripotency [15]. Additionally, global O-GlcNAc has been
reported to decrease in response to induced differentiation of neutrophils [16] and
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cardiomyocytes [17] and excess O-GlcNAc in human ES cells inhibits ectodermal lineage
differentiation [18].
The 𝛽-galactoside and carbohydrate binding family of proteins, Galectins, have members
that are known to be O-GlcNAcylated [14,19]. This family of proteins has an array of
cellular functions including involvement in autophagy, transcriptional regulation, WNT
signaling, and cell division when inside of the cell and interacts with soluble and
membrane-bound glycoproteins when outside of the cell [20,21]. Like O-GlcNAcylation,
Galectins are known to be involved in cellular stress responses [22], where we have
demonstrated increased expression of multiple Galectin family members in response to
oxidative stress [23]. Galectin family member expression is also regulated during
differentiation of neutrophils and in the differentiation of bone marrow and mesenchymal
stem cell precursors [24].
Extraembryonic endoderm (XEN) is a vital structure in the developing embryo,
differentiating from the inner cell mass in mice at E4.5, is essential for later patterning and
segmentation [25]. We have demonstrated a role of oxidative molecules in the
differentiation of the F9 teratocarcinoma cell line, a model of XEN differentiation [26,27].
Although ourselves and others have elucidated much about the differentiation of XEN, to
our knowledge there are no studies investigating the role of O-GlcNAc in this early cell
lineage. Furthermore, very little is known about the role of Galectins in XEN, with only a
single study in the literature citing decreased expression of Lgals3 (the gene encoding
Galectin 3) in F9 cell XEN differentiation [28].
The goal of our study was to understand the role of O-GlcNAcylation, specifically on
galectins, may regulate XEN differentiation. Using established in vitro models, we
demonstrated that O-GlcNAc levels decrease in response to XEN differentiation and that
Galectin 3 alters its intracellular versus extracellular localization depending on its OGlcNAc status during XEN differentiation. However, increasing global O-GlcNAc levels,
and inhibiting the extracellular localization of GAL3 does not affect XEN differentiation.
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7.2 « Materials and Methods »
ES and XEN cell culture, in vitro XEN differentiation, protein extraction, quantification
and immunoblot analysis and RNA isolation, cDNA synthesis and qRT-PCR analysis are
as previously described in Chapter 4 [29,30].

7.2.1

Dot blot assay

Global O-GlcNAcylation status in cells was analyzed using Bio-Dot® Microfiltration
apparatus (Bio-Rad) as described previously [16]. Briefly, nitrocellulose membranes were
pre-wetted with 1X Tris-buffered saline with Tween-20 (TBS-T). 4µg of protein was
loaded into the dot blot apparatus and proteins were transferred to the membrane through
a 1.5-hour gravity filtration. Membranes were incubated in blocking solution (3% bovine
serum albumin (BSA) and 1% skim milk in 1X TBS-T) for 1 hour. After washing blots in
1X TBS-T, they were incubated in primary antibody to detect O-GlcNAc (RL2; 1:1000;
Thermo Scientific) with 5% BSA and 0.1% NaN3 in 1X TBS-T overnight at 4°C. Blots
were washed in 1X TBS-T and incubated with goat anti-mouse secondary antibody
(1:10,000; Millipore-Sigma) in 5% skim milk in 1X TBS-T for 2 hours at room
temperature. After washing in TBS-T, blots were incubated in Luminata™ Classico
Western HRP Substrate (Millipore-Sigma) and imaged using a Chemi Doc Touch Imaging
System (Bio-Rad). Densitometry of dot blots were performed using ImageLab (Bio-Rad).

7.2.2

Galectin-3 ELISA

Extracellular Galectin 3 was detected using the Galectin-3 Mouse SimpleStep ELISA® Kit
(Abcam). Briefly, cell supernatant was collected for 3 days of cell culture and was
centrifuged at 2000 g for 10 minutes. Supernatants were diluted 50% with Sample Diluent
NS (supplied from kit). Subsequent steps were carried out according to manufacturer’s
instructions in triplicate. Data analysis was performed after obtaining a standard curve from
provided reagents in the kit to determine pg/mL concentrations of Galectin 3. Galectin 3
concentrations in E14 and E4 cells were normalized to intracellular protein concentration
which was determined using a Bradford Assay using DC™ Protein Assay (Bio-Rad).
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7.2.3

Statistical analysis

All figures are representative of at least 3 independent biological replicates. For data
comparisons between two groups an unpaired Student’s t-test was performed. For data
comparisons between two groups where one group was set as a relative value of 1, a One
Sample t-test was performed. For data comparisons between 3 or more groups, a One-way
ANOVA was performed with Tukey’s Honest Significant Difference post-hoc analysis.
All statistical analyses were performed using GraphPad Prism version 8.4.2, (GraphPad
Software, San Diego, California USA). P-values were considered statistically significant
at *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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7.3 « Results »
7.3.1

Global reduction in O-GlcNAcylation levels in feeder-free
XEN cells

Using the terminally differentiated, feeder-free mouse XEN cell line E4, hereby referred
to as XEN cells, and the E14 mouse embryonic stem cell line, E14, hereby referred to as
ES cells, we evaluated the global O-GlcNAcylation levels in pluripotent ES cells compared
to XEN cells. Immunoblot probing for O-GlcNAcylation showed high variation in the XEN
line (Figure 7-1A and B), which lead us to adopt the dot blot technique which is commonly
used to assess global levels of post-translational modifications including phosphorylation
and O-GlcNAcylation [31,32]. This technique showed less variation and demonstrated a
significant decrease in global O-GlcNAcylation in XEN cells compared to ES cells (Figure
7-1C and D). O-GlcNAcylation is regulated by two enzymes: OGT and OGA. OGT
catalyzes the addition of GlcNAc to serine/threonine residues and OGA is responsible for
removing the modification. Ogt and Oga expression levels are significantly decreased in
XEN cells (Figure 7-E and F, respectively), however the Ogt/Oga expression ratio in XEN
cells was significantly increased, suggesting that although relative expression of both
enzymes are decreased in XEN cells, there is more relative expression of Ogt than Oga
(Figure 7-1G). Overall, despite observing a higher Ogt/Oga expression, global OGlcNAcylation levels decline in XEN cells.
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Figure 1: Global O-GlcNAcylation levels decreased in XEN cells compared to pluripotent ES cells
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Figure 7-1: Global O-GlcNAcylation is decreased in XEN compared to ES cells.
(A) Immunoblot and (B) densitometry of O-GlcNAc detecting antibody RL2 in ES and
XEN cells. (C) Immuno-dot blot and (D) densitometry and of RL2 in ES and XEN cells.
RT-qPCR of the O-GlcNAc adding enzyme Ogt (E) and the O-GlcNAc removing
enzyme Oga (F) in ES and XEN cells. (G) Ratio of relative expressions from E-F of
Ogt/Oga in ES and XEN cells. Bars represent mean values ± SEM. N=3. *P<0.05,
**P<0.01.

216

7.3.2

OGA inhibition alters pluripotency and XEN marker
expression patterns

To determine the effects of global O-GlcNAcylation levels on pluripotency and
endodermal markers in their respective cell lines, we treated ES and XEN cells with 10𝜇M
Thiamet G (TG), an OGA inhibitor. We confirmed TG is effective in inhibiting OGA after
24 hours as we observed a significant increase in global O-GlcNAcylation in XEN cells
(Figure 7-2A and B). Unexpectedly inhibition of OGA for 24 hours in ES cells resulted in
no change in Oct4 expression (Figure 7-2C) and decreased expression of Nanog (Figure 72D). Conversely, OGA inhibition in XEN cells resulted in no change in Gata6 expression
(Figure 7-2E) and an expected decrease in FoxA2 levels (Figure 7-2F). Together, our
results highlight a role for O-GlcNAcylation in regulating marker of pluripotency and
endodermal lineage.
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Figure 2: OGA inhibition alters pluripotency and XEN marker expression
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Figure 7-2: OGA inhibition alters pluripotency marker expression in ES and
XEN marker expression in XEN cells.
(A) Immuno-dot blot and (B) densitometry of O-GlcNAc detecting antibody RL2 in
XEN cells treated with or without 10 µM TG, an OGA inhibitor. RT-qPCR of
pluripotency gene expression Oct4 (C) and Nanog (D) in ES cells treated with 10
µM TG for 24 hours. RT-qPCR of XEN marker gene expression Gata6 (E) and
FoxA2 (F) in XEN cells treated with 10 µM TG for 24 hours. Bars represent mean
values ± SEM. N=3. *P<0.05, **P<0.01.
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7.3.3

Lgals3 expression is decreased in XEN cells

Since global O-GlcNAcylation is decreased in XEN compared to ES cells and XEN marker
FoxA2 is inhibited when global O-GlcNAcylation is increased through OGA inhibition, we
sought to identify a candidate protein that may play a role in XEN differentiation; one that
is likely regulated through O-GlcNAcylation. We previously demonstrated altered
oxidative stress during XEN-like cell differentiation [26] and have showed that galectins
show altered expression patterns in response to differentiation and oxidative stress [23].
RNA sequencing analysis of transcripts from ES and XEN cells show changes in many
galectin genes and genes involved in O-GlcNAcylation (Figure 7-3A). We validated the
changes observed in galectin genes by RT-qPCR and showed that all but Lgals3 (Figure 73D) showed no difference in expression between ES and XEN cells. Further in silico
analysis of the GALECTIN 3 (GAL3) amino acid sequence identified four putative OGlcNAcylation sites: S6, T189, T151 and S208 [33]. Equipped with the transcriptomic and
expression data and the in-silico work, we sought to elucidate the role of O-GlcNAcylation
on GAL3, and how it can subsequently regulate pluripotency and XEN differentiation.

220

Figure 3: Lgals3 expression is decreased in XEN cells compared to ES cells
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Figure 7-3: RNA sequencing and gene expression analysis of Galectin genes in
ES and XEN cells.
(A) Heat map of RNA sequencing of transcripts in ES and XEN cells showing Lgal
genes 1-4, 7-9 and 12 and genes involved in O-GlcNAcylation Ogt, Mgea5, Gfpt1
and 2. RT-qPCR of Lgal1 (B), Lgal2 (C), Lgal3 (D), Lgal4 (E), Lgal7 (F), Lgal8
(G), Lgal9 (H) and Lgal12 (I). Bars represent mean values ± SEM. N=3. **P<0.01.
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7.3.4

Elevated extracellular to intracellular ratio of
GAL3 in XEN cells

GAL3 was our candidate as a protein that may be regulated by O-GlcNAcylation and a
protein that has functions inside and outside of the cell [20]. Immunoblot analysis of GAL3
showed a significant decrease in intracellular GAL3 levels in XEN cells compared to ES
cells (Figure 7-4A and B), in agreement with the expression data (Figure 7-3D). As
galectins have different function depending on intracellular versus extracellular
localization, we performed GAL3 ELISA to determine the extracellular levels relative to
intracellular protein concentration. XEN cells displayed a significant decrease in relative
extracellular GAL3 when compared to ES cells (Figure 7-4C). However, when comparing
the intracellular to extracellular concentration ratio, we found a significant decrease in
GAL3 in XEN cells relative to ES cells (Figure 7-4D). Although a decrease in Lgals3
expression and GAL3 levels intracellularly was observed in XEN cells, more extracellular
GAL3 is present in XEN cells than their ES counterparts. Therefore, the reduction observed
in GAL3 intracellularly is due to increased GAL3 secretion, and O-GlcNAcylation may
play a role in GAL3 localization, and subsequently function.
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Figure 4: ES cells have higher intracellular and extracellular GAL3 levels compared to XEN cells
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Figure 7-4: ES cells have increased intracellular GAL3 while XEN have
increased extracellular GAL3 levels compared to their own intracellular
levels.
(A) Immunoblot and (B) densitometry of GAL3 in ES and XEN cells. (C) ELISA
of extracellular GAL3 in the media of ES and XEN cells. (D) Relative
intracellular to extracellular ratio of GAL3 in ESC and XEN. Bars represent mean
values ± SEM. N=3. *P<0.05, **P<0.01, ***P<0.001.
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7.3.5

Inhibiting OGT in ES cells increases extracellular GAL3
levels

The intracellular versus the extracellular localization of GAL3 alters its function [20]. We
sought to understand the effects of global O-GlcNAcylation changes on the intracellular
and extracellular levels of GAL3 in ES and XEN cells. OGA inhibition by TG was
confirmed to increase O-GlcNAcylation levels in XEN cells (Figure 7-2A and B). We also
confirmed Alloxan, an OGT inhibitor, was effective in reducing global O-GlcNAcylation
levels in ES cells (Figure 7-5A and B). To confirm that O-GlcNAcylation status of GAL3
was indeed altering its intracellular versus extracellular localization, we performed an
ELISA to detect extracellular GAL3 levels. We observed a significant increase in
extracellular GAL3 relative to intracellular protein concentrations in ES cells treated with
Alloxan, but no change with TG treatment (Figure 7-5E). Alternatively, no change in
extracellular GAL3 in XEN cells treated with either Alloxan or TG (Figure 7-5F) was
observed. Our results suggest that GAL3 localization is dependent on its O-GlcNAcylation
status in ES cells, which implicate GAL3 in regulating pluripotency but not differentiation.
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Figure 7-5: OGT inhibition in ESC increases extracellular GAL3.
(A) Immuno-dot blot and (B) densitometry of O-GlcNAc detecting
antibody RL2 in ESC treated with 5 mM Alloxan, an OGT inhibitor. (C)
ELISA of extracellular GAL3 in the media of ES cells treated with 10 µM
TG or 5 mM Alloxan. (D) ELISA of extracellular GAL3 in the media of
XEN cells treated with 10 µM TG or 5 mM Alloxan. Bars represent mean
values ± SEM. N=3. *P<0.05.
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7.3.6

OGA inhibition is not sufficient to inhibit XEN differentiation
in vitro

Given that global O-GlcNAc levels are decreased in XEN (Figure 7-2C and D) we sought
to determine the role global O-GlcNAc, and thus by proxy the role of extracellular GAL3
on XEN differentiation. ES cells were differentiated towards a XEN lineage for 8 days in
the presence or absence of OGA inhibitor, TG. To our surprise, the relative expression of
pluripotency markers Oct4 (Figure 7-6A) and Nanog (Figure 7-6B) showed either lower
expression or no change in expression with TG treatment during differentiation than
untreated differentiation controls, respectively. This suggests that inhibition of OGA, and
likely the forced intracellular localization of GAL3, does not block ESC exit from
pluripotency. Investigating XEN markers Gata6 (Figure 7-6C) and FoxA2 (Figure 7-6 D),
neither showed any difference in relative expression with TG treatment during
differentiation compared to untreated differentiated controls. This also suggests that global
inhibition of OGA, and thus increasing O-GlcNAc levels, does not inhibit XEN
differentiation.
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Figure 6: OGA inhibition is not sufficient to block XEN differentiation
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Figure 7-6: OGA inhibition is not sufficient to inhibit ES differentiation towards
XEN in vitro.
(A) Representative phase contrast images of ES, XEN and cXEN cells. RT-qPCR of
pluripotency markers Oct4 (B) and Nanog (C) and XEN markers Gata6 (D) and Dab2
(E) of ES cells differentiated towards XEN. RT-qPCR of pluripotency markers Oct4 (F)
and Nanog (G) and XEN markers Gata6 (H) and FoxA2 (I) of ES cells differentiated
towards XEN with control or 10 µM TG. Bars represent mean values ± SEM. N=3.
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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7.4 « Discussion »
The objective of this study was to better understand the role of O-GlcNAcylation during
XEN differentiation and explore how it can regulate galectin expression and localization.
Here, we report that global O-GlcNAc is decreased in XEN cells and that inhibiting OGA
has no effect on XEN differentiation. Lastly, GAL3 localization is dependent on both
differentiation and O-GlcNAc status.
Decreased O-GlcNAc in response to differentiation is consistent in many models. We
observed decreased global O-GlcNAc in XEN compared to ES cells (Fig. 1), which is
consistent with previous work by Kim et al., who showed decreased global O-GlcNAc
when ES cells were differentiated towards cardiomyocytes [17]. In addition, we have
shown that neutrophil differentiation of HL-60 cells also has decreased global O-GlcNAc
[16]. We also observed that this global decrease in O-GlcNAc coincided with decreased
expression of Ogt, the gene expressing the enzyme responsible for adding the modification
(Figure 7-1). The decreased expression of the modifying enzyme has also been observed
in the cardiomyocyte differentiation model [17]. Although previous work has demonstrated
the complexity of the O-GlcNAc modification in response to cell stress [14] the overall
decrease in O-GlcNAc is likely in response to the exit from pluripotency. Jang and
colleagues demonstrated transcription factors involved in pluripotency OCT4 and SOX2
are both modified by O-GlcNAc in pluripotent ES cells and have this modification removed
with induced differentiation [15].
As the O-GlcNAc modification has been shown consistently to be high in pluripotency and
to decrease in response to differentiation, we explored how chemical inhibition of the
modification-removing enzyme, OGA, would affect both cell populations. We expected
blocking OGA, and thus increasing the amount of global O-GlcNAc, would increase the
expression of pluripotency markers in ES cells and would decrease the expression of XEN
markers in XEN. To our surprise OGA inhibition had no effect or the opposite effect on
pluripotency markers in ES cells (Figure 7-2), which may highlight the yet unexplored
complexity of the O-GlcNAc network in pluripotency, as OGA inhibition may be altering
the enzyme’s ability to regulate proteins involved in pluripotency that should not have an
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O-GlcNAc modification. On the other hand, in XEN cells OGA inhibition either had no
change or decreased XEN marker expression (Figure 7-2), which suggests the activity of
the modification enzymes OGT and OGA, and thus the number proteins with O-GlcNAc
may be playing a role in maintaining the XEN phenotype.
Previous work has identified the galectin family of proteins being regulated by
glycosylation [14,19,34] where particularly GAL3 was identified to be modified by OGlcNAcylation [14]. To our knowledge only a single study has been published exploring
galectins in a XEN model, the F9 cell. Consistent with this work we observed a similar
decrease in Lgals3 expression in XEN cells compared to ES cells (Figure 7-3) that was
observed in Lu and colleagues’ differentiation of F9 cells towards the XEN-like lineage
[28]. Unlike the changes in O-GlcNAc levels, which have been consistent in the literature,
galectins appear to have context specific changes in expression [21]. For example, in
contrast to our results, HL-60 cell differentiation towards neutrophils have increased
expression of Lgals3 and Lgals10 [23] and decreased expression of Lgals12 [16], where
we only observed changes in Lgals3 expression.
As Lgals3 expression was the only observed change in XEN cells compared to ES cells,
we further explored the regulation of this protein in pluripotency and differentiation. As a
family of proteins galectins have many functions, and GAL3 has functions both inside and
outside of the cell [20]. We observed decreased intracellular GAL3 in XEN cells, however,
XEN cells also showed an increased extracellular to intracellular ratio GAL3 in when
compared to ES cells (Figure 7-4). Iacobini and colleagues discussed the role of GAL3 in
bone lineage differentiation, however, this group highlighted that GAL3 extracellular, or
intracellular localization could enhance or inhibit specific lineage differentiation [35].
Given our results showing increased intracellular GAL3 in ES cells compared to XEN
cells, it is likely that extracellular GAL3 is playing a role in enhancing XEN differentiation.
To further explore the question of GAL3 regulation through O-GlcNAcylation, we
inhibited the O-GlcNAc addition enzyme, OGT, in ES cells. We determined that OGT
inhibition did decrease global O-GlcNAc levels (Figure 7-5A, B), while simultaneously
increased extracellular GAL3 levels (Figure 7-5C). GAL3 secretion is considered non-
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classical, meaning it does not exit the cell through the secretory pathway and has been
found to exit the cell in exosomes [36]. O-GlcNAcylation has been shown to regulate
protein sorting exosomes, however, it is still unclear if it is binary or a more dynamic
regulation process [37]. To our knowledge no studies have investigated the composition or
role of exosomes in XEN differentiation, so GAL3 may be exiting the cell in response to
altered O-GlcNAc status through this mechanism. Regardless, our evidence indicates that
the change in O-GlcNAc status of GAL3 during the exit from pluripotency induces its
extracellular secretion.
Given the differences in the two populations, ES and XEN cells, we wanted to explore the
role of OGA inhibition when ES cells were induced towards the XEN lineage. We expected
that OGA inhibition, and thus increased global O-GlcNAc, would inhibit XEN
differentiation. When observing pluripotency and XEN marker expression, there was no
change in the OGA inhibited cells during differentiation and the differentiated cells without
OGA inhibition (Figure 7-6). As other groups have demonstrated the importance of
increased O-GlcNAc in ES cells self-renewal and maintenance of pluripotency
transcription factor function [15], we were surprised by this result. Although not entirely
consistent with our results, Maury and colleagues demonstrated that excess O-GlcNAc in
human pluripotent stem cell differentiation inhibited ectodermal marker expression
without inhibiting the cell’s exit from pluripotency [18]. Together this suggests that
although there are changes in O-GlcNAc globally in XEN cells compared to ES cells,
inhibiting only the enzyme involved in removing O-GlcNAc modifications is not sufficient
to inhibit XEN differentiation.
To our knowledge, we are the first to explore the role of O-GlcNAcylation in XEN
maintenance and differentiation. Our work demonstrated the differences in global OGlcNAc between ES and XEN cells, yet OGA inhibition alone is not sufficient to inhibit
XEN differentiation. We also provide a candidate protein, GAL3, whose localization
through O-GlcNAcylation may regulate XEN differentiation. Although this study is a
beginning many questions remain in not only the role of O-GlcNAc but also the role and
regulation of GAL3 in XEN differentiation.
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